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 Phenoxodiol is an isoflavonoid based drug presently in clinical trials in Australia 
and America for use in prostate cancer. It has been shown to work through various 
mechanisms of action, including 5-α-reductase inhibition. The aims of this study were 
to develop new analogues related to phenoxodiol in order to increase 5-α-reductase 
inhibition and to introduce α1A adrenoceptor antagonism in the next generation of 
isoflavonoid derivatives. The α1A adrenoceptor antagonistic activity was expected to 
ameliorate the symptoms associated with prostate enlargement. 
 Work towards the design of synthetic target molecules was the focus of the 
initial stages of the study. Pharmacophores for each of the human 5-α-reductase type I 
and type II and the rat type II isozymes were generated using CATALYST®. Standard 
parameters were used and variable weight options were trialled during the generation 
process. The mapping of phenoxodiol on the human-based 5-α-reductase 
phamacophores predicted that an additional aromatic ring should increase 5-α-reductase 
inhibition. Pharmacophores for α1A adrenoceptor antagonism, which were previously 
generated by Bremner et al, were utilized for the mapping of phenoxodiol. It was 
concluded that a basic nitrogen moiety was required for the introduction of α1A 
adrenoceptor antagonism. 
 In the light of these findings, isoflavonoids derivatised at the 2- and 4- positions 
were designed and assessed on the pharmacophores. Isoflavene derivatives 70 and 67, 
which incorporated a basic nitrogen at the 2- and 4- positions respectively, were 
predicted to have α1A adrenoceptor antagonism. The synthetic targets which 
 xxv 
incorporated an additional aromatic group entailed the 5-methyl thienylisoflavene 71, 
the phenyl hydrazone 76 and the 2-thiazolyl isoflavene 77. In an attempt to integrate an 
increase of 5AR inhibition and α1A adrenoceptor antagonism, the target compound 78 
was designed which encompasses both an extra aromatic moiety and a basic nitrogen. 
 A new approach to 2-substituted isoflavene derivatives was developed based on 
nucleophilic attack on an isoflavylium salt. The isoflavylium salt intermediate was 
generated from a preformed isoflavene by hydride abstraction using a trityl salt. Eight 
derivatives were synthesized using this method.  
            Eight 4-aryl hydrazone derivatives were synthesized by reacting an isoflavone 
with the appropriate aryl hydrazine. A number of other 4-substituted isoflavene 
derivatives were synthesised either by nucleophilic attack on the carbonyl of an 
isoflavone or by electrophilic addition to the enol tautomer of an isoflavone. A new 
rearrangement of a C-4 thienyl substituted isoflavanol to a benzo[b]furan system was 
discovered. Another new rearrangement involving the transformation of the 
imidazolylhydrazone 162 to the benzo[b]furan derivative 163 was also found. While 
nitrile precursors of targets incorporating basic amine groups were obtained, reduction 
to the amines was not successfully achieved. 
A human 5AR type I assay was developed sourcing LnCap cells for the enzyme. 
Unfortunately, LnCap cell line contamination occurred resulting in corruption of the 
assay. Compounds synthesised in this study were also tested for biological activity 
against a variety of cancer cell lines and a number of compounds with potent anti-cancer 
properties were identified. In particular the p-nitrophenylhydrazone 159d showed 
excellent growth inhibitory activity against the androgen dependent prostate cancer cell 
 xxvi 
line and is a potential lead compound for further development. This result indicates that 







































Chapter 1 Introduction 
 
1.1  Prostate Cancer 
By the age of 75, around one in eleven Australian males will confront a disease 
that has the potential to challenge what many men would consider the essence of their 
masculinity and manhood. However, this will just be the first liability for a quarter of 
these men, as it will rob them of their lives.1 This disease is prostate cancer! 
Prostate cancer kills more than 2500 men each year in Australia, while 10% of 
Australian men will be diagnosed with the disease each year.1 Prostate cancer is the 
second largest cancer killer of men in Australia, after lung cancer.1 There has not been 
any obvious trend in the overall incidence of prostate cancer. The symptoms of prostate 
cancer are difficult, painful and frequent urination or ejaculation, blood in the urine, 
pain in the lower back, hips or upper thighs.2 
There are many factors that are thought to influence the initiation, development 
and progression of prostate cancer, including age, familial genetics, race,3 diet4,5 and the 
stage of cancer progression at the time of diagnosis6. These factors are poorly 
understood and there is a great deal of research needed for a reasonable understanding 
of all factors playing a role in prostate cancer. Unfortunately, the public profile of 
prostate cancer in Australia is relatively low and needs to be increased, so that further 
research may be supported. This low profile affects the number of men being screened 
for prostate cancer and unfortunately this could affect prognosis, as prostate cancers 
have an increased chance of going undiagnosed.1 
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1.2  What is the Prostate? 
The prostate is a donut shaped male sex gland that is about the same size as a 
walnut in healthy men. It is located just below the bladder and surrounds the urethra. 
The outer layer of the prostate is called the epidermis and the inner part is called 
the stroma. Its function is to produce a milky white fluid that aids sperm viability during 
sexual intercourse.  
 
1.2.1 Benign Prostatic Hyperplasia 
It is common for older men to develop a condition known as Benign Prostatic 
Hyperplasia (BPH). This condition is defined as an enlargement or swelling of the 
prostate. This enlargement constricts the urethra, which causes the patient pain during 
urination. BPH is not a cancerous condition and is generally, although debatably, not 
considered to be a condition which leads to cancer. Usual treatment is to prescribe α1A 
adrenoceptor blockers (Figure 1.1), which antagonise the action of the endogenous 







Figure 1.1: The smooth muscle relaxant effect of an α1A adrenoceptor blocker on the 



















The adrenoceptor family is part of the peripheral, autonomic, sympathetic 
nervous system. The adrenoceptors control smooth muscles in the body, including heart, 
blood vessel walls, lung, urinary and digestive tracts.  
 
1.3 What is Cancer? 
1.3.1  General 
Cells in our bodies grow and divide each day of our lives. Cell growth and 
division is carried out through a cyclic pattern of cellular events, called the cell cycle. 
The cell cycle is a highly regulated cycle, it contains controls to regiment cell division 
and cell death. When a cell has escaped the cell cycle division and death controls and 
gains the ability to invade other tissues it becomes cancerous.8 Cancer may develop 
from any part of the body. A cancer is named from where the initial cancerous cells 
originate.  
Metastatic cancer occurs when a cancerous cell has escaped its primary site of 
growth and has invaded other sites of the body. Common sites for cells to invade are the 
bone,9 lung10 and brain11. Metastatic cancer is difficult to treat and is far more 
dangerous than a tumour or localized cancer (see next paragraph). Metastatic cancer 
cells commonly possess the ability to degrade membranes and other natural barriers of 
the body to facilitate their escape.12 
Localized cancers consist of a group of rapidly dividing cells in a specific 
region, which also have the potential to invade other tissues. These cases may be 
treatable by surgery. However, when one is diagnosed with a localized cancer, there is a 
risk that there are minute numbers of cells which have metastasised and are 
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undetectable at the time of screening. There is also the risk of impotence with surgery 
for prostate cancer.13 
Localised cancers are often confused with benign tumours, and their similarity 
lies in the fact that both conditions contain cells that are rapidly dividing. However, the 
difference between the conditions is that benign tumour cells do not have the ability to 
migrate to other organs of the body (metastasis). Benign tumours may also be treated 
with surgical removal.8 
 
1.3.2 Cell Cycle 
Cancerous cells divide at a more rapid rate than normal cells and are thus 
understood to be undertaking the cell cycle at an increased rate. The cell cycle contains 
various checkpoints and regulations that disallow a cell to undergo rapid proliferation, 
however in cancer these controls are over-ridden through various mechanisms.14 
The cell cycle is broken up into phases 
and each phase has a specific function essential 
for normal cell growth and division (Figure 
1.2). The two main phases are mitosis (M) and 
interphase. In short, mitosis is where the nucleus 
divides into two and interphase is the rest of the 
cell cycle. Interphase can be further broken 
down into the G1 phase, S phase and G2 
phase. S phase is the time in which the cell 
synthesises DNA, and G1 and G2 phases are 
 M G1 
S G2 
Figure 1.2: Phases of the cell cycle. 
M=mitosis 
G1=Gap1 
S=Synthesis of DNA 
G2=Gap2 
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rest times where the cell is checking its health and repairing any damage.8 
An example of a cell cycle regulation protein is the p53 protein. This protein 
stops the cell from entering mitosis, allowing time for repairing damaged DNA before 
division.15 However, in over 50% of all cancers, the gene encoding the p53 protein is 
mutated, allowing the cell to skip this time for repair and increasing the cell division 
rate. It has been found that 39% of prostate cancers have a mutation in the gene 
encoding the p53 protein.16 
 
1.3.3 Cell Cycle Regulation and How Cancer Cells Escape Regulation 
Cell cycle regulation is an extremely complex process, involving numerous 
interactions between proteins, DNA and RNA. There are many factors and signals 
influencing this regulation system, including endogenous and non-endogenous 
substances. Endogenous substances may be intracellular or extra-cellular. Extra-cellular 
signals that increase cell cycle rate are termed growth factors, which range from small 
molecules to large proteins. An example of a protein growth factor is insulin-like 
growth factor, with a role in many cancers17; and testosterone is an example as a small 
molecule growth factor18. 
As mentioned in the previous paragraph, growth factors are essential for healthy 
cell viability. Upon growth factors binding to their appropriate receptors a signal 
transduction cascade is triggered. This cascade includes the participation of numerous 
protein interactions and modifications, and phosphorylation of proteins by cellular 
kinases is one of the most notable of these modifications.19 The signal transduction 
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cascade then influences DNA expression and induces cellular growth and division. In 
cancer many of the proteins in signal transduction cascades may be upregulated.20 
In prostate cancer kinases are frequently found to be upregulated.21 There are 
many different types of kinases, which are named after the substrate they phosphorylate. 
Common kinases frequently found to be up-regulated or highly active in prostate cancer 
are tyrosine22 and sphingosine kinases23. 
Sphingosine kinases are found on the cell surface and upon activation block the 
activity of the cell’s death receptors. These death receptors activate caspases, which are 
proteolytic enzymes. Activated caspases degrade intracellular proteins inducing cellular 
apoptosis. Therefore a higher sphingosine kinase activity than normal will halt apoptosis 
by blocking the initial death receptor activation.23 
NADH oxidase (c-NOX) is a protein receptor present on living cells. It sets time 
for growth of the cell and defines an allowed growth time.24 If the growth and division 
is not met in this growth time, the cell undergoes apoptosis. Cellular growth associated 
with c-NOX occurs in a 24 minute cycle and responds to the presence of growth factors 
and growth hormones.24 
A variant of c-NOX is t-NOX which is expressed in human cancer cells. Morre 
et al.24 have shown that t-NOX is vital to the survival of all human tumour cells. It has 
the same roles as c-NOX, however associated growth occurs in a 22 minute cycle and is 
unresponsive to the presence of growth factors and growth hormones. t-NOX and c-
NOX are expressed by different genes, indicating that t-NOX expression is usually 




Recently it has been observed that cancers express an enzyme which most non-
cancerous cells do not express. This enzyme is cyclooxygenase-2 (COX-2). There is a 
related COX-1 enzyme that it has not been found to be expressed in cancer cells. COX-
2 converts arachidonic acid into various prostaglandins.25 There is one prostaglandin 
which is of particular interest in cancer development, namely prostaglandin E2 (PGE2). 
PGE2 has been found to inhibit apoptosis and exhibit immunosuppressive properties 
towards various cancer cell lines. PGE2 also induces the production of interleukin-6 
which promotes angiogenesis.26 
 
1.3.5 Metastasising Mechanisms 
A cancerous cell must develop mechanisms which allow it to break free of its 
original growth site, travel throughout the body and implant itself into a new tissue. 
Then it must also find a way to sustain rapid growth at the new site.  
One mechanism which has allowed cancerous cells to break organ and tissue 
membranes is through the expression and secretion of proteases. Proteases are enzymes 
which break down proteins. These proteases degrade inter-cellular adhesive proteins 
which sustain the integrity of membranes and tissues. Cathepsin B is an example of a 
protease which enables some prostate cancer cells to break through tissues and 
membranes.27  
Once a cell has embedded itself into a new tissue, it requires nutrients, oxygen 
and a method for waste removal. An integral mechanism providing cancerous cells with 
these requirements is angiogenesis. Angiogenesis is a process by which a cell sets up a 
 9 
blood supply to itself, which includes the development of local capillaries.28 It is 
actually this process which provides cancer with its name. Original observers of cancers 
thought that a cancer with blood vessels radiating from it looked like a crab (cancer is 
Latin for crab). If this process can be inhibited it has been shown that the cancer can be 
starved and suffocated to death.29 
 
1.4 Prostate Cancer Development 
Non-cancerous prostate cells are dependant on various growth factors for their 
normal growth and development. Androgens, for example testosterone (1), are a class of 
growth factors required for normal prostatic growth. Androgens, which are typically 
steroids, are natural hormones that are necessary for the development of male sex 
organs and characteristics. Androgens primarily are formed in the testes and adrenal 
gland, and to a lesser extent in peripheral tissues.30 
In the early stages of prostate cancer, the cancer is dependant on androgen for 
growth and division. This stage of the cancer is termed androgen dependant cancer. As 
the cancer progresses and advances, its growth becomes independent of androgen 
presence. Once this occurs the cancer usually becomes more aggressive and more 
difficult to treat.31,32  
Androgens exert their effects on cellular growth, division and sex organ 
development through binding with the androgen receptor, which is a membrane receptor 
located in the nuclear membrane.32 
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Testosterone 1 is an androgen which is reductively converted to 
dihydrotestosterone (DHT) 2 by the enzyme 5-α-reductase (Figure 1.3). DHT 2 is 40 
times more potent as a growth factor at the androgen receptor than testosterone. Slowing 
the growth of androgen dependant prostate cancer is therefore achievable by inhibiting 




It has been shown that DHT binds to the androgen receptor within the prostate 
cell, forming a complex, which then binds to the androgen response elements in 
prostatic DNA, inducing DNA synthesis and subsequent cellular proliferation.34 
There are two isozymes of 5-α-reductase, type I and type II. They have different 
anatomical distributions and are encoded by different genes on different chromosomes.  
5-α-Reductase type I is found mainly on the skin and is encoded on 
chromosome 5, by the SRD5A1 gene.35 It is also found to a smaller extent in prostate 
epithelial cells. When prostate cancer originates from these cells the cancer tends to be 
more aggressive than its type 2 counterparts. Excessively active 5-α-reductase type I is 
also responsible for male patterned baldness.36 Interestingly, a correlation between 
specific types of male patterned baldness and aggressive prostate cancer has also been 








Figure 1.3: Conversion of testosterone 1 into dihydrotestosterone 2. 
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5-α-Reductase type II is mainly found in the stroma of the prostate and in 
genital skin, and is encoded on chromosome 2, by the SRD5A2 gene.35,39 
Differences between 5-α-reductase enzymes between species have also been 
ascertained. Specifically, it has been shown that inhibitors of the 5-α-reductase 
isozymes in mice, rats, dogs, monkeys and humans bind to these enzymes with different 
affinities.40,41 This finding leads to the conclusion that the enzymes are different 
between species and calls for caution in the use of animal models during the testing of 
inhibitors of the human enzyme.  
 
1.5  Factors Influencing Cancer Development 
 
1.5.1 Genetics, Familial and Racial Differences 
Statistical studies involving familial history and racial differences of prostate 
cancer patients reveal the important role that genetics plays in the development of the 
disease.3 For example, if a male has a brother who has had prostate cancer, his 
likelihood of prostate cancer development increases by nearly three times42. Genetics 
also comes into play when examining the incidence of the disease between races. 
African American men are 40-60 times more likely to develop prostate cancer than are 
Asian men.3 
Many genetic studies have investigated the reasons behind these prostate cancer 
familial and racial factors. Androgen levels have been implicated for the differences 
between races. Over 22 mutations in the SDA5A2 gene have been reported. The A49T 
mutation (a substitution of threonine for alanine at codon 49) has been investigated by 
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seven different studies. Two of these studies report that this mutation is associated with 
more aggressive prostate cancers to a statistically significant degree, while others did 
not find this association. Four other mutations have been studied, however no 
correlations were made.39 
Many findings from the genetic studies have been debatable and many groups 
have found conflicting results. The main problem with most genetic studies has been 
methodological limitations, such as a low number of participants or mutant alleles 
within the study. Past studies have had a mutant allele population of less than 5%, 
placing limitations on conclusive findings. Typically studies containing less than 500 
men have been performed, however it is now recommended that over 500 men 
participate, so that findings can be statistically significant. The combination of certain 
alleles and the functional consequences of the mutations also need to be considered 
within genetic studies.39 
 
1.5.2 Diet 
Encouragingly, it has been observed that typical Asian diets have produced a 
low incidence of prostate cancer. This is highlighted by the low incidence rate in Asian 
men living in Asia, however as they immigrate to western countries the incidence for 
men with Asian ancestry increased.43 Asian diets are high in soya products.44 Their use 




There are various constituents of soya which have anti-cancer activity.45 These 
constituents include lignans, phytates,46,47 phytoestrols, saponins48 and isoflavonoids 
(Figure 1.5).49 Their biological properties include protease inhibition, kinase inhibition 
and anti-androgenic action. An example of a saponin is Syringaresinol 3 which has been 
shown to possess acetylcholinesterase inhibitory activity.50 In particular, isoflavonoids 
in soya have been shown to possess numerous anti-cancer actions. One isoflavonoid, 
genistein 4 demonstrated a 74% reduction of prostatic cancers in in vitro and in vivo 
animals models of the cancer.51 Another isoflavonoid found in soya is daidzein 5, a 
compound which has been shown to protect against many different types of cancer, 












Figure 1.4: Sources of 
soy in the asian diet. 
From left to right: 
soya beans, soya 




























1.6 Cancer Drug Targets 
1.6.1 Hormonal Regulation of Androgens 
Hormonal regulation of androgens is achieved at various glands in the body and 
relies on the blood stream for transportation of hormones throughout the body. The 
main organs controlling androgen levels are the hypothalamus gland, pituitary gland, 
testes, prostate, and adrenal gland. Dysfunctions in these organs may cause 
inappropriate androgen levels and lead to diseases such as prostate cancer.30 
As discussed in section 1.4, testosterone is converted into dihydrotestosterone by 5-α-
reductase in the prostate. Testosterone is mainly produced in the testes from cholesterol. 






















Figure 1.5: Components of soya products exhibiting anti-cancer activity. 
3 Syringaresinol (a saponin) 
4 genistein (an isoflavonoid) 
5 daidzein (an isoflavonoid) 







released from the pituitary gland. Upon LH release from the pituitary gland and 
transportation through the blood stream, LH binds to the luteinizing hormone receptor 
in the testes, which upregulates the synthesis of testosterone. The release of LH in the 
pituitary gland is upregulated when luteinizing hormone releasing hormone (LHRH) 
(also known as gonadotropin releasing hormone) is released from the hypothalamus.30 
(Figure 1.6) 
The prostate is not the only source of dihydrotestosterone. The adrenal gland 
produces adrenal androgens from cholesterol, which are transported into the prostate 
and there converted into dihydrotestosterone.30 
Androgen synthesis is also regulated by testosterone (T) in the hypothalamus and 
pituitary gland in a negative feedback fashion (Figure 1.6). The presence of testosterone 
itself in the hypothalamus and pituitary gland causes a decrease in the production of LH 
and LHRH. Through this mechanism testosterone (T) regulates its own production, so 





Estrogens (E) down-regulate the LHRH production in the hypothalamus. Upon 
estrogen (E) binding to the estrogen receptor in the hypothalamus, a signal transduction 
cascade occurs, eventually causing a decrease in the LHRH levels. This eventually leads 
to a decrease in T and DHT levels.30 Various drugs can be used to moderate aspects of 






















LHRH=luteinizing hormone releasing hormone 
AR=androgen receptor 
ER=estrogenrecptor     PR=progesterone receptor 
                     Upregulatory effect 



































1.7 Current (Prostate) Cancer Drugs 
The first effective systematic therapy, not just for prostate cancer, but, for any 
type of cancer, was castration in conjunction with oral estrogen (a form of androgen 
ablation) in the 1940s. Remarkably androgen ablation remains the most frequently used 
therapy for prostate cancer, even today.52 Currently however, androgen ablation is not 
achieved through estrogen treatment, but most commonly by the use of Finasteride 7 
(Figure 1.7).30 Once prostate cancer becomes hormone independent, androgen ablation 
techniques are of little use, and then the usual next line of defence is the use of cytotoxic 
agents. 53 
Monotherapy for prostate cancer will almost inevitably lead to drug resistance. 
A way to circumvent this problem is the use of multiple drugs for treatment.54 Multiple 
drug therapy commonly alleviates pain associated with cancer as well as decreasing the 
dosage of some toxic drugs.55 Many trials are in place to evaluate the various regimes of 
multiple drug therapy. 
 
1.7.1 Androgen Ablation 
The prostatic effects of androgen ablation have been observed for centuries, 
initially through castration. These effects include a shrinking in the size of the prostate. 
Androgen ablation can be achieved by surgery and chemotherapeutically through taking 
advantage of androgen synthetic and regulation mechanisms.30 
5-α-Reductase is an attractive biological target for androgen dependant prostate 
cancer as its inhibition will hinder the synthesis of DHT. Finasteride 7 is the most 
frequently utilized drug for androgen dependant cancer. It is a steroidal compound, 
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which inhibits 5-α-reductase type 2.56 However, it produces steroidal side effects. These 
effects include weight gain and moodiness. It has also been shown that finasteride 7 
may be taken to prevent prostate cancer.57 Recently, a dual inhibitor of 5-α-reductase 
type 1 and 5-α-reductase type 2, dutasteride 8 (Figure 1.7), has been developed and it is 
currently in clinical trials.58-60 Dutasteride 8 has been reported to shrink prostate size, 
alleviating urinary obstruction to such a degree in most BPH patients that α1A-
adrenoceptor blockers aren’t required for symptom relief.61 Unfortunately, 8 is also a 
steroidal compound, with the potential to produce steroidal side effects, such as 
gynecomastia (the excessive development of breasts in males). No specific 5-α-








Long term dosing of LHRH agonists reduces serum testosterone levels by 75%. 
Although the response duration is highly variable, the median response duration lasts 
about 14-20 months. This therapy relies on the negative feedback mechanism of 
testosterone (Figure 1.6). A disadvantage of this type of therapy is that in the short term, 
testosterone levels flare up. There are a number of LHRH analogs which have been 




















Figure 1.7: Structures of 5-α-reductase inhibitors. 
      Finasteride 7 
      Dutasteride 8 
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(Zolarex)63, buserelin64 and nafarelin65. Leuprolide 9 has been approved in a depot form 









Another way to utilize androgen regulation mechanisms is by the antagonism of 
LHRH, causing a down-stream decrease in synthesis of T (Figure 1.6). LHRH 
antagonists such as Cetrorelix 10, (Figure 1.8), Abarelix and Ganirelix66 have recently 
been in clinical trials. Preliminary clinical trial data shows that these compounds are just 












































Figure 1.9: Structure of Cetrorelix 10. 
































Androgens produce their effects by binding to the androgen receptor (AR). AR 
antagonists have been developed and they are mainly steroidal compounds. An example 
of a pure AR antagonists is Cyproterone 11,68 (Figure 1.10), while examples of partial 
agonists are Bicalutamide and Nilutamide. Pure antagonists bind the androgen receptors 
competitively without acting as an agonist, whereas a partial agonist binds as well as 
effecting some agonistic response. Pure antagonists bind to the AR in the hypothalamus 
and pituitary gland as well as the prostate. This blocks the negative feedback 
mechanism of testosterone and leads to an increase in serum LH and T.69 
In order to overcome the spiking of LH and T problem associated with 
Cyproterone being a pure AR antagonist, an acetate group was added to the 17α-
hydroxy position. This converts Cyproterone into a partial AR agonist and a potent 
progesterone agonist, inhibiting LH release from the pituitary gland. This decreases the 
amount of testosterone synthesized, while retaining AR antagonism. Cyproterone 
acetate use does incur side effects, namely hot flushes, loss of libido and sexual potency 


















The androgen ablation strategies mentioned above are not able to cure advanced 
prostate cancer as they do not address the fact that adrenal androgens are still being 
secreted into the blood stream. The adrenal gland produces adrenal androgens which 
contribute to the production of DHT in the prostate (Figure 1.6). Ketoconazole71 14 and 
Aminoglutethimide 13 (Figure 1.11) suppress this adrenal androgen synthesis. 
Ketoconazole is currently frequently used as second line hormone therapy and is less 









1.7.2 Cytotoxic Agents 
Cytotoxic agents are regularly used in many cancers as a first line treatment, 
however in prostate cancer they are commonly used as a second choice treatment after 
androgen ablation, for metastatic hormone refractory prostate cancer. Cytotoxic agents 
exert their effects through various mechanisms. Commonly these mechanisms cause 
DNA damage.73 The cell checks for DNA damage at various checkpoints during the cell 
cycle. When DNA damage is detected it is commonly followed by cell death.74 Because 















Figure 1.11: Structures of aminoglutethimide 13 and ketoconazole 14. 
13 14 
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DNA damage is detected more readily in cancerous cells than normal cells. This induces 
a higher rate of death in cancerous cells than normal cells. 
It has been found that many cancers are becoming resistant to cytotoxic agents when 
used as monotherapy. Recently, the synergistic use of cytotoxic agents with androgen 
ablation and/or anti-angiogenic agents is emerging as a new trend and is the focus of 
many new studies.  
Commonly used cytotoxic agents in prostate cancer are Cyclophosphamide75, 
Estramustine phosphate76 (Emcyt), Doxorubicin75 (Adriamycin), Mitoxantrone75 
(Novantrone) and Cisplatin75 (Cisplatinium). More recently, Etoposide75,76 (Vepsid), 
Paclitaxel75 (Taxol), Docetaxel77 (Taxotere) and Vinblastine76 (Velban) have been   
used. 75 
  
       Cisplatin 15 (Figure 1.12) is an extremely commonly used drug in 
many cancers. Cisplatin is known to bind at DNA sites with a high 
cytidine (cytosine) and guanidine content.78 Upon cisplatin entering 
the cell nucleus its two chlorine atoms are exchanged by two 
adjacent guanidine bases from a DNA strand.79 X-ray 
crystallography has revealed that this causes a DNA bend and 
unwinding at the site of attachment. This causes binding of high mobility group (HMG) 
domain proteins at the bent site of the DNA and it is thought that HMG-domain proteins 
prevent cell replication.78 Cisplatin is known to posses neurotoxicity and kidney 











efflux pump which exhibits cross resistance with other cytotoxic agents such as 
cyclophosphamide.82 
 
Cyclophosphamide 16 (Figure 1.13) is a nitrogen mustard, an alkylating agent 
which crosslinks DNA83 and is cell cycle non-specific. Its adverse effects include 
myelosuppression, leukemogenesis, vomiting and diarrhea. It is metabolically activated 
by the hepatic CP450 enzymes (Figure 1.13), through hydroxylation alpha to the 
nitrogen. This first step of this metabolism produces an amino alcohol, which is in 
equilibrium with the ring opened aldehyde compound. This ring-opened compound then 
further degrades into two biologically active components, the amino phosphate 17 and 
the vinylic aldehyde 18.83 Resistance to cyclophosphamide is facilitated through various 







Estramustine phosphate 19 (Figure 
1.14) combines an estrogenic structure with 
a nitrogen mustard moiety and this takes 
advantage of two distinct mechanisms. 





































Figure 1.13: The hepatic metabolism of cyclophosphamide 16 producing biologically  
          active compounds. 
                        
16 17 18 
Figure 1.14: The structure of  
                     Etramustine  
         phosphate 19. 
19 
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androgen ablative pathways through estrogenic receptor binding, while exploiting the 
actions of nitrogen mustards on DNA. Additionally, Estramustine metabolites are 
microtubule inhibitors leading to cellular growth inhibition.85 Adverse effects include 
fluid retention, nausea,86 diarrhea87, dyspnea,88 and allergic reactions,89 while 
gynecomastia87 and impotence are associated with its estrogenic effects.85 
 
Vinblastine 20 (Figure 1.15) comes from the traditional 
folk medicine plant, periwinkle.90 It binds in a specific 
manner to tubulin and inhibits its polymerization, which 
causes ineffective chromosome separation and leads to 
apoptotic cell death.91 It blocks the cell cycle in the G2/M 
phases.92 Resistance to Vinblastine can occur. Mechanisms 
for resistance include cellular production of a multi-drug 
efflux pump93 and altered tubulin causing reduced affinity 
for vinblastine94. Side effects include myelosuppression95, 
neurotoxicity, leukopenia, alopecia and gastrointestinal (GI) disturbances96. 
 
Taxol 21 (Figure 1.15) was first isolated from 
the western yew tree.97 Taxol promotes the 
polymerisation of tubulin.98,99 This induces the 
production of the tumour suppressor gene, p53. 
Taxol blocks the cell cycle in the G2/M phases 
























Figure 1.15: Structure 
of Vinblasatine 20. 
20 
Figure 1.16: Structure of Taxol 21. 
21 
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Resistance also occurs with this drug, and clinically the mechanism for resistance has 
been found to be due to mutant tubulin.100 Bone marrow suppression101,102 and 
peripheral neuropathy102  have been observed in patients using Taxol. 
 
Doxorubicin 22 (Figure 1.17) is an antibiotic derived from 
streptomyces bacteria.103 It exerts its actions in cancer through 
intercalation of DNA. The amino sugar is directed into the 
DNA minor groove during intercalation.104 Preferential sites 
for intercalation are those with two adjacent GC base pairs 
flanked by an AT base pair,104,105 leading to DNA and RNA 
synthesis inhibition. Specifically, Doxorubicin intercalation 
leads to double stranded breaks, mediated either by 
topoisomerase or the generation of free radicals.106 There are three main mechanisms 
responsible for doxorubicin resistance, the production of a multi-drug resistance efflux 
pump,107 increased glutathione peroxidase activity108 and decreased topoisomerase 
activity109. Adverse effects have been found, including myelosuppression,110 alopecia,111 
GI disturbances111 and cumulative cardiac toxicity111. 
 
Mitoxantrone 23 (Figure 1.18) exerts its toxic effects by 
C/G specific DNA intercalation.112,113 It has a lower 
cardiotoxicity than other anthracyclines, such as 
































myelosupression.115 Chemoresistance to Mitoxantrone 23 is also known to occur.116  
 
There is a great need for a wider variety of drugs to treat prostate cancer 
patients, particularly drugs with non-steroidal structures and of low toxicity. There are 
numerous biological targets for prostate cancer and therefore there is a need to explore 
new structural drug types. One place to start looking for such new structural types is in 
nature. In this context, one particular structural type of interest are the isoflavonoids 
found in soya products, as they have been found to possess many beneficial properties, 




The core chemical moiety of isoflavonoids is the benzopyran ring system. 
Benzopyrans are a fascinating class of compounds, whose applications range from 
medicinal use to laser dyes. There are numerous structural variants of the benzopyrans, 
many possessing commonly used nomenclature as a result of their significance in 
natural product chemistry. Numbering of the benzopyran system starts from the oxygen 

















Figure 1.19: Benzopyran derivatives, shown with IUPAC and common nomenclature. 
 
Benzopyrans are a class of compounds widely distributed in the plant kingdom 
and many are biologically active. Some of these activities include anti-coagulant,117 
anti-asthma,118 anti-cancer,119 anti-fungal,120 cardiovascular,121 anti-hypertensive,122 
fragile capillary protectant, sedative relaxant,123 appetite stimulation, respiratory 
stimulatory, contraceptive,124 anti-osteoporotic,125 anti-obesity, non-insulin dependent 
diabetes mellitus agent,126 liver protector,127 anti-oxidant,128 night-blindness treatment 
and anti-parasitic129. To highlight the range involved the activities of some natural 
benzopyrans and synthetic analogues are summarised in Table 1. One compound of 
particular interest in the context of the work in this thesis was the isoflavone genistein 4. 
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 Anti-cancer Protein 
kinase 
inhibition 
Siccanin120  Anti-fungal Inhibits 
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Studies on daidzein 5 have shown anti-prostatic cancer properties. 130-132 
However, it has also been shown to be metabolized by intestinal bacteria to phenoxodiol 
32 (dihydroequol) through the hydroxy intermediate 31 (Figure 1.20).133-135 
Phenoxodiol is a more effective agent than daidzein 5 against prostate cancer.136 
Phenoxodiol also exhibits greater anti-oxidant potency than daidzein.137 Phenoxodiol 
has exhibited activity against breast,138 prostatic,136 ovarian,139 lung, colorectal, head 
and neck cancers, and against mesotheliomas, leukemias, rhabdomyosarcoma and 
neuroglioma in in vitro studies. These studies have also shown that, upon phenoxodiol 
exposure cancer cells cease dividing immediately and show signs of distress within 
several hours. The cells die within 24-48 hours by apoptosis. The remarkable property 
of this compound is its specificity towards cancer cells, with normal cells remaining 




 Figure 1.20: Human Colorectal and intestinal bacterial metabolism of daidzein 5 to  



















In the course of incubation with prostate cancer cells, phenoxodiol causes a 
G0/G1 arrest during the cell cycle.136 It has been established that phenoxodiol has 
numerous additional modes of biological actions against cancer. These actions include 
inhibition of 5-α-reductase type 1 and 2 (with greater inhibition of type 1)141, COX-2 
inhibition, and signal transduction inhibition141. The signal transduction inhibition 
specifically includes insulin growth factor inhibition, tNOX inhibition and down 
regulation of sphingosine kinase expression. In vitro cell line studies incorporating the 
use of other cancer chemotherapy agents, such as cisplatin, carbo-platin and paclitaxel, 
have revealed the synergistic ability of phenoxodiol to restore chemo-sensitivity to 
resistant cell lines. Synergism between phenoxodiol and cisplatin has also been 
reported.142 
Phenoxodiol has been developed by Novogen (Marshall Edwards) as a drug for 
various cancers, including prostate cancer. This is the first isoflavonoid compound to 
enter into clinical trials for use against cancer. It may be given orally or intravenously. 
Phenoxodiol is currently in phase II clinical trials for hormone independent prostate 
cancer in Australia and America as a mono-therapeutic. Other clinical trials with 
phenoxodiol include mono-therapeutic use against ovarian cancer, cutaneous squamous 
cell carcinoma, and basal cell carcinoma in Australia, and monotherapeutic use in 
squamous cell carcinoma and adenocarcinoma of the cervix, vagina and vulva in 
America. 143 
Remarkably, phenoxodiol has shown no or little cytotoxicity during cell based 
and animal testing, which is a huge benefit for anti-cancer drugs.140 
 31 
There is continuing interest in developing further analogues related to 
phenoxodiol as anti-cancer agents, and also to incorporate other activities, for example 
α1A adrenoceptor antagonism which would alleviate symptoms associated with the 
partial blockage of the urethra. 
 
1.10 Aims 
The aims of this project were thus to use phenoxodiol as a lead for the molecular 
design, synthesis and evaluation of a new range of isoflavonoid compounds which 
would be useful for prostate cancer treatment. 
Specifically this included the potential incorporation of α1A adrenoceptor inhibitory 
activity into phenoxodiol-type compounds, as this would alleviate symptoms associated 
with prostate cancer. Increasing 5-α-reductase inhibitory activity was an additional 
biological activity sought which would be beneficial for phenoxodiol-like compounds. 
Increasing 5-α-reductase type 1 inhibitory activity was of particular interest as there are 
no specific prostate cancer therapeutics which have high inhibitory activities against this 
enzyme. Associated with this, it was also planned to develop an appropriate assay for 
the analysis of the reductase-enzyme inhibitory activities of the synthesised compounds. 
In this thesis, Chapter 2 deals with pharmacophore generation and the design of 
synthetic targets, Chapter 3 covers the synthesis of 2-substituted isoflavene derivatives, 
Chapter 4 discusses the synthesis of compounds derivatised at the 4-position of the 
isoflavonoids, Chapter 5 reports on the development of the 5AR inhibitory assay, and 
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Chapter 6 discusses the biological testing results. The full experimental details are then 














































Chapter  2                    Molecular Modeling, Pharmacophore   
  Development and Target Design 
 
2.1  Introduction 
Often the three-dimensional (3D) structure of an enzyme or receptor is unknown and 
the most useful information on its structure comes from ligand binding. The information 
obtained from ligands is especially useful for the drug design process. The 3D structures 
for the 5-α-reductase type I (5AR type I) enzyme, the 5-α-reductase type II enzyme 
(5AR type II), the α1A adrenoceptor, α1B adrenoceptor and α1D adrenoceptor are all 
unknown at the present time making them candidates for a ligand-based drug design 
process. These enzymes and receptors play a role in the treatment of prostate cancer.  
Among other roles, adrenoceptors control smooth muscle tone throughout the body. 
Urethral smooth muscle tone is influenced by the α1A adrenoceptor. Blocking the α1A 
adrenoceptor alleviates symptoms of prostate cancer associated with painful and 
impaired urination.144 Pharmacophores for the human α1A adrenoceptor, α1B 
adrenoceptor and α1D adrenoceptor have been generated by Bremner et al.145 and were 
utilized in this study. Bremner et al.145 generated the adrenoceptor pharmacophores 
using CATALYST® from Accelrys. 
5AR converts the androgen, testosterone to dihydrotestosterone. 
Dihydrotestosterone is 40 times more potent an androgenic growth promoter of prostate 
cells than testosterone. As prostate cancer is androgen dependant in the early stages, the 
inhibition of 5AR is beneficial in treatment.31 Comparative examination of the 
pharmacophores may reveal key features characterizing the differences between the 
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different isoforms of the enzymes and receptors. Pharmacophores for the 5-α-reductase 
enzymes were generated during this study to assist with the design of new chromene 
target compounds for synthesis. CATALYST® version 4.5 from Accelrys was utilized 
for 5AR pharmacophore generation. As there are differences in 5AR inhibitor activities 
between animal species40, pharmacophores must be generated in a species distinct 
manner. 5AR inhibitors are most commonly tested on human and rat enzymes therefore 
human and rat 5AR pharmacophores were generated. 
 
2.1.1  Selection of Training Set Molecules for 5-α-Reductase Pharmacophores 
 For all pharmacophores, compounds from the literature with a range of 5AR 
enzyme inhibitory activities, spanning at least 4 orders of magnitude, were included in 
the training sets (Table 2). This is important as this provides CATALYST with enough 
structural information to differentiate between active and non-active compounds. The 
IC50 values (concentration required to inhibit 50% of T conversion to DHT) were taken 
from the literature; standard deviations were not given. Training set compounds and 
references to the literature are given in Appendix 1. Training sets were collated with no 
redundant information present, as redundant information could bias the pharmacophore 
generated. Redundant information is defined as different compounds with similar 
activities which provide the pharmacophore with the same structural information. This 
is exemplified by the compounds 33 and 34 which are exhibited in Figure 2.1 and have 
the similar 5AR type II activity, however only compound 33 is part of the 5AR type II 
training set. These two compounds both provide the information that an aromatic group 
 36 






                    33        34 
        0.29nM               0.35nM 
Figure 2.1: Compounds 33 and 34 (with their human 5AR type II IC50s) which 
provide redundant information, therefore only compound 33 is included in the  
training set.  
 
 
Table 2: The number of compounds and their range of activities included in each of 
the 5AR inhibitor pharmacophore training set. 
 
Pharmacophore Number of compounds 
included 
Range of activity 
IC50 (nM) 
Human type I 15 3.4 to1400 
Human type II 46 0.29 to 10000 
Rat type II 27 1.1 to 12000 
 
Only non-steroidal molecules with defined stereochemistry were included, so 
racemates were excluded. A range of different structural types was also incorporated 
into the pharmacophores. The human 5AR type I isozyme pharmacophore contains 
biphenyls147, tricyclic lactams148,149 and tricyclic thiolactams148. The human 5AR type II 
pharmacophore includes tricyclic lactams149,150, indoles146,151, piperidines150, 
biphenyls147,150,152 and benzoquinones147, while the rat 5AR type II isozyme 












version 4.5 does not account for a loss of activity as a result of steric hindrance.153 
Compounds which had a low biological activity for suspected steric reasons, were thus 
excluded from the training sets. For example, the biphenyl compound 35, which has a 
very low activity compared to 36, was excluded from the human type II pharmacophore 









   
 
The compounds were also chosen according to the type of biological testing 
performed on them. All the included training set compounds had been tested on protein 
extracts of cells; results obtained from cell-based assays were not included. The source 
of protein was considered to be critically important. Ideally, training set compounds 
should be tested on extracts taken from cells containing recombinant enzyme consisting 
of a pure isozyme. However, compounds tested in this manner are a very limited group 
in the literature and insufficient for meaningful pharmacophore generation. Thus 
compounds tested on human scalp protein extracts were used for the human type I 
O
HOOC
Figure 2.2: The biphenyl compound 35, which was excluded from the human 5AR  
                   type II pharmacophore training set on steric grounds, compared with  





isozyme pharmacophore, while for the human type II isozyme pharmacophore, data 
based on protein extracts from benign hyperplastic prostatic tissue were used. These 
tissues were chosen as the sources as they contained a dominant amount of the relevant 
isozyme.19 For the rat type II enzyme inhibition data from rat prostatic tissue was used. 
 
2.1.2     Conformer Generation 
Conformers of each molecule were generated using the standard 20 kcal/mol limit 
(relative to the lowest energy conformer found) and the best conformer search option. 
While the energy limit of 20 kcal/mol of a conformer is high, it is the recommended 
value for CATALYST®, as it provides a large spread of conformers. CATALYST® 
accounts for conformers of a high energy during the hypothesis generation process 
through a penalty system and CATALYST® is in fact optimised for a 20kcal/mol limit. 




2.1.3  Pharmacophore Generation 
CATALYST® generates hypotheses consisting of features. These features are 
displayed as round mesh balls, which represent an area in space relative to the other 
features where a characteristic of a molecule should be to induce the desired activity 
(location constraints). 
CATALYST® generates hypotheses with a heavy emphasis on a group of molecules 
which are the most active of the training set with activities falling into a certain activity 
range. The upper limit of this activity range is defined by CATALYST® to be the 
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product of the square of the uncertainty value multiplied by the activity of the most 
active compound in the training set.157 The lower limit of the activity range is the 
activity belonging to the most active molecule. It is very important that the hypotheses 
generated are not biased by any one chemical structure type. In order to ensure a non-
biased hypotheses generation, it is necessary that compounds of more than one 
structural type are included in the most active group in the training set, and this can be 
controlled by varying the uncertainty value. 
  In this study, the uncertainty was three, therefore the upper limit of the most 
active group of compounds for each training set was set by multiplying the activity of 
the most active compounds by nine. For example the most active compound in the 
human 5AR type I training set is compound 37  (Figure 2.3, below) with an activity of 
3.4nM, therefore the upper limit for the most active group of compounds is 30.6nM.  
All compounds in the training set with activities between 3.4nM and 30.6nM heavily 
biased the human type I pharmacophore generation, including the biphenyl 36. The 
most active compound in the human type II training set was the biphenyl derivative 38 
(Figure 2.3), with an IC50 of 0.29nM, the compounds which were considered to be the 
most active had an activity up to 2.61nM. For the human type II inhibitor training set, 
this group included compound 38 and the indoles 39 and 40 (Figure 2.3). The 
CATALYST® program again heavily biases pharmacophores on this most active set of 
compounds. As the biphenyl compound 38 is quite different structurally from the 
indoles 39 and 40, it is reasonable to assume that the pharmacophore generated is not 
biased towards one type of compound. The most active compound in the rat 5AR type II 
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training set was 41 which had an IC50 of 1.5nM, which indicated that compounds 41-45 
are in the most active group of the rat 5AR type II training set (Figure 2.3). 
In this study, hypotheses were generated using default parameters including a 
minimum number of features of three. The allowed set of features were hydrophobic, 
hydrophobic (aromatic), ring aromatic, hydrogen bond acceptor and negative ionisable 
groups. A ring aromatic feature is defined as a feature which maps 5- and 6- membered 
aromatic rings (which may be next to a charge) and the negative ionisable feature is 
defined as a feature which maps atoms or groups of atoms that are likely to be 
deprotonated at physiological pH.158 Hydrogen bond donor (HBD) groups were trialled, 
but CATALYST® never included any HBD feature in the generated pharmacophores 
and they were thus omitted. The negative ionisable feature was included in the allowed 
set as a number of the inhibitors had carboxylic acid groups. 
The CATALYST® default mode generates hypotheses where each feature 
relatively has equal importance or weight within the hypothesis. However, it is possible 
to generate a hypothesis with different relative weights for features, thus allowing 
different features to have ranked importance. This variable weight option was 
considered for each pharmacophore generated. For the human type II pharmacophores 
the variable weight option was not utilised, since when this option was trialled, the 
configurational cost (see next section for a discussion of hypotheses costs) was too high 
and the same pharmacophores were generated without this option. However, for the 
human 5AR type I and rat type II pharmacophores, the variable weight option was 
utilized as the correlations increased (from 0.76 to 0.79 and 0.85 to 0.94 respectively; 
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see next section for a discussion of hypothesis costs) making the sacrifice of a high 
configurational cost (22 and 32 respectively) worthwhile. 
 
2.2 Results and Discussion: 
 
CATALYST® generates hypotheses by assigning chemical features to the 
training set molecules, then arranging the features so that the molecules map with a 
ranking which correlates with their activity. The hypothesis generation places a greater 
importance on the molecules contained in the most active group of the training set. 
CATALYST® produces 10 hypotheses (sometimes 9) which are arranged in a 
hierarchical manner according to the CATALYST® cost analysis, which takes into 
account many factors including the size of the training set. The most influential 
parameter contributing to this cost analysis is the correlation between the hypothesis 
estimated activity values and the real activity values. The correlation value can lie 
between zero and one, with one being a perfect correlation. CATALYST® cost analysis 
also takes into account a configurational parameter which describes the complexity of 
the problem. Costs are expressed as the number of bits necessary to describe the 
hypothesis (this parameter should be under 17, otherwise not all possibilities for 
patterns will be searched exhaustively). CATALYST® cost analysis also employs the 
principle of Occam’s razor159 whereby a hypothesis should be as simple as possible. 
This cost analysis allows one to assess the validity of the produced hypotheses. This 
involves the use of three cost parameters:  
1. The null hypothesis cost parameter assumes that all training set 
molecules have the same activity, so that there is no statistically 
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significant structure in the training set. This cost parameter has the 
highest numerical value of all the cost parameters. 
2. The ideal hypothesis cost parameter assumes all training set molecules 
fit the simplest possible hypothesis perfectly. This cost parameter has 
the smallest numerical value of all the hypotheses cost parameters. 
3. The individual hypothesis cost, which results in a ranking of generated 
hypotheses. This parameter takes into account the correlation of the 
training set molecule’s tested activity with the activity estimated by 
the hypothesis. 
To determine whether the pharmacophores produced are statistically significant, 
the individual hypothesis costs are subtracted from the null hypothesis cost, giving rise 
to the resultant cost. If the resultant cost is over 60 bits then the hypothesis is deemed 
statistically significant (over 90% chance that the hypothesis is a true correlation), while 
a resultant cost of 40-60 bits translates into a 75-90% statistical probability and for a 
































































Figure 2.3: Compounds which were included in the most  
active group of the corresponding training sets. Hypotheses shown for inhibition of the 
rat and human 5AR enzymes ((a) human type I, and (b) human type II) with the most 
active compounds 36(hI), 37(hIIB), 38(hIIA), 39(hIIA), and 40(hIIB) in the training 
sets mapped onto them.  
The wire cage spheres represent the pharmacophore features. For hydrogen bond 
acceptor (HBA) and ring aromatic features the smaller sphere represents the area where 
the feature of the molecule lies during the mapping, and the larger sphere represents the 
interaction point of the enzyme. The coloured  circles on the two dimensional chemical 
structures show where a feature has been mapped onto a compound. 
Colour coding: dark blue, negative ionisable; blue, hydrophobic aromatic; light 



































Figure 2.3 cont: Compounds which were included in the most active group of the 
corresponding training sets. Hypotheses shown for inhibition of the rat 5AR type II 
enzyme ((c) rat type II) with the most active compounds 41-45 in the training sets 
mapped onto them.  
The wire cage spheres represent the pharmacophore features. For hydrogen bond 
acceptor (HBA) and ring aromatic features the smaller sphere represents the area where 
the feature of the molecule lies during the mapping, and the larger sphere represents the 
interaction point of the enzyme. The coloured  circles on the two dimensional chemical 
structures show where a feature has been mapped onto a compound. 
Colour coding: dark blue, negative ionisable; blue, hydrophobic aromatic; light 




























    rIIB 
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2.2.1 Hypothesis Analysis 
2.2.1.1  Human type I Inhibitor Pharmacophore 
 Hypothesis generation for the human 5AR type I training set produced 9 
pharmacophores instead of the usual ten. The pharmacophore which was scored as the 
sixth highest hypothesis (hI) was chosen as the most accurate pharmacophore. The 
highest scoring hypothesis was blank and the next four were rejected on the basis that 
they contained a ‘pseudo-feature’ which meant the pharmacophores consisted of less 
than the required three features. A pseudo-feature is defined as a feature which only 
maps the most active compound and none of the other compounds in the training set. 
Although the hypothesis generation was limited to a minimum of three features the five 
top scoring hypotheses each essentially contained two features only.  
Pharmacophore hI consists of (Figure 2.3; Table 3) three features and one 
pseudo-feature: a HBA, a hydrophobic, a hydrophobic-aromatic feature and a HBA 
pseudo-feature. The pseudo-HBA feature was not considered as an accurate feature and 
will not be discussed. The distances and angles between features are shown in Table 4. 
Although the pharmacophore generation was set up for variable weights, the hI 
pharmacophore features had similar weightings of around 2. The resultant cost of the 6th 
scoring hypothesis is -14 (Table 3) and the correlation 0.72. The resultant cost is 
obviously not large enough to deem the pharmacophores statistically significant and 
therefore it was considered a qualitative and not a quantitative pharmacophore. 
 Compound 37 and the structurally different biphenyl 36 (Figure 2.3) are 
considered by CATALYST® to be among the most active compounds in the training set, 
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and they therefore heavily biased the pharmacophore generation. Figure 2.3a depicts 
the mapping of compound 37 onto hypothesis hI. 
 
 
Table 3: Summary of discussed pharmacophores, including features, resultant costs 
and feature weights for inhibition of 5-α-reductase.  
Pharmacophore 
Name 
















































2.2.1.2  Human type II Inhibitor Pharmacophore 
The training set for human 5AR type II produced two different types of 
hypotheses. The highest scoring hypothesis for each type is presented (Figure 2.3), 
these being the top scoring hypothesis (hIIA) and the 4th scoring hypothesis (hIIB). The 
fourth scoring hypothesis was chosen as the top three were the same type of hypothesis. 
The difference between the cost of the null hypothesis and the hIIA and hIIB hypotheses 
are 100 and 96 respectively (Table 3), indicating both are statistically valid. The 
configurational cost for this set of hypotheses is 16.5, thus all pharmacophore options 




Pharmacophore Distance Ranges (Å) and Angles(°) between Featuresa 
h1 HBA-H,3.4-5.4; HBA-HA, 6.2-8.2;  
H-HBA-HA,24.2°-34.2° 
hIIA HBA-NI, 9.3-11.3; HBA-RA1, 8.5-10.5; HBA-RA2, 5.5-7.5 
RA1-NI-RA2, 25.5-°35.5° 
hIIB HBA-H, 3.9-5.9; HBA-RA1, 7.0-9.0; HBA-RA2, 2.9-4.9 
RA1-H-RA2, 31.8°-41.8° 
rIIA HBA-H1, 7.6-9.6; HBA-H2, 3.3-5.3; HBA-RA, 2.8-4.8 
H1-RA-H2, 104.7°-114.7° 
rIIB HBA-HA, 6.8-8.8; HBA-NI, 7.4-9.4;HBA-H, 3.7-5.7 
HA-NI-H, 87.5°-97.5° 
Chen et al161 HBA1-H1, 2.2-2.4; HBA1-HP2, 6.1-8.1; HBA1-HBA2, 9.8-11.8; 
HBA1-H3, 10.8-12.8; H1-H2, 3.2-5.2; 
H1-HBA2, 7.2-9.2; 
H1-H3, 8.9-10.9; H2-HBA2, 3.3-5.3; H2-H3, 5.6-7.6;  
HBA2-H3, 2.3-4.3 
a: Abbreviations used for features: HBA, hydrogen bond acceptor; RA, ring aromatic; 
NI, negative ionisable; H, hydrophobic; HA, hydrophobic-aromatic. 
 
Table 4: Distances and angles of the 5AR inhibitor pharmacophores from this work and 
the pharmacophore of Chen et al. 
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Hypothesis IIA consisted of a hydrogen bond acceptor, negative ionisable group 
and two ring aromatic features (Tables 3 and 4). This pharmacophore mapped all the 
features for the most active compound of the training set. However, the other two 
compounds in the most active group of the training set mapped all but the hydrogen 
bond acceptor feature.  
 Hypothesis hIIB consisted of a hydrogen bond acceptor, hydrophobic and two 
ring aromatic features (Tables 3 and 4). While this hypothesis may be considered for 
deletion due to its high non-specific feature content (non specific features being defined 
as non polarized features) if the importance of the hydrophobic nature of 5AR inhibitors 
is considered,15 then the hypothesis should be deemed valid. Further validation of this 
hypothesis was forthcoming from the fact that all compounds that constituted the most 
active group in the training set plus the next most active compound, mapped all four 
features of the hypothesis, while all other compounds in the training set missed at least 
one feature when they were mapped, which explained their lower activities. 
A distinguishing feature between the hypotheses is the error of the training set 
compound 46 (Figure 2.4), when mapped onto the hypotheses. For hypothesis IIA, 46 
with an experimental IC50 of 9.8nM. had an error of +68, however, in the hypothesis 
hIIB 46 had an error of 5.4; this may be due to the nitro functionality mimicking the 
carboxylate ion.  Thus it was concluded that hypothesis hIIB was more appropriate for 












2.2.1.3  Rat Type II Inhibitor Pharmacophore 
The training set of the rat 5AR inhibitors was trialled with and without variable 
weights. These two trials produced similar results in terms of the cost analysis, however, 
the correlations improved from 0.8 to 0.9 with the introduction of variable weights. 
The pharmacophores produced can be categorized into one of two groups: 
pharmacophores which contain one HBA or negative ionisable feature and 
pharmacophores which contain two HBA or negative ionisable features. The top scoring 
pharmacophores of each group is presented in Figure 2.3. The pharmacophores with 
pseudo-features are not included. 
The two top scoring pharmacophores contained pseudo-features. Therefore, the 
3rd scoring hypothesis (rIIA) is presented as it was the top scoring pharmacophore with 
one HBA group (and no negative ionisable group) which does not contain a pseudo-
feature. The highest scoring pharmacophore containing a HBA and a negative ionisable 
group with no pseudo-features, is the 9th scoring pharmacophore (rIIB). 
Pharmacophore rIIA contained one HBA group, a ring aromatic feature and two 








Figure 2.4: The training set compound 46 that distinguished the two types  
                   of human 5AR type II hypotheses IIA and IIB. 
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the features are shown in Table 4. The resultant cost is 32 bits which was interpreted as 
a hypothesis of moderate statistical validity. 
The pharmacophore rIIB contained a HBA feature, a negative ionisable feature, 
a hydrophobic feature and a hydrophobic-aromatic feature also of unequal weighting 
(Table 3). The distances and angles between the features are shown in Table 4. The 
resultant cost is 30 bits which was interpreted in the same way as for rIIA. 
The resultant costs of the pharmacophores rIIA and rIIB did not reach the 60 bit 
statistical validation threshold, thus an additional statistical analysis was performed. 
This additional analysis is done by generating hypotheses with the same training set, 
however the activities were randomly mixed, and the process was repeated 8 times. 
These generations produced hypotheses with smaller resultant cost and correlation 
values than those of the hypotheses which are attributed to the true training set. This 
gives an additional statistical validation to the rIIA and rIIB hypotheses. It was also 
observed that the decline in the correlations was much more marked in the randomized 





















The isoflavonoid rat 5AR type II inhibitors used in a paper by Chen et al161 were 
mapped onto both rat type II pharmacophores. These inhibitors have larger IC50’s than 
the inhibitors found in the training set. The rat type II pharmacophores predicted these 
isoflavonoid rat 5AR type II inhibitors to be poor inhibitors, thus giving additional 
validation to the pharmacophores. 
 
2.2.1.4 Comparisons between training sets and pharmacophores of human 5AR 
type II inhibitors and previously published work  
 
 Chen et al’s recently published pharmacophore161 for inhibitors of human 5AR 
type II has points of similarity and difference between the human 5AR type II 
pharmacophores which are presented in this thesis. The major difference in the training 
sets is that Chen et al used both steroidal and non-steroidal compounds, while we have 
















Figure 2.5: The correlation trends of the rat 5AR type II non-randomised and 
randomised hypotheses. The solid line represents correlations from the 
unrandomised rat 5AR type II training set and the broken lines represent 
correlations of hypotheses generated using the randomized training sets. 
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only used non-steroidal compounds. As it is not known whether steroidal structures bind 
in the same way as non steroidal structures (and to eventually develop new inhibitors 
free of steroidal side effects), we decided to restrict our training set to non-steroidal 
compounds. The inclusion of steroidal training set molecules may bias Chen et al’s 
pharmacophore. In fact, their most active compound Finasteride 7 (IC50, 0.18nM) is an 
aza-steroidal derivative. Chen et al. also used standard parameters in the generation of 
their pharmacophore. Presumably, this included an uncertainty of three, which meant 
that only compounds with an IC50 of 1.62nM or below were included in their most 
active compound group. This criterion is only met by Finasteride 7 in their training set, 
thus giving their pharmacophore a bias toward this compound. Another difference is in 
the number of compounds used in the training set, with 46 in this study and 15 in that of 
Chen et al. This variation is reflected in the resultant cost of Chen et al.’s and our 
hypotheses (22 and ~100 respectively). The main similarity between the two training 
sets is the use of similar indole compounds 47-51 which exhibit a high degree of 



























Chen et al. presented their top scoring human 5AR type II pharmacophore, 
which consisted of two hydrogen bond acceptor (HBA) and three hydrophobic features 
(Table 3).  The main difference between this pharmacophore and our pharmacophores 
was that the last two only contained four features while the first contained five. Since 





















* Both R and S tested 
Figure 2.6: The similar compounds used in the human type II (this work) 
and Chen et al training sets. Compounds 47 and 49 are from our human 
5AR type II training set, the others are from Chen et al.161  
47 48 49 
50 51 
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pharmacophore can also be thought of as two negatively polarised features and three 
non-polar features.  
When considering the two types of pharmacophores generated from our human 
type II training set, the Chen et al. pharmacophore is most similar to the IIA 
pharmacophore, which included a HBA and a negative ionisable feature. This can also 
be thought of as two negatively polarized functionalities, therefore equating with Chen 
et al.’s HBA features. Strong similarities are evident, however, in the distance ranges 
and angles between these features in each pharmacophore, as can be seen in Table 4. 
The distances between two of Chen et al.’s hydrophobic features and their distances to 
the HBA features correlate with the distances between IIA’s ring aromatic features and 
the corresponding HBA or negative ionisable group (Table 4). 
  Pharmacophore IIA further resembles the Chen et al. hypothesis in that it 
contains two ring aromatic features and a hydrophobic region, which are three non-polar 
features, thus correlating with their three hydrophobic features.  
 
2.2.1.5  Comparisons between Human Type I and Type II Training sets and 
Pharmacophores 
There is a large degree of difference between training sets of the human 5AR 
type I and type II pharmacophores presented in this thesis, the main difference being the 
number of compounds in the training sets. This difference is reflected in the resultant 
costs of the pharmacophores (-14 and ∼100 respectively). This large variation in 
resultant costs is also a reflection of the difference in correlations between hIIA (0.88) 
and hIIB (0.86), and hI (0.73). However, a similarity between the training sets is the 
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presence of similar biphenyls 36 and 38 in the most active compound groups for each 
set.  
A large difference between the actual pharmacophores is that type I only has 
three features, plus one pseudo-feature, while type II pharmacophores contain four. 
The hI pharmacophore was more similar to pharmacophore IIB than IIA 
(overlays in Figure 2.6), with both hI and IIB having a HBA feature and no negative 
ionisable feature, while hypothesis hIIA for the type II isozyme contained both a HBA 
and a negative ionisable feature. The distances between the HBA and hydrophobic 
features in the hI and IIB pharmacophores were similar (within 0.5 Å; Figure 2.7). Also 
the distances between the HBA and hydrophobic-aromatic feature in hI were similar to 
the distances between the HBA and ring aromatic 1 in hIIB (within 0.8 Å), however this 
is not apparent in the overlay shown in Figure 2.7 due to the perspective of the figure 
(see Table 4 for actual distances). The distances between the negative ionisable feature 
and the two ring aromatic features of hIIA also are similar to the distances between the 
HBA feature and the hydrophobic and hydrophobic aromatic features in hI. Furthermore 
the angle RA1-NI-RA2 in hIIA is very similar to the angle H-HBA-HA in the hI 
pharmacophore (within 1.3°). However, the angle H-HBA-RA2 in the hIIB 





















2.2.1.6  Rat Type II and Human Type II Pharmacophore Comparison 
The training sets for these two sets of pharmacophores were quite different in 
terms of the number of compounds included (Table 2), with the human type II training 
set being much larger. This is reflected in the resultant cost, with the human 
pharmacophores having a large resultant cost (∼100) and the rat pharmacophores 
possessing a modest cost (∼32). The differences in resultant costs are not due to 
differences in the correlations of the pharmacophores, with all pharmacophores having 
correlations of about 0.9 (rIIA, 0.91; rIIB, 0.90; hIIA 0.88; hIIB, 0.86). The most active 
compounds of the training sets are generally quite different, however, they both include 









hI and hIIA 









hI and hIIB 
Figure 2.7: Overlays of the rat and human 5AR type II pharmacophores, and the  
                   human 5AR types I and II pharmacophores; see figure 2.3 for details  
                   of each pharmacophore 
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indole compounds, specifically 39 and 40 for human type II and 41, 42, 44 and 45 for 
rat type II (Figure 2.3). 
Two categories of pharmacophores were produced, one of which had two HBA 
/negative ionisable features, while the other category had only one HBA feature and no 
negative ionisable feature. The corresponding rat and human type II pharmacophores 
have been compared within these categories.  
Pharmacophores hIIA and rIIB comprised the category of pharmacophores 
which had two HBA/negative ionisable features, and they contained a HBA and a 
negative ionisable feature. Although similar overall, the distance between the negative 
ionisable group and the HBA group of rIIB is smaller than that of hIIA (Table 4), and 
there is a good overlap between these two features (Figure 2.7). Furthermore they both 
contain two additional non-polar features. For hIIA these features are ring aromatic 
features and for rIIB they are a hydrophobic feature and a hydrophobic-aromatic feature 
(Table 3). From the overlay of the two pharmacophores in Figure 2.7 it can be seen that 
the orientations of these features are quite different in the rat and human 
pharmacophores. It can also be seen that the distances between the two non-polar 
groups from the negative ionisable group in rIIB and hIIA are very similar, but the angle 
enclosed by the non-polar-negative ionisable/HBA-non-polar features is about four 
times smaller in the hIIA pharmacophore than in the rIIB pharmacophore. The two non-
polarised (ring aromatic) features in hIIA are much closer together (4.0-6.0 Å) than the 
non-polarised features in rIIB (9.1-11.1 Å). 
Pharmacophores hIIB and rIIA are the pharmacophores which comprised the 
category of rat and human 5AR type II pharmacophores containing only one HBA 
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feature. An additional similarity between these pharmacophores is that they both contain 
three non-polarized features with some similarities in orientation (Figure 2.7). The ring 
aromatic feature of rIIA and the ring aromatic feature 2 of hIIB are the same distance 
away from the HBA feature in their respective pharmacophores. The ring aromatic 
feature 1 in pharmacophore hIIB is also the same distance away from the HBA feature 
in pharmacophore rIIA, however, as can be seen in Figure 2.7, the orientations of the 
two groups are different. 
 
2.2.2 Hypothesis Assessment by Flavonoids, Indoles and Naphthalene Inhibitors 
 Additional examination to ascertain the quality of pharmacophores can be 
achieved by comparing estimated activities with real activities of non-training set 
inhibitors. 5AR pharmacophores were analysed in this manner with 5AR inhibitors that 
were published after the pharmacophores were generated. Chen et al161 identified 
isoflavonoids from an NCI database as potential 5AR inhibitors 52-59 (Figure 2.8). 
These isoflavonoids were assayed against rat 5AR type II, thereby enabling the rat type 
II pharmacophore evaluation. This was especially valuable in the current investigation 
as the development of isoflavonoid compounds was of concern within this project. Chen 
et al used indolic carboxylic acids as part of their training set which were different to 
the training set compounds in this investigation 47-48, 50 (Figure 2.6), 60-62 (Figure 
2.8). These compounds were assayed for human 5AR type II inhibition. Baston et al162 
have synthesized and evaluated 5AR activity of naphthalene carboxylic acids 63-64 
(Figure 2.8). Compound 64 was tested against human type I facilitating the examination 
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of hI. Compound 63 was assayed against human type II allowing the evaluation of the 
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Figure 2.8: Structures of 5AR inhibitor compounds used to test the 5AR 
pharmacophore. Compounds 52-59 are rat 5AR type II inhibitors. Compounds 60-63 
















 As can be seen in Table 5, the experimental rat 5AR type II activity of six (52-
55, 57, 58) of the eight isoflavonoids 54-61 are better predicted by rIIB than rIIA. 


















































































Table 5: Estimated enzyme inhibitory activities (IC50 values) of compounds 50-62 on 
various 5AR pharmacophores. 
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Therefore only rIIB will be discussed. Of all the Chen et al isoflavonoids, compounds 
52-54 are predicted worst on the rIIB pharmacophore. Notably compounds 52-54 are 
the least active of the isoflavonoid set. As the generation process of the pharmacophores 
focuses heavily on the most active training molecules, less active molecules are less 
accurately predicted. Pharmacophore rIIB generally overpredicted the activity of the 
isoflavonoids 52-59, with the exceptions of 56 and 59. Compounds 53 and 54 were the 
only compounds to be predicted to be more active than their experimental findings by 
two orders of magnitude. It is also notable that these compounds possess two bulky 
benzyloxy substituents on a phenyl moiety, where compounds 52 and 55 have smaller 
methoxy groups in place (Figure 2.8). This indicated these compounds may have steric 
issues. Compound 57 is the best predicted isoflavonoid of the set. Compound 59 is 
predicted among the least active of compounds 52-59, however it is in fact the most 
active. This is because the isoflavonoids 52-59 generally have low activity (Table 5) 
compared to the rat training set compounds (Table 2). 
 In summary, of the pharmacophores rIIA and rIIB which were generated for 
inhibitors of the rat type II enzyme, the rIIB pharmacophore predicted the activities of 
the isoflavonoid compounds 52-59 better than the rIIA pharmacophore. Pharmacophore 
rIIB generally predicted a compound to be more active than experimental findings and 
accurate prediction was not consistent throughout the isoflavonoid testing group. Some 
of these inaccuracies are suspected to be associated with inherent steric problems of the 
isoflavonoid compounds 52-54 and the fact that all isoflavonoids 52-59 were less active 
than the rat 5AR type II training set compounds. 
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 Compound 64 was mapped onto the human 5AR type I pharmacophore hI, 
giving an estimated activity in the same order of magnitude as experimental findings, 
albeit lower (Table 5). As there are no other compounds to compare this to it is not 
possible to ascertain if this difference is due to steric reasons. The fact that estimated 
and experimental IC50 values are in the same order of magnitude is a validating finding. 
 
 Compounds 47-48, 50 and 60-63 have experimental IC50 values for human 5AR 
type II ranging from 4 to 6300 nM. This 4 order of magnitude range serves as an 
excellent opportunity for the assessment of the human 5AR type II pharmacophores, 
hIIA and hIIB. The experimental activity of six (47, 48S, 46R, 61-63) of the eight 
compounds tested for human 5AR type II activity  are predicted better by the hIIB 
pharmacophore than the hIIA pharmacophore. Although hIIA has predicted the activity 
of compound 50 better than hIIB, hIIB also predicts the activity of compound 50 very 
closely (Table 5). Compound 62 was the least active compound of all tested against 
human 5AR type II. Compound 62 was also predicted by the hIIB to be the least active 
compound. It is evident for the reasons mentioned in this paragraph that the hIIB 
pharmacophore is better than the hIIA pharmacophore. This confirms the findings in 
























 The hIIB pharmacophore predicted the least active compound 60 as the least 
active of the compounds 47-48, 50 and 60-63, however it also predicted the second least 
active compound as compound 48S, which is experimentally found to be the most active 
of the set of eight. There is no strong trend in the predictions for the compounds 47-48, 
50 and 60-63 arising from their mappings on the hIIB pharmacophores. As there was a 
large range of activities in this set of compounds, the hIIB pharmacophore is suspected 
Figure 2.9: Mapping of compound 48S, the most active compound with an IC50  
        of 4nM on the hIIB pharmacophore. 
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to be of poor predictive value. Unfortunately the hIIB pharmacophore did not predict 
the IC50 of the most active compound in the set of compounds, compound 48S well. 
Compound 48S has an experimental IC50 value of 4nM, however hIIB predicted it with 
an error of 50 (where error is defined as the factor by which a predicted activity and the 
experimental activity are different). As the pharmacophore concentrated on molecules 
with a low nM activity, this is a concern. As can be seen in Figure 2.9, compound 48S 
is missing the aromatic feature of the hIIB pharmacophore. 
 
 In summary, the hIIB pharmacophore is a better pharmacophore compared to 
hIIA as it predicted training set activities better (specifically 46). The main issue with 
the hIIB pharmacophore is the mapping of compound 48S, which is the most active 
compound of the 5AR type II assessment molecules.  
 
2.2.3  Assessment of Novogen’s Isoflavonoids on 5AR Pharmacophores and 
Design of Synthetic Targets 
Assessment of other known isoflavonoids (available through Novogen) was 
essential for the design of the new target ligands as they were to be based on the 
isoflavonoid scaffold. The following compounds 30 and 32 were then mapped on the 
human based 5AR pharmacophores, and on the α1A adrenoceptor, α1B adrenoceptor 
and α1D adrenoceptor antagonist pharmacophores. Table 6 shows the predicted activities 
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Mapping the isoflavonoids onto the α1B adrenoceptor and α1D adrenoceptor 






















Figure 2.10: Mappings of phenoxodiol 32 on the human 5AR type II 






The mappings of phenoxodiol 32 on the 5AR type II pharmacophores, hIIA and 
hIIB were shown in Figure 2.10. These mappings call attention to a common feature 
missed in all mappings, this being the additional aromatic feature. This indicated that 














Figure 2.11 shows the mapping of phenoxodiol on the α1A adrenoceptor 
pharmacophore. It is evident that the positive ionisable feature is missed in these 
mappings and this calls for the addition of a protonatable nitrogen for adrenoceptor 
activity. This moiety should be carefully placed as α1A adrenoceptor specificity is 
needed over α1B and α1D activity so as to avoid unwanted side effects. 
 






2.2.4  Design of New Targets 
All considered synthetic targets were based on the phenoxodiol lead. Positions 2 
and 4 of the isoflavonoid nucleus were chosen as derivatisation centers as they were 
predicted to be more amenable to synthetic manipulation. 
Separate synthetic targets for 5AR activity and α1A adrenoceptor activity were 
designed to facilitate a larger structure-activity knowledge base for these biological 
targets. Structures which encompassed features for dual 5AR and α1A adrenoceptor 
antagonism were also designed as possible dual action compounds through combining 
moieties from the separate activities. Activities were then predicted utilizing the 
CATALYST® program for conformer searching (best search, 20 kcal/mol limit) and 
mapping onto the human 5AR and the α1 adrenoceptor pharmacophores (fast fit option). 
Resulting predicted activities were then analysed for synthetic target selection. 
From the analysis of isoflavonoid analogues mapped on the adrenoceptor 
pharmacophores a protonatable nitrogen needed to be introduced into a phenoxodiol-
like structure. Targets designed for α1A adrenoceptor binding affinity incorporated a 
protonatable nitrogen in the structure (Figure 2.12). Predicted activities are also shown 






















As can be seen in Figure 2.12 of the modelled compounds 65-70, compound 70 
is predicted to be the most active α1A adrenoceptor antagonist. Due to its synthetic 
accessibility (see Chapter 3 for more detail) it was chosen as a synthetic target. 
Compound 67 was also predicted to be active and as it was thought to be synthetically 
accessible (see Chapter 4 for more detail) it also was chosen as a synthetic target 
Evaluating the biological activity of these isoflavenes was expected to aid in the 
Compound α1A α1B α1D 
65 140 23000 1700 
66 84 8700 1500 
67 91 5600 1500 

















Figure 2.12: Prospective synthetic targets for α1A selective antagonism and 
their predicted α1 adrenoceptor binding Ki value(nM). R and S refer to the 





















































Compound hI hIIA hIIB 
71 870 680 43 
72 220 1200 80 
73 430 1200 100 
74 130 750 760 























































Figure 2.13: Prospective synthetic targets for human 5AR inhibition and their 
predicted activity (IC50 nM). R and S refer to the absolute configuration of the 
enantiomers. E and Z refer to the appropriate  double bond geometries. 
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There were three pharmacophores for 5AR generated in this study, hI and hIIA 
and hIIB, which should be taken into account during the design of inhibitors. However, 
due to the findings that hIIB was a better predictive pharmacophore than hIIA and that 
hI was not a statistically valid pharmacophore, hIIB predictions are considered more 
reliable than those from the other 5AR pharmacophores. It is for this reasons that only 
hIIB predictions were considered. 
  Figure 2.13 contains compounds 71-77 which were considered as synthetic 
targets. Pharmacophore hIIB predicts the 5AR type II activity of the lead isoflavene 
compound 32, with an IC50 of 910 nM (Table 6). Pharmacophore hIIB predicts the most 
active compound of all considered compounds to be compound 71 with a predicted IC50 
activity of 43 nM. As this was thought to be synthetically accessible it became a 
synthetic target. Compounds 74 and 75 were predicted to have similar 5AR type II IC50 
values as the lead compound 32 by the hIIB pharmacophore. However, as these 
compounds contained additional aromatic rings to the isoflavonoid core structure and 















   
 
Figure 2.14: Prospective synthetic target for a dual action anti-prostatic cancer 
derivative. The dual actions are human 5AR inhibition (IC50 nM predicted) and α1A 
adrenoceptor blockade (Ki nM predicted). 
 
As it was desired to incorporate dual action into the isoflavonoid lead 
compound, phenoxodiol 32, the synthetic target 78 incorporating both an aromatic ring 
for 5AR activity and a basic nitrogen for α1A activity was proposed. The activities for 
both biological actions are predicted to increase compared to the predicted activities of 
the lead compound 32 (Figure 2.14). Predicted α1A adrenoceptor antagonism increased 
due to the interaction of the basic nitrogen of 78 with the positive ionisable feature of 
the pharmacophore. Selective α1A adrenoceptor antagonism was predicted especially for 
the R enantiomer. The presence of the thienyl moiety increased the predicted 5AR 
activities due to its interaction with the aromatic feature. Compound 78 was thus also 
chosen (see Chapter 3 for more detail). 
 
2.3  Summary and Conclusions 
 Human 5AR type I, human 5AR type II and rat 5AR type II inhibitory 
pharmacophores were generated. The pharmacophore for the human 5AR type I 
 α1A α1B α1D hI hIIA hIIB 
76R 2.8 3800 64 2100 860 110 








isozyme did not have a satisfactory cost analysis due to a small number of compounds 
in the training set. The generation of the human 5AR type II inhibitory pharmacophore 
resulted in two distinct pharmacophores each with excellent cost analysis. The rat 5AR 
type II inhibitory pharmacophore possessed a moderate analysis. The human type II 
pharmacophores were compared with a previously published pharmacophore. 
 Lead isoflavonoids were assessed on the human-based 5AR inhibition and 
adrenoceptor antagonist pharmacophores. In order to increase predicted 5AR activities 
of the lead isoflavonoid 32 an additional aromatic interaction was required and to 
increase predicted α1A adrenoceptor antagonism a basic nitrogen was required. To this 
end the aminomethyl derivatives 67 and 70, the phenyl hydrazone 76, the thienyl 





































Chapter  3         Substitution Reactions at the 2-Position  
of Isoflavenes 
 
3.1  Introduction 
 
Soya products have been used in traditional Asian medicine for many centuries, and 
these products are known to be beneficial in the prevention of prostate cancer. 
Isoflavonoids are biologically active constituents of soya products. Isoflavonoids have 
exhibited various anti-cancer activities, including against prostate cancer. The 
isoflavonoids genistein, 4 and daidzein 5, which are contained in soya, have been shown 
to have 5-α-reducatse (5AR) inhibitory activity.49 The 5AR enzyme is involved in the 
early stages of prostate cancer.31 Novogen, an Australian pharmaceutical company, 
currently has an isoflavonoid-derived isoflavene compound, phenoxodiol 32, in clinical 






A symptom of prostate cancer is painful urination, caused by prostate enlargement 
and consequent obstruction of the urethral path. In an effort to alleviate this symptom, 
α1A adrenoceptor antagonists can be prescribed, since these antagonists result in urethral 















In the current project, investigations were targeted at increasing the effectiveness of 
the anti-prostatic cancer activity of phenoxodiol 32 derivatives. This was attempted 
through a dual action design concept which involved, firstly, increasing 5-α-reductase 
activity over that for phenoxodiol 32, thereby aiding the inhibition of prostate cancer 
development; and, secondly, through α1A adrenoceptor antagonism alleviating the 
urological symptoms of prostate cancer. While this dual action concept had not been 
applied previously to isoflavonoids, some work by Sato et al.163 had shown proof the 
general concept with indole-based derivatives. In order to aid the design of synthetic 
targets, pharmacophores were generated for human 5AR type I and human 5AR type II 
inhibitors. Pharmacophores for α1A antagonism generated by Bremner et al.145 were 
utilized for the α1A antagonist target design. Computational pharmacophore studies 
were carried out using the program CATALYST® version 4.5 from Accelrys (see 
Chapter 2 for more detail).  
Conformational models of feasible 2-substituted isoflavonoid derivatives were 
generated as described in Chapter 2. Overlays of these derivatives onto the 
pharmacophores were performed and their biological activities estimated. These studies 
produced hypotheses indicating that an additional aromatic feature added to 
phenoxodiol would increase 5-α-reductase activity and a basic nitrogen would introduce 
α1A adrenoceptor antagonism. 
The pyran ring contains a number of synthetically viable derivatisation centres, but 
the 2-position of the pyran ring was the primary focus of this work to introduce a basic 
nitrogen (and α1A adrenoceptor antagonism) in the phenoxodiol isoflavene framework.  
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The main 2-substitiuted phenoxodiol target derivative indicated through the 
computational studies to increase α1A adrenoceptor activity was an (R)-2-substituted 










Figure 3.1: The amine synthetic target 70R overlayed onto the α1A pharmacophore. 
 
 
 The presence of the basic amine group in compound 70 facilitates a mapping of 
the positive ionisable feature in the α1A adrenoceptor pharmacophore (Figure 3.1) 
which is not possible in phenoxodiol. This should then introduce selective α1A 
adrenoceptor antagonism, alleviating some of the pain associated with urination during 




















Figure 3.2: Overlay of the 2S-thiazoyl synthetic target 77S on the hIIA 
pharmacophore. 
  
The 2-thiazolyl isoflavene 77 was predicted to have approximately the same 
5AR type II inhibitory activity as phenoxodiol 32 (Figure 3.2), by the hIIB 
pharmacophore, however, it was predicted to be more active then 32 by the hIIA 
pharmacophore. The addition of the 2-thiazole ring in compound 77 increased the 
predicted activity (IC50) from 2400nM to 880nM and 1200nM for the R and S 
stereoisomers respectively. However, as this compound only possesses a weakly basic 
nitrogen, binding to the α1A adrenoceptor was predicted to be weak. It was noted in the 
overlay of 77 on the α1A pharmacophore in the modelling studies that there was no 








As 2-substituted isoflavene derivatives such as 70 and 77 were desired for testing 
against prostate cancer, approaches to the synthesis of 2-substituted isoflavene (2-aryl-
2H-1-benzopyran) derivatives were then investigated.  
 
3.2 General Synthetic Approaches 
 
There are various synthetic routes to 2-substituted 2H-1-benzopyrans. Most 
commonly, 2-substituted compounds are synthesized with a putative 2-substituent 
already in place prior to pyran ring construction (Schemes 3.1-3.3, Schemes 3.5-3.6). 
This substituent may have a role as a good leaving group or be the final substituent. The 
most common cyclisation procedures for the preparations of the pyran ring involve O1-
C2 bond formation or C3-C4 bond formation. These general approaches may also be 
used to access 2-substituted analogues and details of these approaches are given in the 
following sub-sections. 
 
3.2.1 2-Substituted-2H-Benzopyran Synthesis via Ring Closure through O1-C2 
Bond Formation 
A recent synthesis of a 2-substituted benzopyran 80 was reported by Parker et 
al164.  They used an electrocyclic ring closure synthesis for the benzopyrans, with the 
vinyl quinone 79 as a starting material (Scheme 3.1). The vinyl quinone 79 was 
converted into its enol form 79a in situ, and subsequently was converted to the 
benzopyran 80 by a thermal electrocyclic ring closure. This was done by heating 79 at 
reflux in toluene with hexamethylphosphoric triamide for 2 hours, with 80 being 
 81 
obtained in 86% yield. It was found that the reaction could be accelerated (reaction time 
45 minutes) by the addition of the Lewis acid FeCl3, however this reduced the yield of 
80 to 76%. 
 
 
        79                                          79a                                         80 
Scheme 3.1: Electrocyclic cyclisation of the enol form of a vinyl quinone through O1-
C2 bond formation resulting in a 2-substituted benzopyran.164 
 
 
A common route to 2-substituted isoflavenes is through a carbonyl group 
addition and ring opening reaction with coumarins. One such synthesis of 2-substituted 
isoflavenes starting from the coumarin 81 involved a Grignard reaction to give the 
dihydroxy ring opened product 82 (Scheme 3.2).  Compound 82 was then cyclised by 





           81                                  82                                   83 
a: CH3MgBr  b: H+/H2O 
 































Synthesis of the 2-substituted benzopyran 86 starting from the coumarin 84, 
proceeded initially by a reductive ring opening reaction with di-
isobutylaluminiumhydride (DIBAL-H) (Scheme 3.3). This produced the highly reactive 
aldehyde intermediate 85, which was stabilized through aluminium co-ordination with 
the phenolic oxygen. Subsequent in situ treatment with the Grignard reagent, methyl 
magnesium bromide, and acid catalysed cyclisation then gave the 2-methyl substituted 





                   84                                     85                                    86 
Scheme 3.3: Synthetic route to a 2-substituted isoflavene utilizing coumarin as a   
                      starting material and proceeding via a ring opened intermediate.167 
 
A variation on the synthesis shown in Scheme 3.3 was developed by Grese et 
al167  and led to the synthesis of 2-aryloxy derivatised isoflavenes for example 89 
(Scheme 3.4). They used DIBAL-H reduction for the generation of the 2-
hydroxyisoflavene 88 from the coumarin 87 in 83% yield. The 2-hydroxy group was 
then converted to the phenoxy group by heating with phenol. The resulting aryloxy 
isoflavene 89 could then be used for further derivatisation though reaction with 
Grignard reagents. This reaction involves the displacement of the phenoxy group in the 
2-position by the R group from the Grignard reagent and is thought to proceed through 
the magnesium co-ordinated intermediate 89a.  











        87                                            88                                    89 
 
         
  
 
       
 
R=CH3, CH3CH2, iPr, Ph, 4-FPh, 4-anisyl, 1-naphyl, 2-thienyl, vinyl 
 
Scheme 3.4: Synthetic route to 2-substituted isoflavenes utilizing coumarin as a 
            starting material. 
 
 
A solvent free, microwave reaction has been developed for the ring construction 
of a 2-amino substituted isoflavene (Scheme 3.5)168. The initial step in this synthesis 
involved reaction of a secondary amine 92 with the aldehyde 91 to form the enamine 93 
in solvent free conditions and assisted solely by microwave irradiation. The addition of 
salicaldehyde 94 and ammonium acetate as a catalyst then formed the isoflavan 96 via 
the intermediate 95. The key step of this reaction series is the isomerisation of 95 
involving ring closure through O1-C2 bond formation to give the isoflavan 96. Under 



















X 90 89a 
 84 
for the synthetic pathway was 80% using microwave irradiation, while with 
conventional heating this pathway yielded the desired isoflavene 97 in only 55% yield.  
 
 
                              91                        92                              93 
MW=microwave                                                     
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                                96                                                   97 
Scheme 3.5: A microwave assisted synthetic route to a 2-substituted isoflavene. 168 
 
3.2.2 2-Substituted 2H-1-Benzopyran Synthesis through Ring Closure by C3-C4 
Bond Formation  
Doodeman et al169 have accessed the 2-benzyloxy substituted benzopyran 102 
by way of C3-C4 formation (Scheme 3.6) through a ring-closing metathesis reaction. 
This synthesis involved the generation of the allylic acetal 100 from a vinylic phenol 98 
and benzyloxy-1,2-propadiene 99 through an oxypalladation reaction. Compound 100 




















benzyloxy substituted benzopyran 102. Using the catalyst 101a the metathesis occurred 
in a 77% yield at room temperature in DCM, however this reaction required a reaction 
time of 4 hours due to problems encountered with catalyst decomposition. This 
decomposition problem was overcome by using an alternative ruthenium-based catalyst, 
101b, which reduced the reaction time to three hours and gave a similar yield (78%), 
although heating to 80ºC in toluene was required. Doodeman et al169 utilized the 
benzyloxy substituent as a good leaving group to form a benzopyrylium salt which 
could then be converted to 2-substituted-2H-1-benzopyran derivatives by nucleophilic 
addition (see section 3.2.3). 
 
 
                98              99                            100                                        102 
 
dppp: 1,3-Bis(diphenylphosphino)propane     
Scheme 3.6: Synthesis of a 2-benzyloxy-2H-1-benzopyran through C3-C4 bond 
formation by ring closing metathesis. 
 
 
3.2.3 Synthesis of 2-Substituted Isoflavenes through Benzopyrylium-Based 
Approaches 
The isoflavylium salt is a versatile synthetic intermediate as it may undergo 
various reactions, including coumarin formation and addition reactions.170 
Derivatisation at the 2-position has been achieved through nucleophilic addition to the 
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An early synthesis of an unsubstituted isoflavylium salt was through an acid 
catalysed condensation reaction of a 2-phenylethyl acetal 103 and salicaldehyde 94171 
(Scheme 3.7). Initially this involves ethanol loss from the phenyl ethyl acetal forming 
the 2-ethoxyphenylethene 104. The pyran ring in intermediate 105 is then formed by 
acid catalysed addition of 94 to 104. Isoflavylium ion 106 then results from elimination 
of ethanol and water from 105. 
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94                      104                              105                                     106 
 




Doodeman et al169 have synthesised the 2-substituted benzopyrans 108 via 
nucleophilic additions to the benzopyrylium ion 107 (Scheme 3.8). The generation of 
107 was achieved by use of a Lewis acid (BF3-etherate) catalysed dissociation of the 
benzyloxy leaving group in 102. Subsequent nucleophilic addition using TMS- or 





















                           102                                107                                   108 
Compound Number Reagent     (NR) R Yield 
(%) 
108a TMS allyl Allyl 100 
108b TMS cyanide CN 75 
108c Bu3Sn propargyl Propargyl 35 
108d Ph-C(=CH2)OTMS phenacetyl 63 
 
Scheme 3.8: Lewis acid dissociation of good leaving group to generate the 




An isoflavylium salt intermediate 110 was also accessed from the a 2-N-
morpholino substituted isoflavene 109 (Scheme 3.9). The morpholine serves as a good 
leaving group and is removed by reaction with trityl perchlorate. The anion associated 
with the salt is the non-nucleophilic perchlorate, which is commonly used as the counter 




                       109                                                    110 
Scheme 3.9: Isoflavylium salt formation from an isoflavene with a nitrogen based 
leaving group at the 2-position. 172 
 
Trityl perchlorate has also been used to abstract a hydride from 4H-pyrene 111 












providing the benzopyrylium salt 114174 (Scheme 3.10). However this reagent has not, 
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         113   114 
Scheme 3.10: Pyrylium173 and benzopyrylium174 formation via hydride abstraction, 
through the use of trityl perchlorate. 
 
 
3.2.4 Synthetic Proposal for the 2-Substituted Isoflavene Derivatives 
In our study, we wished to adopt an approach to the target 2-substituted 
isoflavenes based on preformed 2-unsubstituted isoflavene derivatives available from 
Novogen and then to introduce a variety of 2-substituents. A readily accessible route to 
the 2-substituted isoflavonoid derivatives 115 and 116 utilizing preformed benzopyrans 
was thus proposed via the isoflavylium salts 117 (Scheme 3.11). The addition of a 
nucleophile would then produce the 2-substituted product 116. Previous methods of 
acquiring 2-substituted isoflavonoid products from a preformed pyran ring through an 
isoflavylium salt included a good leaving group, such as a morpholine (Scheme 3.9) in 
the 2-position of the starting isoflavene. As the isoflavene starting material available to 














no prior leaving group was needed in the 2-position. Therefore we required a reagent 
which would oxidise the pyran ring through hydride abstraction from the 2-position of 
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       118a)  P=Ac 
       118b) P=t-BDMS 
 119 
 
Scheme 3.11: Retrosynthetic route to 2-substituted phenoxodiol derivatives. 
 
The phenolic hydroxyls of phenoxodiol 32 must be protected for the synthesis of 
the isoflavylium salt 117, because of the nucleophilic properties of the hydroxyl group. 



















An additional precursor to compound 118a which was readily available from 
Novogen was the hydroxy compound 119 (P=Ac), which could be converted to the 
former compound by dehydration. 
 
3.3  Results and Discussion 
3.3.1  Synthesis of Phenol-Protected Isoflavenes 
The protection of the phenolic hydroxyls was essential for a successful synthetic 
route involving an isoflavylium salt. The phenolic hydroxyl protecting groups chosen 
for trial were the acetate group and the tert-butyldimethylsilyl group (t-BDMS group). 
The acetate group was also considered as phenoxodiol was supplied in the acetate 
protected form at the time. The t-BDMS group was chosen for trial as this group also 
proved useful for reactions in the 4-position (see Chapter 4) and it was hoped to later 
synthesize 2,4-disubstituted isoflavene target compounds. 
There were two isoflavonoid precursors obtained from Novogen leading to the 
protected phenoxodiol analogues. The first was the racemic 4-hydroxy isoflavan 
analogue 119 and the other was phenoxodiol 32 itself.  The 4-hydroxy isoflavan 119 
was supplied as the diacetoxy protected form and was used to access the diacetoxy 
protected derivative 118a of phenoxodiol.  
Dehydration of the hydroxy compound 119 to the diacetoxy phenoxodiol 
derivative 118a (Scheme 3.11) could be achieved by various reagents. A strong driving 
force for this reaction is the creation of conjugation between the two aromatic rings. 
There were numerous reagents available for such dehydration reactions. Two reagents 
were trialled for the dehydration step (Scheme 3.12), phosphorus pentoxide (P2O5) and 
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anhydrous copper sulfate (CuSO4). The former has long been a versatile dehydrating 
reagent for the formation of double bonds for example in the preparation of aryl 
substituted conjugated esters.175 Anhydrous CuSO4 has been used previously by various 
groups for the dehydration of alcohols.176 The copper ion of copper sulfate typically 
coordinates with five water molecules in a hydrated environment. Anhydrous copper 
sulfate strongly coordinates to hydroxyl groups, thus increasing their leaving group 
ability. Copper sulfate absorbed on silica gel has also been used for dehydration 
reactions and the rate of these heterogeneous reactions are increased through the 
increase in surface area.177  
Treatment of compound 119 (P=Ac) with P2O5 gave the diacetoxy compound 
118a as a cream coloured powder in 82% yield (Scheme 3.12). 1H NMR spectroscopy 
provided evidence of double bond formation by the conversion of the multiplets  
between 4.20 ppm and 4.49 ppm assigned to the H-2 protons 119 (P=Ac) to a singlet at 
5.14 ppm. Additional 1H-NMR evidence for compound 118a was the appearance of a 
singlet at 6.75 ppm which was assigned to the H-4 proton. MS (CI+) provided further 
















Scheme 3.12: Preparation of diacetoxy protected phenoxodiol from 119. 
 
Finely ground anhydrous CuSO4 was also found to be a successful reagent for 
the dehydration reaction producing the diacetoxy product 118a (Scheme 3.12). The 
product was obtained in 97% yield as a white powder. Although hydrated CuSO4 is 
blue, the gray colour of the reaction mixture did not change during the reaction as a 
large excess of anhydrous CuSO4 was used.  There were advantages in using anhydrous 
CuSO4 over P2O5. Besides the fact that the anhydrous CuSO4 method afforded the 
product in a higher yield, it also did not produce emulsions during the reaction workup 
procedures; this was a problem with the P2O5 based reactions. Additionally, the reaction 
with anhydrous CuSO4 took a shorter time, although it did require heating (Scheme 
3.12).  
The acetate 118a could also be obtained from phenoxodiol 32 through 
acetylation with pyridine and acetic anhydride (Scheme 3.13). Evidence for product 
formation was obtained from the 1H-NMR and MS spectroscopic data. The 1H-NMR 
spectrum showed two singlet peaks at 2.29 ppm and 2.31 ppm, each with an integration 
(i) Solvent Temperature Time Yield 
P2O5 DCM rt 2 h 82% 














of three. These peaks were assigned to the two acetate methyl groups. The CI-MS also 
showed only one peak at m/z 325, corresponding to the M+1 peak for 118a. 
Protection of the phenolic hydroxyls with the t-BDMS group was achieved by 
stirring 32 with imidazole and t-butyldimethylsilyl chloride at room temperature for 32 
hours (Scheme 3.13). This reaction is likely to proceed through a N- t-butyldimethylsilyl 
imidazole intermediate.178 This reaction must be performed under rigorously anhydrous 
conditions, and this was enabled through the use of powdered 3Å molecular sieves.  
Evidence for the formation of the product 118b was obtained from the 1H-NMR and MS 
data. The 1H-NMR spectrum showed singlet peaks at 0.78 and 0.77 ppm which could be 
ascribed to the t-butyl groups of the t-BDMS group. There was also a singlet at 0.00 
ppm due to the methyl groups in the silyl substituent of the t-BDMS group. The 
presence of an M+1 peak at m/z 469 in the CI-MS was consistent with the formation of 
the t-BDMS product.  
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3.3.2 Synthesis of a Boc Protected TMS Amine. 
In order to introduce aminomethyl functionality in the isoflavenes at the 2-
position by nucleophilic attack, the use of a protected amino trimethylsilyl derivative 
was considered. Trimethylsilylmethylamine 120a was commercially available and it 
was necessary to protect the amine group so that only attack on the isoflavylium salt by 
the methylene group would occur. Protection of the amine by t-butyloxycarbonyl (boc) 
groups was then investigated. 
In this study, boc anhydride was used to synthesise the boc protected amine. 
This method also required a base to deprotonate the primary amine 120a (and carbamate 
intermediate 121a and the benzyl amine 121b to enable effective nucleophilic attack. 


































Stirring of the TMS aminomethyl compound 120a, boc anhydride and DMAP at 
room temperature for 48 hours gave the mono-boc protected carbamate 121a in 72% 
yield.  Evidence that the mono carbamate was formed was that the peak attributed to the 
t-butyl group integrated for 9 protons in the 1H-NMR spectrum relative to the 
integration for the methylene protons and the signals for the other groups. Additional 
structural evidence arising from the 1H-NMR spectrum was the doublet signal at 2.70 
ppm corresponding to the methylene protons, with coupling to the nitrogen proton. The 
1H-NMR spectrum exhibited a broad singlet at 3.10 ppm ascribed to the NH group. 
Additional confirmation of the mono-boc product came from the ES+MS with an (M+1) 
peak at m/z 204.2. 
Attempts to produce the bis-boc compound by stirring the mono-boc product 
121a at room temperature over four days gave some bis-boc product 122a, however 
only in 20% yield. More severe reaction conditions were then investigated. 
Heating 121a, boc anhydride and DMAP at reflux in THF for 48 hours produced 
the bis-boc compound 122a in 84% yield. Also, heating the primary amine 120a with 
the anhydride and DMAP for 48 hours gave 122a in 92% yield. Evidence for the bis-
boc protected product 122a came from the 1H-NMR spectrum which showed a singlet at 
1.45 ppm and integrating for 18 protons which was consistent with the presence of two 
equivalent t-butyl groups. Also the methylene protons could be assigned to a singlet at 
3.10 ppm. The shift downfield of the methylene protons relative to the corresponding 
signal in 121a is supportive of a further carbamate addition. An M+1 peak at m/z 304 
was apparent in the CI-MS spectrum of 122a. The common t-butyl group loss also 
occurred in this spectrum, with a fragment ion at m/z 248.  
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The reaction between the benzyl boc amine 121b, boc anhydride and DMAP 
afforded the boc protected amine 122b in 75% yield. The peak at 1.42 ppm in the 1H-
NMR spectrum integrated for 9 protons and was ascribed to the tert-butyl protons. In 
the 13C-NMR spectrum the peak at 149.8 ppm was attributed to the carbamate carbonyl. 
The tertiary carbon of the tert-butyl group was ascribed to the peak at 79.3 ppm and the 
tert-butyl methyl carbons were credited to the peak at 28.5 ppm. Further confirmation 
for the formation of 122b came from the mass spectral data where the molecular ion 
peak appeared at m/z 294. 
 













The use of isoflavylium salts as a synthetic pathway leading to 2-substituted 
chromenes is well documented. This study explored the potential of both the diacetate 
118a and t-BDMS 118b protected compounds as precursors of the stable isoflavylium 
salts 117 (Scheme 3.15). The source of the isoflavylium ion stability is aromaticity, 
which also provides the driving force for formation. To our knowledge, all previously 








Scheme 3.15: Retrosynthetic scheme of 2-substitution of phenoxodiol type compounds. 
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a good leaving group in the 2-position of the isoflavylium precursor.169 An example of 
one such good leaving group is the morpholine group (Scheme 3.9). The leaving group 
is eliminated from the pyran ring to form the salt. However, to form the isoflavylium 
salt from the protected compounds 118a or 118b, a hydride must be abstracted from the 
2-position, which is not considered to be a good leaving group. To our knowledge this 
had not been attempted before on an isoflavonoid system.  
 
The isoflavylium salt 117 is readily susceptible to addition by nucleophiles at the 2-
position and also, potentially, at the 4-position. However, nucleophilic addition occurs 
selectively at the 2-position of the isoflavylium ion rather than the 4-position. There are 
three reasons for this: firstly, the 2-position is more electrophilic than the 4-position; 
secondly the 4 position is more sterically hindered; and thirdly, substitution at the 4-
position would break conjugation between the two aromatic rings. The conjugation is 
broken during 4-position addition as it would cause double bond migration to the 2-3 
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Scheme 3.16: Products of 2 and 4 nucleophilic additions to the isoflavylium cation. 
116 
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Similar nucleophilic attack in benzopyrylium salts, such as 124, has been observed 
where the 2-position is preferred over the 4-position; steric factors may also favour 
attack at the 2-position in this case. However, it is observed that the usual position for 
nucleophilic attack is at the 2 position (Scheme 3.17)169. It should however be noted that 
methanol addition to the 3-carboxyl benzopyrylium salt, 126174 gave the 4-methoxy 
product 127 and not the 2-substituted product (Scheme 3.17). This is thought to be due 
to the electron withdrawing ester substituent at the 3 position of the benzopyran making 
the 4-position more electrophilic. 
 
                                                                                                                     
 
 
                                                                                                               
 
 
Scheme 3.17:Position of nucleophilic attack of the benzopyryliums 124169 and 126 174. 
 
3.3.3.1 Optimisation of Isoflavylium Salt Formation 
The formation of the isoflavylium salts 117 was a key step in the synthesis of the 
2-substituted derivatives, and it required extremely anhydrous conditions to prevent 
nucleophilic attack by water and formation of the 2-hydroxy compounds 128 (Scheme 
3.18). For this reason freshly distilled anhydrous solvents and powdered 3Å molecular 




















117                128 
Scheme 3.18: Addition of water to the isoflavylium 117. 
 
Trityl (triphenyl carbenium) salts have been used previously to form the 
isoflavylium system where a good leaving group was present in the 2-position.172 We 
required the trityl reagent to abstract a hydride from isoflavene 118. Trityl salt reagents 
have been used previously to abstract a hydride to form pyrylium 112 and 
benzopyrylium 114 salts (Scheme 3.10). Trityl salts contain a highly electrophilic 
positively charged carbon. It is this carbon which abstracts the hydride ion from the 
pyran ring forming the pyrylium derivative and triphenylmethane 129. A notable 
characteristic of benzopyrylium salts is that they are usually coloured red, orange or 

























Various trityl salts were trialled as reagents for the formation of the isoflavylium 
salts 117. Non-nucleophilic counter anions were necessary so as to avoid their addition 
to the isoflavylium salt. Previous studies using trityl salts have most commonly used the 
perchlorate anion, but such salts are potentially explosive, and they were not used in the 
current work. The PF6-, SnCl5- and BF4- salts were trialled on the diacetoxy protected 
compound 118a. The trityl PF6- salt was trialled on bis-t-BDMS protected phenoxodiol 
118b. (Table 7, Scheme 3.19) 
In order to gauge the most suitable salt for the project syntheses, model reactions 






















      118      117      116a 
Protecting Group (P) Counter Anion (X-) Yield (%) of 116a 
Ac BF4- 43% 
Ac SnCl5- 76% 
Ac PF6- 80% 
t-BDMS PF6- 0% 
 
Isoflavylium salt formation proved to be a quick reaction as starting material 
disappeared within 30 minutes (as determined by TLC analysis) for all the reactions 
mentioned in Table 7. The use of the SnCl5- and the PF6- trityl salts proved to be the 
better of the trialled salts and were equally successful with good percentage yields of 
116a of 76% and 80 % respectively where the acetate group was in the starting material. 
As tin has worse potential environmental and health effects and the PF6- salt produced a 
slightly better percentage yield, the PF6- salt was chosen for the synthesis of other 2-
substituted phenoxodiol derivatives over the SnCl5- salt. 
The use of the BF4- trityl salt with the diacetoxy compound 118a only gave 116a 
in moderate yield.  This was possibly due to degradation of the BF4- ion to BF3 and F-. 
This is a problem because BF3 attacks acetate protected phenolic groups and deprotects 
Table 7: Yields of 2-nitrile substitution reactions trialing various trityl salts and 














them thereby allowing them to attack unreacted isoflavylium salts. This would lead to a 
lower percentage yield. Also the F- ion could add to the 2-position of 116a. 
The t-BDMS group was not suitable as a protecting group in the presence of the 
trityl PF6- salt and no nitrile product could be detected. This may be because the PF6- ion 
acted as a source of fluoride to remove the t-BDMS groups, and resulting in subsequent 
intermolecular nucleophilic attack by phenoxide ion on the isoflavylium ion moiety 
leading to polymeric products.  
 
3.3.3.2 Synthesis of 2-Substituted Derivatives 
The 2-substituted isoflavene derivatives 116a-d were synthesized from 118a 
using the trityl hexafluorophosphate reagent forming the isoflavylium salt intermediate 
117, followed by nucleophilic addition. Nucleophiles investigated included trimethyl 
silyl (TMS) derivatives, a tributyl tin ((Bu)3Sn) derivative, alcohols and amines. Table 8 















  118a   117       116 










TMS-CN a CN 80 6.01 64.3 6.97 
 b  78 6.44 74.7 6.89 
TMS-acetylene c ethynyl 7 6.19 91.7 6.91 
TMS-CH2N(BOC)2 d CH2NHBOC 32 5.15,  72.4 6.91 
TMS-
CH2NbenzylBOC 
e - 0 - - - 
(Bu)3Sn allyl f allyl 68 5.34 75.6 6.71 
HOCH3 g OCH3 63 5.85 98.3 6.98 
HOCH2CH3 h OCH2CH3 46 5.98 64.1 6.98 
HOCH2CH2CH2Br i OCH2CH2CH2Br 66 6.00 97.5 7.01 
 118a H - 5.14 67.4 6.75 
 
 
The nitrile 116a was produced in 80% yield. 1H NMR spectroscopy showed the 
peak representing the H-2 proton had shifted downfield from 5.14 ppm in the diacetate 
118a to 6.01 ppm in the product 116a and the integration of the signal only corresponds 
to 1 proton. Also a characteristic downfield shift of the peak ascribed to the H-4 proton 
to 6.97 ppm was observed in the 1H-NMR spectrum, relative to the chemical shift of the 
corresponding peak (5.14 ppm) in the 2-unsubstituted isoflavene 118. Attempts at 
obtaining an infra red spectrum were made, however a reasonable spectrum was not 
obtained. Further confirmation beyond the 1H-NMR spectrum was needed in order to 


















The 13C-NMR spectrum of 116a revealed eight quaternary carbon signals, 
corresponding to the number of such carbons expected in the nitrile product. The peak 
at 116.0 ppm was assigned to the nitrile carbon. The CI mass spectrum showed a small 
M+ peak at m/z 349 (8%) which substantiates nitrile addition. The base peak of the CI 
mass spectrum was at m/z 323 (M+-CN) corresponding to the isoflavylium ion 117. The 
isoflavylium ion is generated in the mass spectrometer during the ionization process as 
this ion is stabilized by the aromatization of the pyran ring. Also elemental 
microanalytical data was consistent with the formula of 116a. The ES+ MS for 116a 
exhibited only one peak at m/z 367 corresponding to the desired product with the 
addition of water, indicating possibly the formation of the corresponding amide. This 
product was likely to have been formed in the mass spectrometer as an aqueous solution 
was used to introduce the sample. 
  
The thiazole derivative 116b was produced in 78% yield. Evidence for the 
addition came from the ES+ MS showing the molecular ion at m/z 407.8. Additionally 
the 1H NMR spectrum showed a singlet at 6.44 ppm which integrated for 1 proton and 
was attributed to the H-2 proton. The shift of the H-2 proton downfield relative to the 
diacetate 118 was expected in the thiazole compound 116b as the thiazole substituent 
introduces an additional aromatic environment for the proton. The 13C-NMR spectrum 
also exhibited evidence for thiazole addition, through at 169.3 ppm, 143.3 ppm and 
121.1 ppm which could be attributed to the C1”, C4” and C3” thiazole carbons 
respectively. These chemical shifts are in accordance with literature values for the 13C-
NMR spectrum of thiazole.180 
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The ethynyl compound 116c was produced in 7% yield. This product was only 
seen when the reaction was stirred at room temperature for an hour. Elemental 
microanalysis data concurred with the formation of the ethynyl derivative 116c. Further 
evidence of ethynyl addition was provided by the 1H-NMR spectrum as the H-2 proton 
was represented by a one-proton doublet at 6.19 ppm which had characteristically 
shifted downfield relative to the corresponding H-2 proton peak at 5.14 ppm in 118a; a 
doublet signal at 3.71 ppm was attributed to the ethynyl proton. The peak corresponding 
to the H-2 proton is represented as a doublet and this is due to long range coupling with 
the ethynyl proton (Figure 3.3). Long range coupling, with a coupling constant typically 
of 2 Hz for the ethynyl proton has been reported previously in the literature,181,182 
however the long range coupling in 116c was surprisingly found to be 7 Hz; the gCOSY 










Figure 3.3: Long range coupling between the H-2 proton and the ethynyl proton of 












Another product formed in the reaction of 117 with TMS acetylene was the 
dimeric compound 130. This was thought to arise via anion formation from the terminal 
alkyne mediated by fluoride ion (from PF6-) as a base then attack on  another 
isoflavylium group producing the dimeric compound 130 (Scheme 3.20). Evidence for 
this mechanism came from the fact that the ethynyl product 116c was only produced 
when the reaction mixture was stirred for 1 hour. When the reaction was extended to 12 
hours only the dimeric product was isolated. The CI-MS and ES-MS spectra did not 
provide firm evidence for 130, as each only exhibited a peak at m/z 323, corresponding 
to the isoflavylium ion formed after elimination of the 2-substituent. The 1H-NMR 
spectrum of 130 contained only the appropriate aromatic, H-2 and H-4 peaks and 
notably no other peaks corresponding to an ethynyl proton. Evidence for the synthesis 
of this dimeric compound came from the 13C-NMR spectrum as all carbons in the 
isoflavonoid skeleton were accounted for except for an additional peak at 92.5 ppm, 
which corresponded to an ethynyl carbon. Elemental microanalysis data was also 
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In an effort towards the synthesis of the target 2-aminomethyl isoflavene 70 the 
bis-protected TMS methylamine 122 was reacted with the isoflavylium salt 117. 
However, only the mono-boc protected amino methyl product 116d was obtained in 
32% yield. This deprotection demonstrates that bis-boc protected amines are not stable 
in the presence of good electrophiles. The ES+-MS spectrum exhibited the M+ ion at m/z 
453 (33.3%) and a fragment ion corresponding to the loss of the t-butyl group at m/z 
396 (9%), loss of the t-butyloxy group with a peak at m/z 379 (25%), and the loss of a 
boc group with a peak at m/z 338 (100%), and the isoflavylium ion at m/z 323 (14.5%). 
Integration data for the t-butyl protons (2.16 ppm) from the 1H-NMR spectrum 
supported the production of the mono-boc protected amine 116d. The signal ascribed to 
the methylene group protons appeared as a doublet of doublets at 2.59 ppm, resulting 
from coupling with the H-2 proton and their diastereotopic nature. The proton on the 
nitrogen was ascribed to 3 different peaks (integrating for 1 proton in total) in the 1H-
NMR spectrum, reflecting different rotamers and the diastereotopic nature of the 2-
substituent. The H-2 proton was also assigned to a doublet of doublet of doublets peak 
at 5.15 ppm. This multiplicity can be explained by the coupling with the diastereotopic 
methylene protons. The 13C-NMR spectrum confirmed the addition of the boc protected 
methyl amine by the presence of peaks ascribed to the boc carbonyl, the t-butyl 
quaternary carbon, the methylene carbon and the t-butyl methyl groups at 155.2 ppm, 
75.5 ppm, 43.1 ppm and 30.7 ppm respectively. 
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The boc and benzyl protected amino methyl compound 116e was not 
synthesized successfully. Chromatography of the crude material gave no pure products. 
The only material was baseline material which was assumed to be polymeric. This 
reaction was thought to be unsuccessful due to hydride abstraction of the benzylic 
carbon of the nucleophile. This would provide an opportunity for further reactions of the 
isoflavylium ion. 
 
The 2-allyl derivative 116f was produced in 68% yield. This yield was 
acceptable for the purposes of this study, however this yield may be improved by the 
use of molecular sieves.  Allyl addition to the isoflavylium salt was established through 
low resolution and high resolution CI-MS by observation of the M+1 at m/z 365 (46% 
relative intensity). The base peak of the CI-MS spectrum was the isoflavylium ion at 
m/z 323. However, the molecular ion peak was not seen at all in the CI-MS spectrum of 
the 2-methoxy and 2-ethoxy derivatives 116g and 116h respectively and only just 
detected in the nitrile and bromopropoxy derivatives 116a and 116i respectively.  
 
The methoxy compound 116g was produced in 63% yield. Methoxy addition 
was established through elemental microanalysis. The CI+-MS spectrum only contained 
a peak at m/z 323 which is due to the isoflavylium ion fragment. The isoflavylium 
fragment is generated through in situ elimination of the methoxy group in the mass 
spectrometer. The 1H-NMR and 13C-NMR spectra also contained evidence for the 
methoxy compound 116g with the peaks at 3.58 ppm and 55.5 ppm assigned to the 
methoxy protons and methoxy carbon respectively. 
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The ethoxy compound 116h was produced in 46% yield. Elemental 
microanalysis was consistent with the molecular formula for 116h. The CI-MS and ES-
MS spectra only contained the m/z 323 peak for the isoflavylium fragment, through 
ready ion loss of the ethoxy group. Vul’fson et al.183 have also reported the loss of an 
ethoxy group in the mass spectrum substituted from a dihydropyran. 
  In the 1H-NMR and 13C-NMR spectra of 116a diagnostic triplet signal at 2.30 
ppm was ascribed to the methyl protons of the ethoxy group. The diastereotopic 
methylene protons of the ethoxy group gave two sets of multiplet signals in the 1H-
NMR spectrum, at 4.00 ppm and 3.78 ppm, which integrated for one proton each. A 
similar signal pattern was observed for the ethoxy group methylene protons  in the 1H-
NMR spectrum of the 2-ethoxybenzpyrene 131, where the methylene protons were 
represented by signals at 3.50 ppm and 3.75 ppm in an ABX3 pattern (Figure 3.4).184 
               OCH2CH3 
 
 
      131 
  
Figure 3.4: Section of the NMR spectrum of the 2-ethoxypyrene 131184, containing 
the peaks corresponding to the diasterotopic methylene protons. 
 
The bromopropoxy compound 116i was produced in 66% yield. Bromopropoxy 
addition was indicated on the basis of the CI-MS spectral data by the 79Br/81Br M+1 
peaks at m/z 463/461. The presence of these molecular ion peaks is notable in this 
O O
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spectrum as there was no observable molecular ion in the CI-MS spectra of the other 
alkoxy substituted analogues. This molecular ion appearance may possibly be due to the 
protonation of bromine instead of the acetal oxygen and the increased size of the 
substituent. The isoflavylium ion fragment again appeared as the base peak in this 
spectrum. Notably, this CI-MS spectrum also exhibited peaks corresponding to the 
deprotected compound, however deprotection must have occurred within the mass 
spectrometer as the 1H-NMR spectrum showed both acetoxy groups were present.  
 
 For all the nucleophilic addition products, establishment of 2-substitution and 
the exclusion of 4-substitution was facilitated by the analysis of the gHMBC spectra of 
the derivatives. Typically in the gHMBC spectrum the H-5 proton correlated with the 
C4 carbon, and the H-4 proton likewise with the C5 carbon, while none of the protons 
or carbons of the added substituents correlated with the H-4 proton or the C4 carbon. 
For the purposes of establishing the C2 substitution by a gHMBC analysis, the products 






     (A)                                            (B)                                         (C)                         
Figure 3.5: Correlations observed in the gHMBC spectra of the nucleophilic addition 























 Derivatives containing substituents attached by a tertiary carbon include the 
nitrile 116a, the thiazole 116b and the ethynyl product 116c. The H-2 proton of these 
compounds was correlated in the gHMBC spectrum, with the directly attached tertiary 
carbons (Ca) of the 2-substituents (Figure 3.5A). 
Derivatives with 2-substituents attached to the isoflavene skeleton through a 
methylene carbon were the boc protected methyl amine 116d and the allyl derivative 
116f. In the gHMBC spectrum of these compounds the expected Cb-H2 and Hb-C2 
correlations were observed (Figure 3.5B). 
 The alkoxy isoflavene derivatives were the methoxy 116g, the ethoxy 116h, and 
the bromopropoxy 116i, and in these cases Cc-H2 and Hc-C2 gHMBC correlations were 
seen (Figure 3.5C). 
 
 
3.3.4 Reactions of 2-Substituted Products 
3.3.4.1 Attempted Triazole Synthesis 
From the pharmacophore studies, increased inhibitory activity was also 
predicted with a triazole in the isoflavene 2-position. A triazole in the 2 position would 
provide an additional aromatic ring which could to increase 5AR binding. Triazoles are 
accessible from acetylene precursors and they are commonly synthesized by an azide 








       116c      132 
Scheme 3.21: Attempted synthesis of the 2-triazole compound 132. 
 
Balle et al185 have described a method for triazole synthesis by heating a mixture 
of the acetylene starting material and neat azidotrimethylsilane at 170°C in a sealed 
tube. Katritzky et al186 have used a milder method of heating an azide with an acetylene 
at reflux in diethyl ether for seven days. Rostovtsev et al187 have also avoided heating 
azidotrimethylsilane to potentially explosive high temperatures, by using sodium 
ascorbate and copper (I) sulfate and stirring the reaction mixture at room temperature. 
However, in the current study an attempt to utilize the milder Rostovtsev et al187 method 
was unsuccessful and only starting material was recovered. 
 
3.3.4.2 Attempted Reduction of Nitrile Compound 116a to Form 70 
 The target amino methyl compound 70 incorporated a basic nitrogen in an effort 
to introduce α1A adrenoceptor antagonism. It was planned that this amine could be made 
by reduction of the nitrile in 116a, with concomitant acetate cleavage. There are many 
reducing agents available, including numerous hydrides. A very common reagent is 
lithium aluminium hydride (LiAlH4). This reagent has previously been used by Pierre et 
al188 to reduce a nitrile to an aminomethyl group. Mayer  et al189 have also used LiAlH4 























a) r.t or 43°C 
Scheme 3.22: A reductive synthetic pathway to the target 2-aminomethyl isoflavene 
70. 
 
Attempts to synthesise the compound 70 through reduction of 116a were 
performed at two temperatures, diethyl ether at reflux and at room temperature (Scheme 
3.22). The CI+-MS data showed a M+2 peak at m/z 271, signifying 70 formation. 
Analysis by 1H-NMR spectrometry of the crude reaction mixture of both reactions 
revealed a diagnostic triplet at 4.34 ppm which was assigned to H-2 and no H-2 peak at 
5.14 ppm, also indicating the synthesis of 70. Purification of the desired product was 
difficult as it remained on the base line of silica and alumina TLC plates, reflecting the 
highly polar nature of the compound. As a result crude material recovery was poor and 
attempts at further extractions were unsuccessful at producing more material; this was 
thought to be due to strong product coordination with aluminium hydroxide produced 
on addition of water during the workup. In an attempt to overcome this by cleaving the 
amine-aluminium bond, ethylene diamine was added to the extractions. It was hoped 
that the ethylene diamine would preferentially coordinate to aluminium over the 
product. However, this approach was unsuccessful at obtaining further material, even 
















3.3.4.3 Deprotection of the Acetoxy Isoflavene Derivatives 
In order to obtain the free phenolic compounds from the diacetoxy isoflavenes 
two common methods were used. One involved heating with imidazole in absolute 
ethanol at reflux, and the other, milder, method of stirring with sodium hydroxide 
solution at room temperature. 






a) 5M imidazole, abs. ethanol, ∆ 




Product  R Method Yield (%) of 
115 




116f 115f Allyl Imidazole 97 
116h 115h Ethoxy NaOH 53 
116i 115i bromopropoxy NaOH 65 
 
 
Heating imidazole with the 2-nitrile compound 116a did not produce the desired 
free phenolic product. The 1H-NMR spectrum of the crude reaction product showed no 
observable H-2 proton between 5 and 6 ppm and a messy aromatic section, indicating 
degradation of the starting material 116a. There was also no peak in the CI-MS 












failure of this method is attributed to the harsh reaction conditions, which may have lead 
to imidazole attacking an isoflavylium salt formed after imidazole based elimination of 
the nitrile group. 
The desired nitrile product was formed successfully by using a milder method 
which involved stirring the isoflavene 116a in a dilute aqueous sodium hydroxide 
solution. Evidence for acetate loss is found in the 1H-NMR spectrum by the loss of the 
two singlet signals previously attributed to the acetate methyl protons at 2.31 and 2.29 
ppm. The 13C-NMR spectrum also indicated the loss of the acetate groups by the 
disappearance of the carbonyl peaks and the methyl peaks of the acetate at 169.1 ppm, 
168.9 ppm and 21.1 ppm respectively. Additional structural evidence came from the 
absence of methyl proton signals in the DEPT NMR experiment. Confirmation of the 
free phenolic form of the product came from the ES-MS which established a small 
molecular ion peak at m/z 266. 
 
 The deprotection of the allyl isoflavene 116f with imidazole was achieved in a 
near quantitative yield of 97%. In the 1H-NMR spectrum of the product 115f no peaks 
were present which could be ascribed to the acetate methyl protons while two other 
signals at 8.33 ppm and 8.27 ppm, each integrating for 1 proton, were attributed to the 
phenolic hydroxyls. Confirmation of the desired product also came from the ES-MS 
spectrum which exhibited an M+1 peak at m/z 281. The imidazole method was 
successful in this case presumably because elimination of the 2-allyl group would not be 
a favourable process. This provides evidence that the C2-CH2(allyl) bond is a 
chemically robust carbon-carbon bond. 
 116 
 
Deprotection of the two alkoxy isoflavenes, 115h and 115i to give 115h (53% yield) 
to 115i (65% yield) respectively was successfully achieved using sodium hydroxide in 
53% and 65% yield respectively. However, the solution of NaOH (0.1M) was less 
concentrated compared to that used with the nitrile (1M). The CI-MS spectrum of the 
deprotected ethoxy product only exhibited the isoflavylium ion peak at m/z 239 with no 
molecular ion, however supportive evidence for 115h was provided by elemental 
microanalysis. The CI-MS spectrum of the deprotected bromopropoxy product 115i did 
have M+1 peaks at m/z 379/377 (9/10%) and the isoflavylium ion at m/z 239 (100%). 
The 1H-NMR and 13C-NMR spectra of the deprotected compounds lacked peaks 
attributable to acetate groups. 
 
3.4     Summary and Conclusions 
A new convenient procedure for the synthesis of 2-substituted isoflavenes was 
developed using trityl salts and isoflavene precursors. This involved nucleophilic attack 
on the isoflavylium ion 117. A range of nucleophiles were utilised, including TMS, tin 
and alcohol based nucleophiles. Phenolic acetate protection was found to be compatible 
with this procedure, while t-BDMS protection was not. The ethynyl compound 116c 
was found to undergo further reaction with an isoflavylium ion to for a dimerised side 

































Many naturally occurring isoflavonoids possess a keto group in the 4-position. 
Examples include genistein 4 and daidzein 5. As ketones are synthetically useful 
moieties, derivatisation at the 4-position was expected to provide access to a variety of 
isoflavonoid derivatives. As ketones are such versatile moieties, it was surprising to find 
that there were only 26 publications based on the derivatisation at the 4-keto position in 
isoflavonoids (Scifinder Scholar, Nov 2004). 
 
 
4      5 
Computational studies contained in this thesis (Chapter 2), identified three target 
isoflavonoid-based compounds with new functionalities at the C4 position which could 
incorporate the biological activities required. These compounds included the amine 67, 
the phenyl hydrazone 76 and the thienyl derivative 71. Compound 67 incorporated a 
basic nitrogen desired for α1A adrenoceptor activity. Compounds 76 and 71 incorporated 
an aromatic moiety which was predicted to increase 5AR type II activity. Figure 4.1 
shows compounds 71 and 76 superimposed on the human 5AR type II pharmacophores 





























Phenylhydraone 76 on hIIA    Phenylhydrazone 76 on hIIB 
Figure 4.1: Compounds 71 and 76 on the hIIA and hIIb pharmacophores and 




4.2 General synthetic approach 
 
4.2.1 Approach to the Amine 67 
It was proposed that an aminomethyl derivative at the 4-position could be 
accessed through reduction of a nitrile group, this latter group being introduced in turn 
by nucleophilic addition to the C4 carbonyl group (Scheme 4.1).  The retrosynthetic 
sequence proposed thus involved the key nitrile intermediate 133, which could be 




67                      133                134a 
Scheme 4.1: Retrosynthetic scheme for the synthesis of the 4-amino compound 67. 
 
In the case of the isoflavone 134a, the ketone at the 4-position is an aryl ketone. 
This type of ketone is less reactive than an alkyl ketone, and hence for addition to these 
types of ketones, the ketone must be activated. For example, Jacobs et al190 have added 
a nitrile group (from trimethylsilyl cyanide) to the aryl keto moiety in 135 through 
ketone activation by the use of a Lewis acid, BF3 (Scheme 4.2); this resulted in the 
cyano ether 136 in good yield. Elimination of the ether group with phosphorus 
oxychloride and pyridine then gave the α,β-unsaturated nitrile 137 (Scheme 4.2). In the 
case of 134a, acetate protecting groups were incorporated to prevent any competitive 
















        135            136     137 
Scheme 4.2: Nitrile addition to the benzylic ketone 136 and elimination to the α,β 




4.2.2 Aryl Hydrazones 
Further C4 derivatised isoflavonoid targets included the aryl hydrazone 76. 
Hydrazones are easily accessible moieties, with their formation involving a 
condensation reaction between a hydrazine and a ketone. For example, with the ketone 
138 and phenyl hydrazine 139, the mechanism of formation involves an initial attack on 
the ketone 138 by the primary amine 139 and loss of a proton forming the hydroxy 



































The oxime 142 (Figure 4.2) was also a desired target in the current studies in 
order to assist with structure-activity relationship (SAR) studies. Oxime formation 
proceeds via a similar mechanism to hydrazone formation, with hydroxylamine as the 
attacking nucleophile. An isoflavanone 4-oxime has previously been synthesized by 





                   142 
Figure 4.2: The oxime synthetic target 142. 
 
 
4.2.3 Thienyl Derivatives 
 The synthetic target 71 (Scheme 4.4) contains an additional thienyl group on the 
isoflavonoid skeleton. The formation of a carbon-carbon bond between a thiophene and 
the isoflavonoid is required for the synthesis of compound 71.  
The carbon-carbon bond formation was required in the 4-position. As the 
isoflavone 134 was readily available from Novogen, it was decided that the 4-keto 
group was a synthetic handle appropriate for accessing the desired thienyl compound 
71.  
Addition of the thienyl group was attempted via three distinct synthetic 






group of 134 with an organozinc bromide reagent, generating the hydroxy intermediate 
144 and subsequent dehydration to introduce the double bond. This approach would 
involve a common Grignard-type addition to the carbonyl moiety. The second approach 
considered was through the synthesis of a triflate intermediate 145 and subsequent 
Negishi type coupling with a thienyl moiety through a palladium-mediated reaction. The 
triflate intermediate 145 could be obtained through the generation of the enolate ion 146 
(Scheme 4.4). This general approach had previously been carried out by Ishizuka et 
al192, where they produced a 4-phenylbenzopyran derivative 151 in  99% yield from the 



























LG= leaving group 





Scheme 4.4: Retrosynthetic analysis of thienyl addition. 
 
The variation of this second approach was based on a precedent reported in a 
patent by Ishizuka et al193. In this case the 4-methoxy substituent of the benzopyran 
carboxylic ester 148 was substituted with a thienyl group to afford 149 (Scheme 4.5). 





























benzopyran derivatives in good yields. The reagents used for these substitution reactions 
were Grignard and organozinc reagents. The substitution was activated through 
















































































All of these approaches would require protection of the phenolic hydroxyl 
groups and this aspect is discussed in the following sections. 
 
4.3 Results and Discussion 
4.3.1  Free Phenolic Compound 
 The 4-ketone derivative 134a was supplied by Novogen. While the acetoxy 
protecting groups were expected to be viable ones for the phenyl hydrazone and oxime 
reactions, for the projected thienyl bromide reactions, alternative phenolic protective 
functionality would be required. In order to protect the ketone isoflavonoid with other 
protecting groups, the free phenolic compound 30 had to be made. The most facile 
method to the free phenolic compound from the phenolic ester was by reaction with 
imidazole. The known phenolic compound 30 was obtained in 93% yield194 (Scheme 
4.6). With the phenol 30 in hand, other ether-based protection for the hydroxy groups 




   134a      30 
Scheme 4.6: Acetate hydrolysis in 134a forming the free phenolic isoflavone 30. 
  
4.3.2  Attempted Cyclohexyl Ether Protection 
The cyclohexyl protecting group is not a common phenolic protecting group, 














152  to produce 153. Ether formation was achieved using cyclohexene and BF3-etherate 





                       152      153 
Scheme 4.7: Protection of a phenolic hydroxyls as a cyclohexyl ether. 
 
In order to protect the phenolic hydroxyls of compound 30 with the chemically 
sturdy cyclohexyl protecting group, the phenolic compound 30 was treated with 
cyclohexene and BF3-etherate (Scheme 4.8). However 134b was not observed and only 







      30        134b 
 




















4.3.1.2 t-BDMS Protection 
The t-BDMS group is a common protecting group for hydroxyl groups, 
including phenolic hydroxyl groups, and it is stable in Grignard-type reactions.196 
Protection of the phenolic hydroxyls in 30 with the t-BDMS group was achieved 
by stirring imidazole and t-butyldimethylsilyl chloride at room temperature for 32 
hours. This reaction is likely to proceed through an N-t-butyldimethylsilyl imidazole 
intermediate.178 This reaction must be performed under rigorously anhydrous conditions 
and powdered 3Å molecular sieves were used to assist this.  Evidence for formation of 
the product 134c was obtained through 1H-NMR and MS data. The 1H-NMR showed 
singlet peaks at 0.78 and 0.77 ppm ascribed to the t-butyl groups in the two t-BDMS 
groups. There was also a singlet at 0.00 ppm which was ascribed to the trimethyl silyl 
groups. The mass spectrum (CI+) of 134c had an M+1 ion peak at m/z 485. A fragment 
peak corresponding to t-butyl loss in the mass spectrum, a characteristic of t-BDMS 
compounds, was also observed. 
 
4.3.2 Amine Formation 
In order to prepare the target amine 67, a facile route involving the reduction of 
the 4-nitrile isoflavene 133 was devised (Scheme 4.9). The synthesis of this intermediate 
was enabled by TMS nitrile addition to the ketone 134a, resulting in the TMS ether 154 






    
   a       b 
  
a: p-TsOH/TMSCN, BF3/TMSCN 
       b: POCl3/pyridine 
       c: LiAlH4 
 
Scheme 4.9: Synthesis of the 4- aminomethyl target 67. 
 
4.3.2.1 Attempted Acid Catalysed Nitrile Addition 
The first step in the proposed synthesis of the isoflavene 67 involved the 
addition of the nitrile. This process required the activation of the ketone group and the 
first attempts involved the use of a Brönsted acid to do this. The acid, p-toluenesulfonic 
acid (p-TsOH) was employed to protonate the carbonyl oxygen.  
When the isoflavone 134a was allowed to react with TMS cyanide in the 
presence of p-TsOH (Scheme 4.9a) the desired ketone addition was unsuccessful, 
yielding only starting material. The reason for the failure of this reaction is probably due 






















4.3.2.2 Lewis Acid-Catalysed Addition 
Lewis acid activation of ketones for the addition of nucleophiles is a commonly 
used method. For example, this approach has been utilized by Jacobs et al190 for the 
addition of TMS cyanide to the p-TsOH activated benzylic ketone 155 (Scheme 4.10). 
The resulting TMS ether 156 then underwent an elimination reaction using phosphorus 







Scheme 4.10: Nitrile addition to the p-TsOH activated ketone 156 by Jacobs et al and 
subsequent elimination to form the α,β-unsaturated nitrile 157.190 
 
 
In the present work, ketone activation by BF3-etherate was employed for the 
synthesis of the nitrile TMS ether 154. The reaction mixture turned a dark brown colour 
and compound 154 was produced in ca 5 % yield, however the purity was not high. The 
evidence for the synthesis of 154 came from a signal representing the trimethylsilyl 
methyls at 0.07 ppm in the 1H-NMR spectrum. A peak at 117.3 ppm in the 13C-NMR 
spectrum corresponds to the nitrile carbon and confirms its addition, along with the 
TMS methyl peaks at 0.02 ppm. The low yield observed in this reaction is attributed to 









155 156 157 
 131 
 Ketone activation by BF3-etherate, TMS nitrile addition and subsequent TMS 
ether elimination by phosphorus oxychloride did however give the desired 4-nitrile 
isoflavene 133 in 12% yield. 13C-NMR spectral data confirmed the nitrile group 
incorporation with the appearance of a new peak at 126.4 ppm. The low yield of this 
reaction is probably caused by the deprotection of the phenolic acetates during the TMS 
nitrile addition. 
  Due to time constraints an attempt at the synthesis of the target compound 67 by 
LiAlH4 reduction of 133 was not performed. 
 
 
4.3.3 Oxime and Aryl Hydrazone Formations 
The oxime 142 was prepared in 64% yield from the isoflavone 134a on reaction 
with hydroxylamine. Evidence for oxime formation came from the CI-MS spectrum, 
which exhibited an M+1 peak at m/z 272 as the base peak. Notably this spectrum also 
exhibited a fragment peak at m/z 257, corresponding to the ketone 30; this probably 
resulted from oxime cleavage during the acquisition of the CI-mass spectrum. 
Additional evidence for oxime formation was forthcoming from a comparison of the 1H-
NMR spectrum of the ketone 30 and the oxime 142. Due to the higher electron 
withdrawing properties of the carbonyl moiety compared to the oxime it would be 
expected that the H-3 proton, α to the carbonyl carbon (C4) of the ketone 30 would be 
further downfield in the 1H-NMR spectrum than the H-3 signal in the oxime 142. 
However this was not observed in the 1H-NMR spectrum with the H-3 of the ketone  30 
represented by the peak at 3.83ppm and the H-3 proton of the oxime represented by the 
 132 
peak further downfield at 4.51 ppm (Table 10). The reason for the H-3 proton appearing 
more downfield in the oxime in the 1H-NMR spectrum can be explained by taking into 
consideration intra-molecular electronic interactions between the benzylic H-3 proton 
and the oxime oxygen, when 142 has an E configuration. This configuration would be 
favoured due to this electronic interaction; also the Z conformation would encounter 
steric clashes between the oxime hydrogen and the H-5 proton. The 1H-NMR spectrum 
contains further evidence for oxime formation when examining the peaks attributed to 
the H-2 protons and comparing them to the isoflavone 30 peaks. The peaks for the H-2 
protons in the oxime appear at 4.39 and 4.21 ppm as doublets of doublets. As the H-2 
protons appear as doublets of doublets and appear at two different places in the 1H-
NMR spectrum it is apparent that they are non-equivalent. This non-equivalence arises 
from the lack of rotation due to the rigidity of the pyran ring. 
 




Figure 4.3: Structure of the oxime 142. 
 
The two phenolic acetate groups were removed during the oxime formation as a 
result of the nucleophilic attack by the nitrogen of the free amine on the carbonyl of the 
acetate group (Scheme 4.11). CI-MS spectral analysis of the crude reaction mixture at 
2hr revealed the mass of the mono-deprotected 158 (m/z 299) and the fully deprotected 












acetate groups were removed prior to oxime formation (Scheme 4.11). As the C4 ketone 
is electron withdrawing rendering the para C7 pyran oxygen delta positive and therefore 
more electrophilic the C7 acetate group would then be attacked first before the C4’ 













Scheme 4.11:  Stepwise acetate deprotection and Oxime/Hydrazone formation. 
 
Reacting aryl hydrazines with the isoflavone 134a produced the aryl hydrazones 
76 and 159a-g in 34%-82% yield (Table 10). Where the aryl hydrazine was supplied as 














































134a 158 30 
 134 
Table 10: Tabulation of the yields, proton and carbon NMR chemical shifts for H-2, 


















30 - N/A 4.53 (d) 72.0 3.83 (d of 
d) 
51.1 
142 - 64 4.39, 4.21  
(d of d) 
70.9 4.51 (bd) 60.8 
76  82 4.36 (d of 
q) 
71.5 4.20 (bs) 38.7 
159a  
 
64 4.42, 4.33  
(d of d) 
71.4 4.29 (bs) 38.7 
159b  56 4.46, 4.37  
(d of d) 
71.4 4.34 (bs) 38.7 
159c  62 4.39, 4.35  
(d of d) 
71.9 4.23 (t) 40.5 
159d  69 4.48, 4.35  
(d of d) 
71.3 4.25 (bs) 39.0 
159e  67 4.37 (d of 
q) 
73.1 4.18 (bs) 39.8 





34 4.41 (bs) 71.8 4.39 (bs) 39.3 
b, broad; s, singlet ; d, doublet; t, triplet; q, quartet; m, multiplet. 
 
It was noted that during the synthesis of the oxime the phenolic acetate 
protecting groups were lost. CI-MS analysis during the formation of the unsubstituted 
phenyl and p-chlorophenyl hydrazones at two hours revealed that the acetate groups 














would be removed before the 3-phenyl phenolic acetate for the same reasons as 
mentioned for the oxime. 
Evidence of aryl hydrazone formation came from the CI-MS data for the 
products 76 and 159a-g. MS spectra supplied the molecular ion peaks (M+1) with 
intensities between 22% and 100%, with the exception of the p-nitrile phenyl hydrazone 
160f which gave a M-1 peak (7%). For CI-MS spectra the base peak corresponded to 
the ketone compound 30. This peak arises from the hydrolysis of the hydrazone 
products. This hydrolysis occurs as all the steps of the reaction mechanism for the 
formation of the hydrazones are reversible (Scheme 4.3). 
Additional evidence for the formation of the hydrazone products came from the 
1H-NMR spectra. It was expected that the peak representing the H-3 proton of the 
hydrazone products 76 and 159a-h would be further up-field than in the ketone 30, as 
oxygen is more electronegative than nitrogen. However, this was not the case as can be 
seen in Table 10. All H-3 protons produced peaks in the 1H-NMR spectrum between the 
range of 4.20 ppm and 4.48 ppm, while the H-3 proton of the ketone appeared further 
up-field at 3.83 ppm. This result is attributed to electronic interactions between the 
nitrogen of the hydrazone bond and the H-3 proton similar to the oxime (Figure 4.3).  
The 13C-NMR provided further evidence for the formation of the aryl hydrazones from 
the up-field shifting of the C3 carbon signal from 51.1 ppm in the ketone 30 to a range 
of 38.7 ppm to 43.9 ppm in the aryl hydrazones 76 and 159a-g. 
Two doublets of doublets in the 1H-NMR spectra provide additional evidence 
for the formation of the hydrazone products. These peaks were ascribed to the H-2 
protons. This pattern was found in all hydrazone products with the exception of the 
 136 
hydrazones 160e-g. This pattern in the 1H-NMR spectrum is caused by the H-2 protons 
becoming non-equivalent upon hydrazone formation. The H-2 protons in the 1H-NMR 
spectrum of the p-CH3 compound 159e appeared as a doublet of quartets at 4.37 ppm. 
The doublet splitting was due to non-equivalent H-2 protons and provides evidence for 
the formation of the hydrazone 159e. The H-2 protons of the p-nitrile phenyl hydrazone 
compound 159f appeared as a multiplet at 4.37ppm and integrated for two protons. In 
the 1H-NMR spectrum of the pyridyl hydrazone, the signal for the H-2 protons was 
ascribed to a broad singlet at 4.41 ppm and integrated for two protons.  
In the 13C-NMR spectrum of the aryl hydrazone products the peaks attributed to 
the C4 carbon were observed between 140.3 ppm and 154.5 ppm, consistent with 
hydrazone formation. The C4 carbon in the ketone appeared at 191.4 ppm. The peaks 
attributed to the C4 carbon were shifted up-field in the 13C-NMR spectrums of the aryl 
hydrazone products 76 and 159a-g due to the weaker electron withdrawing properties of 
the hydrazone nitrogen compared to the carbonyl oxygen, providing substantiation for 
hydrazone formation. 
Interestingly the p-nitrophenyl hydrazone synthesis also produced the diacetate 













       160 
Figure 4.4: Structure of the diacetate protected phenyl hydrazone 160. 
 
Attempted Synthesis of the Diphenyl Hydrazone 161  
In order to increase structural diversity in the aryl hydrazone derivatives, the 
diphenyl hydrazone derivative was considered as a synthetic target. As the diphenyl 
hydrazone isoflavonoid possessed an extra phenyl ring compared to the aryl hydrazones 
in Table 10, it was thought that this would increase 5AR inhibition. Diphenyl hydrazone 
synthesis was attempted through hydrazone formation from the diphenyl hydrazine and 
ketone 134a. As the diphenyl hydrazine was supplied as the hydrochloride salt, sodium 
acetate was added to the reaction to create the free hydrazine in situ (Scheme 4.12). 
However no diphenyl hydrazone product was observed even after heating at reflux 
overnight. The only compound isolated from this reaction was the free phenolic ketone 
intermediate 30. The failure of this synthesis is most likely due to the high steric bulk of 






















Scheme 4.12: Attempted synthesis of the diphenyl hydrazone 161. 
 
 
Attempted Imidazolyl Hydrazone and Pyrimidyl Hydrazone Synthesis 
 In an attempt to synthesise the imidazolyl hydrazone 162 and the pyrimidyl 
hydrazone 164, the isoflavone 134a was reacted with the respective hydrazines. As the 
imidazole was supplied as the hydrobromide salt sodium acetate was added to the 
reaction to create the hydrazine in situ. These attempts were unsuccessful at producing 
the desired products. The attempted imidazolyl hydrazone synthesis unexpectedly 
produced the benzofuran 163 (Scheme 4.12). The formation of this compound was 
confirmed by CI-MS, 1H-NMR and 13C-NMR. The endeavour to synthesis the 
pyrimidine hydrazone 164 by reacting the isoflavone 134a with p-trifluoromethane 


































Scheme 4.13: Attempted synthesis of the imidazolyl hydrazone 162 and the pyrimidyl 
hydrazone 164. 
 
The possible mechanism for the formation of the benzopyran 163 during the 
attempted synthesis of the imidazole hydrazone 162 could involve an initial enamine 
tautomerisation forming 165. As the imidazole nitrogen is quite basic, the 2-amino 
substituent becomes a good leaving group and the pyran oxygen then attacks C3 
facilitating the construction of an imine. This would give the short lived oxiranium 
intermediate 166. As this reaction was not performed in an anhydrous manner, water 




























































Scheme 4.14: Proposed mechanism for the production of the benzofuran 163 from 















































166 167 168 
163 
 141 
4.3.4 Thienyl Group Addition  
4.3.4.1 Attempted Direct Addition 
Additions of Grignard reagents to isoflavones 169 has been performed by 
Irmscher et al197, producing the aryl alcohols 170 in good yield. (Scheme 4.15). The aryl 
alcohols 170 then underwent acid-catalysed dehydration to form the respective 









R2=H/ethyl, R4=Ph/cyclohexyl/ethyl/p-OCH3Ph, R7=H/CH3O 
Scheme 4.15: Grignard addition to the isoflavones 169 and subsequent acid catalysed 
dehydration producing the isoflavenes 171. 
 
 
It was noted that reactions with some aryl alcohols produced ring opened 
products. Irmscher et al197 also noted the formation of two ring opened side products 
174 and 175 in the Grignard reaction. They proposed a mechanism for the ring opening 
(Scheme 4.16). This involved α-proton abstraction and the initial formation of the 














the ketone and the migration of the negative charge to the former pyran oxygen, 
affording a stabilized phenoxide anion 173. The Grignard reagent then may react with 
the β-unsaturated carbon or to the ketone of 173, producing the ring opened products 










Scheme 4.16: Mechanism proposed by Irmscher et al197 for the ring opened products 
174 and 175 produced during the Grignard additions with isoflavones 169. 
 
 
In order to explore this chemistry further, the synthesis of the hydroxy 
methylthienyl isoflavonoid 144 through a direct Grignard-type addition to the 
isoflavone and subsequent dehydration was undertaken. In an attempt to achieve dual 
α1A adrenoceptor antagonism and 5AR inhibition in the one molecule, the ultimate 2,4-
disubstituted isoflavene target 78, was thought to be accessible by first synthesising the 
4-thienyl isoflavene 144 then executing 2-substitution giving 176, it was desirable that a 


























t-BDMS and acetate protected isoflavones 134 were readily accessible. Even though the 
t-BDMS protecting group would be stable to a Grignard reagent, the thienyl zinc 
bromide reagent was used because it was not expected to react with either t-BDMS or 
acetate protecting groups, and the latter would also be suitable for later 2-substitution of 










Scheme 4.17: Synthetic route to achieve the 2,4-disubstituted isoflavene 78. 
 
Reaction of the isoflavone 134c with the thienyl zinc bromide reagent 177, was 
undertaken at room temperature (Scheme 4.18). This reaction provided the 
corresponding thienyl alcohol 144 in 40% yield, as estimated by 1H-NMR analysis of 
the crude material. It also unexpectedly provided a benzofuran compound 178 which 
possessed an exocyclic double bond in 60% yield, as ascertained by 1H-NMR analysis. 
Purification of these compounds from the reaction mixture through silica gel 

























When the chromatography was performed rapidly (25 minutes), the thienyl alcohol 144 
was obtained in only 8% yield, while the benzofuran compound 178 was obtained in 
80% yield. Notably when the chromatography was performed more slowly (1 hour) 
only double bond compound 178 in 91% yield and no thienyl alcohol 144 was 
recovered. This indicated that silica gel is converting the thienyl alcohol 144 into the 
double bond compound 178. Attempts to purify products by chromatography using 
alumina was surprisingly also unsuccessful and none of the product 144 or side-product 








Scheme 4.18: Products from reaction with the isoflavone 134c with the thienyl zinc 
bromide reagent 177. 
 
In the 1H-NMR spectrum of the desired thienyl alcohol compound 144 a triplet 
at 4.65ppm was ascribed to the H-3 proton. Two doublet of doublets signals at 4.44ppm 
and 3.16ppm each integrating for one proton were ascribed to the H-2 protons. The fact 
that the peaks for the H-2 protons had separated into two positions and that they 
appeared as doublets of doublets, indicated that these protons were not chemically 


















evidence for the methyl thienyl compound 144 with the presence of doublet peaks 
corresponding to the H-3” and H-4” protons at 6.68 ppm and 6.98 ppm  respectively and 
the methyl group was assigned to a singlet at 1.96 ppm with an integration of 3 protons. 
The singlet peak at 12.69 ppm was attributed to the hydroxy proton. The 13C-NMR 
spectrum also confirmed the synthesis of the thienyl alcohol by the thienyl carbons C3” 
and C4” appearing as peaks at 129.9 ppm and 122.4 ppm. The peak at 22.8 ppm was 
ascribed to the methyl carbon. Confirmation of the thienyl alcohol 144 was also 
provided by ES+-MS with an M+1 peak appearent at m/z 583 and an M-1 peak from ES-
-MS at m/z 581. The base peak (m/z 313) in the ES+-MS spectrum corresponded to that 
for the ketone 134c consistent with the loss of a methyl thienyl fragment. This indicated 
that the methylthienyl fragment was a better leaving group than the hydroxy moiety. 
Elemental microanalytical data for the thienyl alcohol 144 was also consistent with this 
formula. 
The benzofuran side-product 178 produced by the thienyl zinc bromide addition 
was identified through ES-MS, 1H-NMR and 13C-NMR spectroscopy and elemental 
microanalysis. The ES+-MS contained a base peak at m/z 485 corresponding to either 
the benzofuran 178 or the ketone starting material 134c, as did the elemental 
microanalysis results. However the ketone starting material 134c was ruled out as the 
1H-NMR spectrum did not correspond with previous 1H-NMR spectra of this 
compound. The 1H-NMR spectrum contained diagnostic singlets for the five-membered 
ring compound 178 at 5.66 ppm and 5.16 ppm integrating for one proton each. The g-
HSQC spectrum revealed that the proton associated with these peaks was attached to the 
same carbon, substantiating the presence of the exocyclic double bond. Comparable 
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exocyclic vinylic protons from a benzofuran have been reported at 4.2 and 4.6 ppm.198 
Additional evidence that the side product 179 also contained a benzylic hydroxyl group 
came from the 1H-NMR spectrum which contained a singlet at 12.30 ppm. This 
hydroxyl peak appeared in a similar position in the thienyl alcohol 144 (12.69 ppm).  
The proposed mechanism for the formation of the unusual product 178 in acidic 
environments such as silica gel involves the loss of the H-3 hydrogen as a proton 
resulting in the loss of the thienyl group and the formation of the 4-hydroxyisoflavene 
179. An indication that the thienyl group is a better leaving group than the hydroxy 
group under acidic conditions is contained in the ES-MS spectrum of the thienyl alcohol 
144 as the base peak observed corresponded with a fragment without the thienyl group. 
Ring opening could then occur through isomerisation of the enol 179 to the α,β-
unsaturated ketone 180. Attack of the phenolic anion (or the phenol itself) at the keto-α 
carbon, aryl group migration and keto group attack could then form the benzofuran 
compound 178. (Scheme 4.19) Such a rearrangement and ring contraction does not 
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Scheme 4.19: Proposed mechanism for the formation of benzofuran 178. 
 
The next stage in the synthesis of the thienyl isoflavene 71 involved the 
dehydration of the thienyl alcohol 144. As the thienyl alcohol 144 was isolated in poor 
yield, it was decided to attempt subsequent dehydration reactions on crude material. 1H-
NMR spectroscopic analysis of the crude material revealed that 40% of it was the 
thienyl alcohol 144, and this was taken into account when yields were calculated. There 
are numerous reagents facilitating dehydration reactions, but only CuSO4, P2O5 and the 
Burgess reagent were trialled here. 
 
Anhydrous CuSO4 has previously been used for the dehydration of various 
primary, secondary and tertiary alcohols176. These alcohols were dehydrated at 
temperatures between 95ºC and 180ºC, over 0.5h to 15 h, with yields in the range of 4-




















An attempt to use CuSO4 for the dehydration of the thienyl alcohol 144 was 
unsuccessful as this only returned starting material. As this reagent was successful for 
the dehydration forming the 4-unsubstituted isoflavene 118, a plausible reason for the 
dehydration failure for compound 144 is due to steric hindrance caused by the thienyl 
group, hindering copper complexation to the tertiary hydroxyl group.  
An attempt to dehydrate the thienyl alcohol 144 using P2O5 was then performed 
on crude reaction material from the thienyl addition, as there were problems associated 
with the purification of the thienyl alcohol 144. Unfortunately dehydration did not occur 
with P2O5 and unexpectedly only returned the initial ketone starting material 134c in 
31% yield; no other products were obtained. Assuming that the ketone came from the 
thienyl alcohol 144, a proposed mechanism is presented in Scheme 4.20.  This 
mechanism initially involves the formation of the phosphoric ester 181 and subsequent 
attack on the P=O bond to afford the intermediate 182. Elimination of the 





      181       182    134c 
Scheme 4.20: Generation of the ketone 134c starting material from the thienyl 
























A further attempt at dehydration was carried out utilizing the Burgess reagent 
((methoxycarbonylsulfamoyl)triethylammonium hydroxide inner salt). Since Burgess et 
al 199 described their mild method for the dehydration of secondary and tertiary alcohols 
in the 1970s, a number of applications have been described in the literature, especially 
towards the synthesis of natural products. For example,  the formation of the exocyclic 
double bond in 184 from 183, which then facilitated the synthesis of the oxygen-
containing four membered ring in taxol 185200 (Scheme 4.21). Another example of the 
use of the Burgess reagent is in the synthesis of the anti-tumour  alkaloid (+)-
narciclasine 188201, an alkaloid from the Amaryllidaceae. The Burgess reagent was used 
for the formation of the endocyclic double bond in the narciclasine precursor 187 from 




























Scheme 4.21: Examples of the use of Burgess reagent in the synthesis of Taxol 185 
and (+)-narciclasine 188  for the formation of exocyclic and endocyclic double bonds. 
 
A reaction mechanism for dehydration of alcohols using the Burgess reagent has 
been proposed by Rinner et al202. This involves initial attack by the hydroxyl oxygen of 
189 on the sulfur displacing the tertiary amine of 190. The negatively charged nitrogen 
is then able to act as a base for the β-proton, resulting in syn-elimination of the 











































































Scheme 4.22: Reaction mechanism for the Burgess reagent alcohol dehydration 
reaction.202 
 
The Burgess reagent was trialled on a sample of the crude mixture of the thienyl 
alcohol 143 and the benzofuran 178,. Although the Burgess reagent was successful for 
the examples in the previous paragraph, it did not form the desired dehydrated product 
from 143 and gave a mixture of unidentified compounds. As a result attention was 
turned to an alternative approach to the 4-thienyl isoflavene 78 via an enolate anion. 
 
4.3.4.2 Attempted 4-Thienyl Isoflavene Synthesis through Enolisation and Negishi 
Type Couplings 
An alternative route to isoflavenes starting from an isoflavone is through α-
proton abstraction and enolate anion formation. Enolisation produces the isoflavene 
double bond and the anionic 4-oxygen is then able to attack an electrophile. O-
Alkylation or O-acylation would then give isoflavenes such as 148 or 150 respectively 
(Scheme 4.5). This general approach has been used successfully by Isizuka et al192 
(Scheme 4.5). 
 In an attempt to synthesise the thienyl isoflavene 71 it was decided to explore 
the potential enolate anion route (Scheme 4.23). It was planned that once the enolate 
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phenyl bis(trifluoromethane) sulfonimide would produce the intermediates 145a 
(R=CH3) and 145b (R=SO2CF3) respectively. A Negishi type coupling with the 
methylthienylzinc bromide would then provide the methylthienyl isoflavene 143. 












Scheme 4.23: Synthetic route resulting in the 4-thienyl isoflavene 143 through the 
enolate anion 146. 
 
Negishi couplings typically use a nickel or palladium-based catalyst to couple a 
zinc halide with a halide, triflate or phosphine. Corley et al203 have combined 
Cl2Pd(dppf) and CuI to catalyse the coupling between the triflate 192 and the zinc 
a Product b R 
Triflic anhydride 145a Methylthienylzinc 
bromide/ Pd(PPh3)4 
Triflate 
Methyl iodide 145b Methylthienylzinc bromide CH3 


























iodide 193  to give 194 in 41% yield (Scheme 4.24). A nickel based catalysis was 
involved in the Negishi coupling of the coumarin phosphate 195 and a thienyl zinc 















Scheme 4.24: Examples of a palladium catalysed Negishi coupling between the 
triflate 192 and the zinc halide 193203 and  a nickel based coupling to achieve the 4-
thienyl coumarin 196204. 
 
 
In order to determine the stability of the enolate anion 146 the t-BDMS 
protected isoflavone 134c was treated with the strong base sodium hydride. This 
abstracted a proton from the 3-position of the isoflavone 134c and generated the enolate 
anion 146. This produced a characteristic yellow colour in the reaction mixture for the 
anion. The reaction mixture was then treated with an aqueous work up. When this was 
performed at room temperature the ketone 134c was produced in 85% yield and the 





















the partial instability of the enolate anion which must proceed via a ring opening and 







Scheme 4.25: Addition of water to the enol tautomer 146 which gave a mixture of the 
starting ketone 134c the benzofuran 178. 
 
One pot generation of 146, triflation and a subsequent Negishi coupling attempt 
between the triflate 145a (R=SO2CF3) and methylthienyl zinc bromide was attempted. 
Unfortunately the desired 4-methylthienylisoflavene 143 (Scheme 4.23) was not 
observed in the 1H-NMR spectrum of the crude final reaction product. In an attempt to 
determine whether the failure of this reaction was associated with the Negishi coupling 
step or the synthesis of the triflate intermediate 145a, an effort to isolate or observe the 
triflate intermediate 145a was made. This attempt was unsuccessful as no material was 
returned after purification and it could not be verified whether the triflate intermediate 
145a was synthesised. 
 
A trial reaction to produce the 4-methoxy isoflavene 145b (R=CH3) was 
performed to investigate the reactivity of the enolate 146 in view of the failure to isolate 























methoxyisoflavene 145b would serve as alternative Negishi coupling agent (Scheme 
4.4). Upon generation of this anion at -48ºC with sodium hydride, methyl iodide was 
added (Scheme 4.23), forming the 4-methoxy isoflavene 145b (R=CH3) in 63% yield. 
 
1H-NMR spectrum provided evidence for the synthesis of the 145b (R=CH3).  
No signal was present which could be ascribed to the H-3 proton, while a singlet 
ascribed to the H-2 protons appeared at 4.57 ppm. The 3-proton singlet at 3.85 ppm was 
assigned to the protons from the methoxy substituent. Also the carbon of this substituent 
was attributed to the peak at 30.9 ppm in the 13C-NMR spectrum. A peak assigned to the 
C4 carbon was present at 133.4 ppm in the 13C-NMR spectrum. An M+ ion was 
observed in the ES+ mass spectrum at m/z 498. 
 
Ishizuka et al192 have utilised 4-methoxy benzopyran 148 (Scheme 4.5) in a 
Grignard coupling with a methylthienyl magnesium bromide to afford the 4-thienyl 
benzopyran. Attempts to utilise the 4-methoxy isoflavene 145b (R=CH3) in a similar 
Negishi-type reaction were carried out, however this reaction returned 90% of the 
starting material and a small amount of an unknown compound. A further attempt to the 
4-methoxy isoflavene 145b (R=CH3) utilizing NiCl2 as a catalyst in this type of 
coupling returned only the same unknown compound in good yield and no starting 
material was recovered. Due to time constraints of this project further attempts to 
synthesise the 4-thienyl compound 71 were not carried out. 
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4.3 Summary and Conclusions 
Nitrile addition to the isoflavone 134a was achieved through BF3 activation of 
the isoflavone 134a, however in poor yield, subsequent reduction was achieved 
however purification of the desired product was not accomplished. Eight aryl 
hydrazones were obtained through reaction of the isoflavene 134a with the 
corresponding hydrazine. A rearranged benzofuran product 163 was obtained from the 
attempt to synthesise the imidazole hydrazone in a similar manner. Efforts to achieve a 
4-methylthienyl isoflavene were undertaken, however unsuccessfully. These also efforts 







































Chapter 5 Development of the 5-α-reductase type I assay 
 
5.1 Introduction 
 As mentioned in Chapter 1, the 5-α-reductase (5AR) enzyme plays a role in 
many disorders and diseases, including some prostate cancers. The 5AR enzyme 
catalyses the synthesis of dihydrotestosterone (DHT) 2 from testosterone (T) 1 (Scheme 
5.1). The 5AR enzyme employs NADPH as a hydride source for the reaction. There are 
two isozymes of 5AR, type 1 and type 2, which are encoded by from two different 
genes and, other synthesis are distributed differently throughout the body. The 5AR type 
1 is the dominant isozyme in the skin, while 5AR type 2 is the dominant isozyme in the 
prostate. They also bind inhibitor molecules with different affinities. The isozymes also 








Scheme 5.1: The conversion of testosterone (T) 1 to dihydrotestosterone (DHT) 2 and 
androstenedione (A) by the 5-α-reductase enzyme and the metabolism of T by 















 Both hormones T and DHT act individually as growth promoters upon 
binding to the androgen receptor, however DHT is forty times more potent as a growth 
promoter than T. This conversion can be upregulated in some prostate cancers and in 
such cases inhibiting this conversion is a beneficial treatment. It should be noted that 
androstenedione (A) is another metabolite of T, and this conversion is carried out by the 
aldosterone synthase enzyme. 
 
There is currently only one drug clinically available as a selective 5AR type 2 
inhibitor, namely Finasteride 7 (Figure 5.1). Finasteride 7 has a steroidal structure and 
therefore patients may suffer from steroidal side effects including sterility. The dual-
isozyme 5AR inhibitor, Dutasteride 8, is currently in clinical trials which also has a 
steroidal structure and therefore will also produce steroidal side effects. As there is only 
these two steroidal compounds which are available for 5AR inhibition there is a great 






Figure 5.1: The structures of Finasteride and Dutasteride. 
 
As 5AR is a nuclear membrane enzyme, there is no crystal structure available 





















this thesis has detailed ligand-based pharmacophore generation for human 5AR type 1 
and type 2 isozymes. The 5AR type 1 pharmacophore (Figure 5.2) generated contained 
three features (HBA, hydrophobic and hydrophobic-aromatic) and one pseudo-feature 
(HBA). The presence of the pseudo-feature in a pharmacophore is considered to render 
the pharmacophore non-valid. The statistics of the pharmacophore also rendered the 
pharmacophore non-valid. The reason for the non-validity of the pharmacpohore is that 
the training set used for the generation was too small, with only fifteen compounds 
included, where 14 compounds is normally considered to be the minimum number of 
compounds in a training set for a quality pharmacophore generation. As the number of 
non-steroidal compounds assessed for their 5AR type 1 inhibitory activity is limited, it 








Figure 5.2: The 5AR type 1 pharmacophore hI with the most active molecule in the 
training set mapped onto it. 
The wire cage spheres represent the pharmacophore features. For hydrogen bond 
acceptor (HBA) the smaller sphere represents the area where the feature of the 
molecule lies during the mapping, and the larger sphere represents the interaction point 
of the enzyme. The coloured  circles on the two dimensional chemical structures show 
where a feature has been mapped onto a compound. 








5.2 5AR Type I Testing 
There are various ways of performing a 5AR inhibitory assay. These include 
whole cells assays, extracted protein assays, partially purified protein assays and 
enzyme expressed assays.  
While there are a variety of 5AR sources, they can be categorised into one of 
two classifications: tissue sources or cell cultures. Obtaining 5AR from a tissue source 
involves collecting from an animal an organ or tissue and homogenising it until there is 
no structure on the tissue level. This method is more likely to afford the native 5AR 
enzyme, than materials from a cell culture. Human 5AR tissue sources include human 
scalp tissue and prostate tissue for the 5AR type 1 and type II isozymes 
respectively.205,206 Cell culture sourcing involves the source of a cell culture which 
produces the required enzyme protein. Many prostate cancer cell lines are available 
including the LNCaP (androgen-dependent, 5AR type I)207, PC3 (androgen independent, 
5AR type I)208, Du145 (5AR type I209 and type II208) cell lines. This method involves an 
increased risk of mutation as cell cultures are cancerous cells which are known to have a 
higher probability of mutation than non-cancerous cells.  
 
5.2.1 Whole Cell Assays 
5AR whole cell assays have been carried out by Picard et al210 and Kaefer et 
al206 on DU145 cells and by Kaefer et al206 from human scalp homogenates. This 
method involves incubation of T and inhibitor with the whole intact cell and subsequent 
analysis of the percentage conversion to DHT.  
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The advantage of this method lies in its simplicity. However the disadvantage 
lies in the accuracy of the results. The results here are dependent on a number of 
interfering factors. One of these factors originates from the inhibitor diffusing into the 
cell, as different may have different hydrophobicities, therefore their diffusion rates will 
be different and as the 5AR enzyme is a nuclear membrane protein the actual 
concentration of inhibitor will differ in the vicinity of the enzyme, producing inaccurate 
results. Another source of inaccuracy comes from other proteins within the cell which 
may bind or modify the inhibitor, hence changing the concentration at the enzyme.  
 
5.2.2 Extracted Protein Assays 
Negri-Cesi et al207 have performed a 5AR assay using LNCaP cells as the 5AR 
source. Protein extraction assays involve lysing a cell, discarding all the cell debris and 
extracting the protein contents of the cell. The protein contents are then incubated with 
T and inhibitor and subsequent analysis of percentage conversion of T into DHT affords 
an estimate of enzyme inhibition. 
The advantage of using this method over the whole cell assay method arises 
from the lack of a cell membrane through which the inhibitor has to diffuse. This results 
in a more accurate assay as the concentration of inhibitors in the region of the enzyme is 
kept constant. However, as the 5AR protein is not purified and there other proteins 
which may bind or modify the inhibitor. 
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5.2.3 Enzyme Expressed Assays 
Relatively recent technology has allowed enzyme assays to be performed in an 
extremely accurate manner. This technology is based on enzyme expression assays. 
These assays entail the expression of a particular enzyme DNA on the cellular 
membrane of CHO cells. The DNA of the enzyme has been transfected into these cells. 
This enables the assay to be executed with the highest purity of the enzyme and no other 
protein expression to interfere inhibitor metabolism or binding and without diffusion 
factors which produce inaccuracies. Difficulties can be encountered with the method as 
a result of the high level of accuracy required by the method. This method, has 
previously been used by Guarna et al205 for the 5AR type I enzyme.  
 
5.3  Methodology for Assay Development 
In the current work, an in-house assay was developed based on the requirement 
for data on a greater number of training set inhibitors for the refinement of the 5AR type 
I pharmacophore. The source of 5AR type I used for the assay was the prostate cancer 
cell line, LNCaP. This cell line has been shown to contain 5AR type I and not 5AR type 
II isozymes by Negri-Cesi et al.207 LNCaP cells are known to grow in an androgen 
dependant manner.211 As it was not known whether the 5AR enzyme is up- or down- 
regulated in the presence of androgen during cell culture, the assay was performed on 
protein extracted from both testosterone treated and untreated cells. 
Protein concentration determinations were carried out according to Pearsons 
method.212 Protein extraction assays were chosen as the most appropriate and 
manageable assay type to undertake. Tritiated testosterone was used to trace 
 164 
testosterone metabolism. With tritium radiation, the β particle (an electron) may be 
detected in various ways, including scintillation counting and development of a 
photosensitive film. 
Tritiated T was used and two methods were trialled for T and DHT detection: 
TLC photo-development and scintillation counting. Photo-development was 
unsuccessful as it required over two weeks for development which was not an 
acceptable time frame. Scintillation counting was successful as it was sensitive enough 














5.4 Results and Discussion of the 5AR Assay 
The method chosen for separating T and DHT was by TLC on silica gel with a 
mobile phase of 15% ether in DCM (Scheme 5.4).157 As the tritiated testosterone and 
Relationship between Tritiated Testosterone 



































tritiated metabolite concentrations on the TLC were too low to view by UV light the 
TLC plates were spiked with additional untritiated T, A and DHT. T and A were 
detected under UV light at 254nM, however DHT was detected by the heat-assisted 
development of a molybdate dip. Each spot was then scraped off the TLC plate and β-
radiation counts obtained. As molybdate dip was contained in the assay samples, 
scintillation from controls with varying concentrations of tritiated testosterone from a 
molybdate stained TLC plate were compared to counts from a non-stained sample with 
the same concentration of tritiated testosterone to determine whether the molybdate dip 
affected the scintillation counts. The molybdate dip samples were found produce the 









Figure 5.4: TLC plate for the separation of testosterone and its metabolites 









As can be seen in Figure 5.5, it was quite clear that at 500nM assay activities 
using protein extracts from both testosterone treated and untreated decline with 
increased inhibitor concentration. It was noted that for the assay which used protein 
from testosterone treated cells the activity dropped to about half when incubated with 
500nM Finasteride. Since the human 5AR type I IC50 for Finasteride 7 has been 
reported as 410 nM,213 this assay was considered to be consistent with IC50 data 
reported for this compound in the literature. 
Published assays have used various concentrations of testosterone. During the 
development of the 5AR assay the concentration of testosterone was adjusted so that the 
experimental IC50 value of Finasteride 7 matched the literature value. Figure 5.5 shows 
the results of an assay determining the optimal concentrations for the assay. It can be 
seen from Figure 5.5b that testosterone concentrations of 10nM to 100nM using 
extracts from both testosterone treated and untreated cells had no real decline in activity 
as the amount of inhibitor (Finasteride) increased. 
These results indicated there may be a negative feedback mechanism with 
testosterone incubation of the cells since in the assays where no Finasteride was used 




























Figure 5.5: Graphical results of the assays containing different concentrations of 
testosterone on T treated (T) and untreated (U) cellular protein extracts (a), with an 
expansion (b) of the results of the 500nM T assays for T treated and untreated cells. 
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Unfortunately, further assays did not reproduce these initial encouraging results. 
This appeared to be due to the fact that the LNCaP cell line has mutated and changed its 
characteristics. The modified cell line produced less protein, grew more slowly, and 
gave decreased 5AR activity and produced increased IC50’s for standard inhibitors in 
whole cells assays. 
In order to overcome this problem a new batch of LNCaP cells were obtained 
from the NCI, however these cells also exhibited signs of contamination. In a further 
effort to over come this contamination problem LNCaP cells were obtained from Gillian 
Lehrbach at the Garvan Institute, Sydney and the assay was carried out in the School of 
Biology, University of Wollongong. The results from this assay are displayed in Figure 
5.6. While these results showed a decrease in DHT production as the Finasteride 
inhibitor concentration increased, the IC50 value did not match the literature data. 
Optimisation to correlate the experimental and literature IC50 values was required to 
gain meaningful results from the assay. Due to time constraints it was decided that any 
















































































Chapter 6  Cell Based Biological Testing of Isoflavonoids 
and COX, Thromboxane Synthase Inhibition Studies. 
 
6.1 Introduction 
While it is important to test compounds on specific enzymes and receptors to aid 
their design, it is just as important if not more so, to assess their activity on the whole 
cell. Whole cell assays provide information pertaining to a more complex cellular 
environment and may indicate other biological targets which were not contemplated 
before. 
 This Chapter includes testing results of the isoflavonoids on eight different 
cancer cell lines. The testing was performed by Novogen in Sydney. Among these cell 
lines are prostate cancer, breast cancer, ovarian cancer, lung cancer and leukaemia cell 
lines. 
Cyclooxygenases (COX) and thromboxane synthase are important enzymes in 
cancer development. Cancer initiation and progression facilitation by excess 
prostaglandins in inflamed tissue has been suggested.214 Cyclooxygenases (COX) 
produce prostaglandins from arachidonic acid.25 Strong evidence exists that the COX 
inhibitor Celecoxib reduces the risk of colon cancer215, also that many metatheses 
contain elevated COX-2 expression. COX-2 has been shown to drive angiogenesis and 
halt cellular apoptosis.216 Thromboxane is related to prostaglandins and is derived from 
arachidonic acid by thromboxane synthase. It has been found that prostate cancer cells 
have elevated levels of thromboxane synthase compared to normal prostate cells. An 
increase in cellular motility of these prostate cancer cells is associated with the elevated 
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levels of this enzyme.217 Testing of various compounds against these enzymes was also 
performed by Novogen and the results are included in this Chapter. 
 
6.2  Cell Line Descriptions  
Isoflavonoids were tested on three different prostate cancer cell lines, namely the 
LNCaP, PC3 and DU-145 cell lines. The LNCaP cell line is an androgen dependent cell 
line which only contains 5AR type I and not 5AR type II.207 The PC3 and DU-145 cell 
lines are androgen independent prostate cancer cell lines.208 
 The MDA-MB-468 cell line is an estrogen receptor negative (estrogen 
independent) breast cancer cell line,218 MCF-7 is an estrogen receptor positive breast 
cancer cell line219. The NCI-H460 cell line is a large cell lung cancer cell line.220 A2780 
and CP70 are cis-platin resistant ovarian cancer cell lines.220 HPAC is a pancreatic 
cancer cell line.221 CCRF-CEM is a leukaemia cell line which readily becomes resistant 
to methoxtrexate.222 RMPI-8226 is a myeloma cell line.223 HTB-138 is an astroglioma 
cell line.224  
 
6.3  Results and Discussion 
6.3.1 Cell Line Inhibition Results (Cytotoxicity) 
Cell line cytotoxicity assays were performed according to the methods of Alley 
et al.225 Optimal seeding densities were determined over five days. Cells were 
trypsinised, resuspended in culture medium and seeded at appropriate densities, then 
incubated at 37ºC under 5% CO2. After a predetermined lag time the cells were 
incubated with the test compound (performed in serial dilutions and with a negative 
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control) for five days. MTT (3-(4,5-dimethylthiazol-2-yl)-2,5diphenyltetrazolium 
bromide)(0.5 mg/mL) in buffer was then added and incubated at 37ºC with the cell 
cultures for an additional 3 hours. DMSO was added  and absorbance was read at 
570nm. 
Table 11 outlines the results from the cell line cytotoxicity assays. The results of 
this assay represent the concentration required to kill half the population of the cell line 
and is presented in µM. 
 
 
Table 11: LD50 (µM) values of various isoflavonoid compounds against a panel of 
cancer cell lines. Where there is more than one entry in a cell the assay has been run a 
second time. Results which have a standard deviation have been run in triplicate, if 
there is no standard deviation shown the assay was run once. A blue cell denotes active 
results and the yellow cell denotes very active results. 
 
Compound
/ cell line 




Cell type Prostate Prostate Prostate Breast Breast Glioma 
116a 57.3±26.8 71.1±43.8 35.0±6.4 48.4±23.2 9.1 65.8 
115a 87.4±37.2 23.2±1.5 34.8 18.4 53.1±4.7  










159a 29.9±2.8 16.8±3.5 19.1 8.8   
159b 32.2±0.0 18.3±6.1 25.2 14.6   






















Table 11 (cont.): LD50 (µM) values of various isoflavonoid compounds against a 
panel of cancer cell lines. Where there is more than one entry in a cell the assay has 
been run a second time. Results which have a standard deviation have been run in 
triplicate, if there is no standard deviation shown the assay was run once. A blue cell 









Cell type Ovar Ovarian Pancreatic Leukem Leukem Lung 
116a 17.4 31.0±5.3 121.4±9.5 15.7 30.5 100.7±19.8 
115a 39.4 59.4±33.7     
142 111.2 81.3±60.7 >150 13.4 >150 >150 
76 33.3 29.8±8.4    27.7 
25.5 
159a 13.7 23.5±5.2    14.1 
159b 18.0 27.2±1.5    21.7 
159c 22.0 31.6±5.7    18.7 
159d  38.2±11.1 34.3±20.5 12.0 31.5 32.7 
40.6±14.1 




Most compounds revealed moderate activity against cancer cell lines (between 
20 and 120 µM). This is especially true for the phenyl hydrazones 76, 159a-e which 
generally exhibited an increase in activity relative to the oxime 142, demonstrating the 
benefit of the additional aromatic group. The most active compound against any cell 
line was the phenyl hydrazone 159e against the leukaemia cell line CCRF-CEM with an 
LD50 of 5.71µM. The most active compound against a prostate cancer cell line was the 
unsubstituted phenyl hydrazone 76, against the DU-145 cell line. The most active 
compounds against the LNCaP cell line were the phenyl hydrazones 76 and 159c. The 
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most active compounds against the PC3 cell line were 76, 159a, 159b and 159c, all 
within 16µM and 20µM. The most active compounds against the DU145 cell line were 
76, 159a and 159e. The acetate protected cyano isoflavene 116a was the most active 
compound tested against the MCF-7 breast cancer cell line. 
Compounds which were revealed to be active against the CR70 ovarian cancer 
cell line were the acetate protected 116a and the phenyl hydrazones 159a and 159b. No 
compounds tested were highly active against the A2780 ovarian cancer cell line. This 
was also the case for the HPAC pancreatic cancer cell line. The four compounds which 
showed activity against the RPMI-8226 leukaemia cell line were 116a, 142, 159e and 
the 159d. Three compounds were active against the lung cancer cell line NCI-H460, 
these being the phenyl hydrazones 159a, 159c and 159e. 
 
Table 12: Concentrations found to inhibit 50% of testosterone induced proliferation 
for three phenyl hydrazone derivatives. 
 
Compound /Cell Line LNCaP  IC50 (µM) 
76 2.25 
159e 0.68 
159d Less than 0.035 
159d 
          
Table 12 outlines the result from a testosterone induced LNCaP proliferation 
assay. These results are the concentrations in µM required at which 50% of testosterone 








cells are androgen dependent. As can be seen in table 12, all three phenyl hydrazones 
assayed were very active in the proliferation assay, especially the p-nitro 159d. This 
provides support that an aromatic ring is beneficial for 5AR activity (see Chapter 2 for 
more details). 
 
6.3.2 COX Assay Results 
Buffy coats obtained from the Red Cross Blood Bank and diluted with buffer, 
were overlayed onto Lymphoprep density gradient medium. A mononuclear cell layer 
was obtained through centrifugation and monocyte enriched cells obtained through 
counter-current centrifugal elutriation. Monocytes were resuspended in RPMI tissue 
culture medium with foetal calf serum and incubated at 37ºC with test compound (in 
DMSO) for 30 min. Bacterial lipopolysaccaride (LPS) was added and incubated at 37°C 
in 5% CO2 for 18 hours. Cell free supernatants obtained through centrifugation were 
then assayed for prostaglandin production by radioimmunoassay. 
 
Table 13: Percentage COX inhibition by various isoflavonoid phenyl hydrazones. 





The three phenyl hydrazones tested showed significant COX inhibitory activity 
(Table 13), with 100% inhibition at 10µM for the unsubstituted phenyl hydrazone 76 
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and the p-tolyl hydrazone 159e. The p-nitro phenyl hydrazone 159d followed with 77% 
inhibition at 10µM concentration. 
 
6.3.3 Thromboxane Synthase Assay Results 
 
Cell free supernatants obtained through centrifugation as described in section 
6.3.2, were then assayed for thromboxane production by radioimmunoassay. (As the 
direct thromboxane synthase product, Thromboxane 1 (TXA1), is labile in aqueous 
media the metabolite of TXA1, Thromboxane 2 (TXB2), the stable hydrolysis product of 
TXA1, was measured). 
 
 
Table 14: Percentage thromboxane synthase inhibition by various isoflavonoid 
phenyl hydrazones at 10 µM. 
 






The three phenyl hydrazones showed thromboxane synthase inhibitory activity 
(Table 14), with the p-tolyl hydrazone 159e exhibiting the greatest activity with 60% 
inhibition at 10µM concentration. The unsubstituted phenyl hydrazone 76 followed with 
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33% inhibition at 10µM concentration and the p-nitro phenyl hydrazone 159d had a 
similar inhibitory activity with 27% inhibition at 10µM. 
 
6.3.4 Activity at α1 Adrenoceptors 
Unfortunately, as the target amines were not synthesised, the α1 adrenoceptor 
results were not obtained. One compound, the pyridyl hydrazone 159g was tested (at the 
Victor Chang Cardiac Research Institute, Sydney) but was shown to be inactive. 
 
6.4 Summary and Conclusions 
As a general trend the phenyl hydrazones exhibited more cytotoxic activity 
against a battery of cancer cell lines than the other isoflavone derivatives tested. When 
comparing this trend with the oxime derivative 143, it can be concluded that an extra 
aromatic ring was beneficial to activity, as had been suggested by the pharmacophore 
modelling (see Chapter 2). Generally, both the acetate protected and deprotected 2-
cyano isoflavenes 116a and 115a, displayed moderate cytotoxicity activities against a 
panel of cancer cell lines. Of notable activity was the acetate protected 2-cyano 
isoflavene against the breast cancer cell line, MCF-7. Three phenyl hydrazones, 76, 
159d and 159e were tested for proliferation inhibition of the LNCaP prostate cancer cell 
line, and all three exhibited good proliferation inhibition, especially the p-nitro 




























Chapter 7  Conclusions and Future Directions 
 Computer aided techniques were employed to facilitate the synthetic target 
design process. Pharmacophores for inhibitors of human 5AR type I, human 5AR type 
II and rat 5AR type II enzymes were generated. The human 5AR type I enzyme training 
set provided pharmacophores with a poor statistical analysis. This was due to a small 
number of compounds comprising the training set, and, as there were a limited number 
of compounds in the literature, it was decided that additional training set molecules 
could be generated by setting up an in house 5AR type I assay. Two pharmacophores 
were produced for the human 5AR type II enzyme, each with excellent statistical 
analysis. For the rat 5AR type II isozyme two pharmacophores were also generated, 
both with moderately good statistical analysis. Multiple generations for a randomized 
variation of this training set produced different pharmacophores with less consistent 
correlation values compared to the non-randomized pharmacophore thus increasing our 
confidence in the statistical relevance of the rat 5AR type II enzyme. The isoflavanone 
30 and phenoxodiol 32 were mapped onto the human 5AR pharmacophores and these 
mappings indicated that addition of an aromatic ring to these types of compounds would 
increase 5AR inhibitory activity. Mappings of these compounds on to α1 adrenoceptor 
pharmacophores revealed that the inclusion of a basic nitrogen could introduce α1A 
adrenoceptor antagonism. In light of these findings 2- and 4- substituted isoflavonoids 
were designed as potential dual action agents for the treatment of prostate cancer and its 
symptoms. Future work should ensure that additional inhibitors of 5AR type I are used 
in the training set of the next 5AR type I pharmacophore, in particular, isoflavonoid 
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5AR inhibitors. These latter should be assessed on all the pharmacophores, and 
correlations between them examined. 
 A versatile route to 2-substituted isoflavenes was developed through utilizing an 
isoflavylium salt 117. It was found that this salt could be synthesised through oxidation 
of the 2-unsubstituted isoflavene 118a by the use of various trityl salts. The trityl 
hexafluorophosphate salt and the trityl pentachlorostannate salt were found to be the 
most successful. Acetate protecting groups were found to be stable under these 
conditions, while tBDMS groups were found to be labile.  Subsequent nucleophilic 
addition to the salt gave 2-substitited derivatives. Eight new 2-substituted isoflavene 
derivatives were synthesized from the acetate protected isoflavene 118a. These 
derivatives included compounds with heteroaryl, cyano, allyl, ethynyl and alkoxy 
substituents in the 2-position. The 2-ethynylisoflavene 116c was found to undergo a 
dimerisation process involving further nucleophilic attack on the isoflavylium salt 
intermediate. A deprotected 2-aminomethylisoflavene 70 was synthesized through 
reduction of the 2-cyano derivative 116a but it could not be purified. A boc and acetate 
protected 2-aminomethyl derivative 116d was synthesised, however due to problems 
with purification and degradation on silica of 116d, removal of the boc and acetate 
protecting groups was not carried out. In order to achieve a stable protected form of the 
2-aminomethylisoflavene 70, investigations into various amine protecting groups should 
be included in future projects. Deprotections of 2-substituted isoflavenes, including the 
cyano, allyl and two alkoxy derivatives, were carried out using either imidazole or 
NaOH. 
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 Synthesis of the 4-cyano isoflavene 133 was achieved, however in poor yield. 
Attempts to reduce 133 to the target amine 67 were not performed due to time 
restrictions, however this should be included in future work. Eight new 4-aryl 
hydrazones 76, 159a-g were synthesized by reaction of the isoflavone 134a with the 
respective hydrazines Another new rearrangement involving the imidazolyl hydrazone 
162 and affording the benzo[b]furan derivative 163 was also found. Approaches toward 
the 4-thienyl isoflavene 71 derivative were also undertaken. One approach employed a 
direct addition of the thienyl substituent to the isoflavanone 134c producing the 
corresponding hydroxy isoflavan 144. This compound was difficult to isolate as it was 
found to rearrange to a novel benzofuran 178. Numerous attempts to form the 2-thienyl 
isoflavene 143 by dehydration of the alcohol 144 were unsuccessful. An alternative 
route involving enolisation and the formation of an isoflavene 4-triflate or 4-methoxy 
isoflavene intermediate which would then undergo a Negishi type coupling to achieve 
the 4-thienyl isoflavene 71 was devised. Attempts at synthesis of 143 through a triflate 
intermediate were unsuccessful and it is in fact not certain whether a triflate 
intermediate was generated as isolation of the triflate was not possible. Reaction of the 
enol isoflavene 146 with methyl iodide gave the 4-methoxy isoflavene 145b. 
Subsequent attempts at coupling the methoxy isoflavene with the thienyl zinc bromide 
reagent 177 were unsuccessful with an unidentified compound being formed; this 
reaction was found to be catalysed by NiCl2. Further investigation into the elucidation 
of the unidentified compound, as well as the synthesis of the thienyl isoflavene 71 is 
required. Regarding further attempts to synthesise the 4-thienyl compound through the 
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Negishi route, trials with various appropriate catalysts, possibly nickel-based, are 
recommended.  
 In order to provide additional isoflavonoid and non-isoflavonoid 5AR type I 
inhibitors for an iterative pharmacophore generation process, a 5AR type I assay was 
developed. A crude protein assay was successfully developed using LNCaP cell lines as 
the enzyme source. The assay was standardised through the use of Finasteride. 
Unfortunately the LNCaP cells were contaminated shortly after the set up of the assay, 
altering the activity of the 5AR type I enzyme. Attempts to overcome this by obtaining a 
new batch of the cell line were unsuccessful. The assay needs to be re-developed with a 
new batch of LNCaP cells and compounds tested for their inhibition. 
Cell based cytotoxicity testing of various synthesised isoflavonoids was carried 
out at Novogen, Sydney using numerous cancer cell lines. The compound which 
showed the most cytotoxicity was the p-tolyl hydrazone 159e against the CCRF-8226 
leukaemia cell line with an LD50 of 5.71 µM. The phenyl hydrazone derivatives were 
generally moderately cytotoxic against most cancer cell lines. 
Three phenylhydrazones, 76, 159e and 159d were tested for proliferation 
inhibition in the androgen dependent prostate cancer cell line LNCaP. Notable growth 
inhibitory activity was shown by all three of the phenyl hydrazones and especially by 
the p-nitrophenylhydrazone 159d against LNCaP cells with an IC50 of less than 0.35 
µM. This indicates that the 5AR pharmacophores are predictive. These three phenyl 
hydrazones were also tested for COX inhibition and thromboxane synthase inhibition. 
Significant COX inhibition was exhibited, while moderate thromboxane synthase 
inhibition was revealed. 
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Further cell based testing of all synthesised derivatives is required. Also testing 
of the amine-based derivatives for α1A adrenoceptor binding should be included in 
future projects. Future projects should consider the phenyl hydrazones as lead 












































Chapter 8 Experimental  
8.1 Molecular Modelling 
Molecular modelling was undertaken using CATALYST version 4.5 (Accelrys) 
on a Silicon Graphics work station. 
 
8.2 Chemistry Experimental Section 
8.2.1 General Experimental for Synthesis 
Masses were measured using an OHAUS Analytical Standard Balance. Melting 
point determinations were carried out on a Reichert hot stage melting point apparatus 
and are uncorrected. 
 
Low Resolution chemical ionization (isobutene, CI+) and electron impact (EI+) 
mass spectra were obtained on a Shimadzu QP-5000 mass spectrometer by a direct 
insertion technique with an electron beam of 70eV. High resolution mass spectra 
(HRMS) (methane, CI+, EI+) were determined on a Fisons/VG Autospec spectrometer 
using PFK (perfluorokerosene) as the internal standard. Low resolution electrospray 
(ES+/ES-) spectra were obtained on a quattro triple quadrapole mass spectrometer. High 
resolution  electrospray mass spectrometry (HRMS) (ES+/ES-) was carried out on a G-
Tof mass spectrometer. The m/z values are stated with their peak intensities as a 
percentage in parentheses. 
 
Microanalysis was carried out by George Blazak at the University of Queensland. 
Microanalysis results are expressed in elemental percentages based on atomic weights.  
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Proton, carbon, two-dimensional and one-dimensional NMR experiments were 
carried out on a Varian Mercury 300 MHz or a Varian Innova 500MHz spectrometer. 
Spectra were recorded in deuterated solvent denoted in parentheses, and referenced to 
the residual non-deutertated solvent signal. Chemical shifts (δ) in parts per million 
(ppm) were measured relative to the internal standard. 
 
Analytical thin layer chromatography (TLC) was carried out on Merck silica gel 
60 F254 pre-coated aluminium plates with a thickness of 0.2 mm. 
 
Chromatography refers to column chromatography, performed under ‘flash’ 
conditions on Merck Silica gel 60 (230-400 mesh), unless otherwise stated. Sigma 
Aldrich aluminium oxide (58 Å mesh) was used when alumina chromatography was 
performed and alumina TLC was performed using Merck neutral aluminium oxide 60 
F254 pre-coated aluminium plates with a thickness of 0.2mm. Chromatography solvent 
mixtures were measured by volume and are reported in parentheses. Compound spots 
on the TLC plates were detected by UV (λ 254 nm) or by reaction with ammonium 
molybdate226. 
 
Solvent removal was carried out under reduced pressure (in vacuo) with a Büchi 
rotary evaporator. The temperature for solvent removal was 50°C unless otherwise 
stated. Solvent extracts were dried with anhydrous sodium sulphate or magnesium 
sulphate as indicated. 
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 Anhydrous solvents were purified and dried according to the method described 
in Perrin and Amarego227 and distilled immediately before use. Other solvents were 
analytical reagent grade and were used as received, with the exception of 
dichloromethane (DCM) which was laboratory reagent grade and was distilled before 
use. Pet. Spirit refers to the fraction with boiling points between 40°C and 60°C. 
Starting materials and reagents were purchased from Sigma Aldrich Pty Ltd, or 
Lancaster Chemicals and used as received. The diacetoxy isoflavonoid precursors 118a, 
119a and 135a were obtained from Novogen, Sydney, and were recrystallised from 



























8.2.2 Experimental Relating to Chapter 3 
 
Synthesis of 7-acetoxy-3-p-acetoxyphenyl-2H-1-benzopyran (118a) from 7-
hydroxy-3-p-hydroxyphenyl-2H-1-benzopyran 
(32)using P2O5 
The diol 32 (4.062 g, 11.88 mmol) was heated at reflux 
in acetic anhydride (20mL) and pyridine (5mL) for 2.5 h. 
The cooled reaction mixture was then added to water (200mL). The crude material was 
then extracted with DCM (2x100 mL). The DCM extract was dried (Na2SO4), the 
solvent removed and the residue recrystallised from ethanol to give 118a (3.387 g, 
10.45 mmol) as a cream powder in 88% yield; mp 177-178 °C. 
 
 
1H-NMR (300MHz, d6-acetone): δ 7.42 (d of d, 2H, J=8.4, 1.5, H-2’), 7.11 (d of d, 2H, 
J=9.0, 2.1, H-3’), 7.06 (d, 1H, J=7.8, H-5), 6.75 (s, 1H, H-4), 6.65 (d of d, 1H, J=8.1, 
2.1), 6.61 (d, 1H, J=1.5, H-8), 5.14 (s, 2H, H-2), 2.31 (s, 3H, CH3CO), 2.29 (s, 3H, 
CH3CO). 13C-NMR (75MHz, CDCl3): δ 169.6 (C=O), 169.6 (C=O), 154.1 (C8a), 151.3 
(C7), 150.6 (C4’), 134.5 (C1’), 130.6 (C3), 127.6 (C5), 126.1 (C2’), 122.2 (C3’), 120.9 


















Synthesis of 7-acetoxy-3-p-acetoxyphenyl-2H-1-benzopyran (118a) from the 
isoflavanol (119) 
The alcohol (119) (1.500 g, 4.385 mmol) was stirred with P2O5 (12.46 g, 87.78 mmol) 
in dry DCM at rt for 2 h. The suspension was then added to water (100mL). Ethyl 
acetate (50 ml) was added and the organic layer was collected, and then washed 
successively with water, and then brine, before being dried over sodium sulfate. The 
solution was then filtered and evaporated to dryness.  The resulting solid was then 
passed through a short silica column using 100% DCM as the eluting solvent, to afford 
118a as a white amorphous solid (1.193 g, 3.683mmol) in 84% yield. 
 
Synthesis of 7-acetoxy-3-p-acetoxyphenyl-2H-1-benzopyran (118a) from the 
isoflavanol (119) using CuSO4 
The alcohol (119) (0.846 g, 2.474 mmol) was heated at reflux in a suspension of 
anhydrous CuSO4 (2.645 g, 15.44 mmol) in dry toluene (5mL) for 30min. The 
suspension was then filtered. The resulting filtrate was then evaporated to dryness under 
reduced pressure, affording 118a as a powder (0.777 g, 2.399 mmol) in 97% yield. 
 
Synthesis of 7-tert-butyldimethylsilyloxy-3-p-tert-butyldimethylsilyloxyphenyl-2H-
1-benzopyran (119b)  from 7-hydroxy-3-p-hydroxyphenyl-2H-1-benzopyran (32) 
A mixture of 32 (1.365 g, 5.686 mmol), 
imidazole (3.986 g, 58.555 mmol), t-
butyldimethylsilyl chloride (3.996 g, 26.515 




















DMF (25 mL) was stirred at rt for 30 h. The reaction mixture was then filtered. Ice-
water (50 mL) was added to the filtrate resulting in precipitate formation. The product 
was extracted from the mixture with DCM (2 x 50 mL), washed with water (3 x 50 mL), 
then brine (50 mL) and then dried over MgSO4. The solution was then filtered. The 
filtrate was evaporated under reduced pressure. The resulting solid was recrystallised 
from absolute ethanol and to give 119b in 67% yield (1.785 g, 3.810 mmol) as 
colourless crystals mp 54-55ºC. 
 
1H-NMR (300MHz, CDCl3): δ 7.08 (d, 2H, J=8.7, H-2’), 6.71 (d, 1H, J=7.8, H-5), 6.63 
(d, 2H, J=8.7, H-3’), 6.46 (s, 1H, H-4), 6.20 (d of d, 1H, J=8.1, 2.4, H-6), 6.16 (d, 1H, 
J=2.4, H-8), 4.89 (s, 2H, H-2), 0.78 (s, 9H, SiC(CH3)3), 0.77 (s, 9H, SiC(CH3)3), 0.00 (s 
6H, SiCH3). 13C-NMR (75MHz, CDCl3): δ 156.3 (C8a), 155.4 (C7), 154.0 (C4’), 130.1 
(C1’), 128.6 (C3), 127.2 (C5), 125.7 (C2’), 120.2 (C3’), 118.3 (C4), 117.0 (C4a), 113.4 
(C6), 107.5 (C8), 67.2 (C2), 25.7 (SiCCH3), 18.3 (SiCCH3), -4.4 (SiCH3). MS (ES+): 
m/z 469.4 (M+1, 100%). HR (ES+) MS: m/z calcd for [MH+] C9H21NO2Si: 469.2589, 
found: 469.2592. 
 
Preparation of t-butyl N-(trimethylsilyl)methylcarbamate (121a) 
A solution of DMAP (0.091 g, 0.8446 mmol) and (BOC)2O (3.402 g, 
15.588 mmol) in acetonitrile (6 mL) was added to 
trimethylsilylmethyamine 120a (0.703 g, 6.805 mmol) with ice cooling. The reaction 
mixture was then stirred at rt (30°C) for 48 h. The reaction mixture was added to water 






filtered. The DCM was evaporated under reduced pressure. The residue was redissolved 
in DCM (2 mL) and applied to a silica column. A column was then run with 100% 
DCM as the mobile phase, with TLC monitoring of the fractions using a molybdate dip. 
The product (121a) was obtained as a colourless oil in 72% yield (0.991 g, 4.873 
mmol). 
 
1H-NMR (300MHz, CDCl3): δ 3.10  (bs, 1H, NH), 2.70 (d, 2H, J=5.1, CH2), 1.46 
(s, 9H, C(CH3)3) 0.00 (s, 9H, Si(CH3)3). 13C-NMR (75MHz, CDCl3): 152.9 (C=0), 81.8 
(C(CH3)3), 37.1 (SiCH2), 28.0 (C(CH3)3), -2.9 (Si(CH3)3). MS (ES+): m/z 203 (M+1, 
14%), 147 (M+-C(CH3)3+2, 32%), 132 (M+-O-C(CH3)3+2, 100%).  HR (ES+) MS: m/z 
calcd for [M+] C9H21NO2Si: 203.1432, found: 203.1429. 
 
BOC protection of tert-butyl N-(trimethylsilyl)methylcarbamate (120a). 
A solution of DMAP (0.175 g, 1.624 mmol) and (BOC)2O (4.775 g, 21.879 mmol) in 
acetonitrile (8 mL) was added to trimethylsilylmethylamine 120a (0.957 g, 9.269 mmol) 
at 0°C and the mixture then stirred at rt (30°C) for 100 h. The reaction mixture was 
added to water (150 mL) and extracted with DCM (2 x 75 mL). The DCM was dried 
over Na2SO4 and filtered. The DCM was evaporated under reduced pressure. The 
residue was redissolved in DCM (2 mL) and applied to a silica column. A column was 
then run with 100% DCM as the mobile phase to afford (121a) in 69% yield (1.302 g, 




Synthesis of tert-butyl N-(tert-butyloxycarbonyl)-N-
(trimethylsilyl)methylcarbamate (122a) 
A solution of DMAP (0.081 g, 0.757 mmol) and (BOC)2O (0.253 g, 
1.159 mmol) in THF (2 mL) was added to t-butyl N-
(trimethylsilyl)methylcarbamate (120a) (0.086 g, 0.422 mmol) with 
ice cooling and then the reaction mixture was heated at reflux for 48 h. The reaction 
mixture was then added to water (150 mL) and extracted with DCM (2 x 75 mL). The 
DCM was dried over Na2SO4 and filtered. The DCM was evaporated under reduced 
pressure. The residue was redissolved in DCM (2 mL) and applied to a silica column. A 
column was then run with 100% DCM as the mobile phase. This gave the product 
(122a) as a clear solid in 92 % yield (0.123 g, 0.388 mmol), mp 52-53 °C. 
 
1H-NMR (300MHz, CDCl3): δ 3.10 (s, 2H, CH2), 1.45 (s, 18H, C(CH3)3), 0.00 (s, 9H, 
Si(CH3)3). 13C-NMR (75MHz, CDCl3): δ 155.8 (C=O), 155.4 (C=O), 82.3 (C(CH3)3), 
37.1 (SiCH2), 28.0 (C(CH3)3), -2.9 (Si(CH3)3). MS (ES+): m/z 304 (M+1, 12%), 248 
(M+- C(CH3)3+2, 27%), 233 (M+-O- C(CH3)3+2, 100%), 175 (M+-C(CH3)3-O-C(CH3)3, 
54%), 131 (M+-COO-C(CH3)3-O-C(CH3)3, 38%). HR (ES+)MS: m/z calcd for [MH+] 










Synthesis of tert-butyl N-benzyl-N-(trimethylsilyl)methylcarbamate (122b) 
A solution of DMAP (0.088 g, 0.8185 mmol) and (BOC)2O (1.972 
g, 9.037 mmol) in acetonitrile (3 mL) was added to TMS methyl 
benzyl amine 121b (0. 403 g, 2.082 mmol) on ice and stirred at rt. 
The reaction mixture was added to water (150 mL) and extracted with DCM (2x 75 
mL). The DCM was dried over Na2SO4 and filtered. The DCM was evaporated under 
reduced pressure. The residue was redissolved in DCM (2 mL) and applied to a silica 
column. A column was then run with 100% DCM as the mobile phase. This provided 
122b as a clear oil in 75% yield (0.459 g, 1.562 mmol). 
 
1H-NMR (300MHz, CDCl3): δ 7.19-7.35 (m, 5H, ArH), 4.42 (s, 2H, PhCH2), 2.69 (s, 
2H, SiCH2), 1.42 (s, 9H, C(CH3)3), 0.04 (s, 9H, Si(CH3)3). 13C-NMR (75MHz, CDCl3): 
δ 149.8 (C=O), 128.5 (ArCH), 127.2 (ArCCH2), 79.3 (C(CH3)3), 52.8 (PhCH2), 37.9 
(SiCH2), 28.5 (C(CH3)3), -1.4 (Si(CH3)3). MS (ES+): m/z 294 (M+1, 38%), 238 (M+1-t-
Bu, 92%), 222 (M+1-TMS, 100%). HR (ES+) MS: m/z calcd for [MH+] C16H27NO2Si: 
294.1901, found: 294.1903. 
 
Synthesis of 7-acetxoy-3-p-acetoxyphenyl-2cyano-2H-1-benzopyran (116a) using 
trityl tetrafluoroborate 
Freshly distilled anhydrous DCM (50 mL) was 
added to 118a (0.504 g, 1.554 mmol), trityl 
tetrafluoroborate (0.768 g, 2.296 mmol) and 



















temperature for 30 min. Trimethylsilyl cyanide (0.318 g, 3.215 mmol) was then injected 
into the reaction mixture and left to stir at room temperature overnight. The solution 
was filtered. The filtrate was then dried (Na2SO4) and dissolved in DCM (4 mL) and 
applied to a silica column. Elution with DCM gave the product 116a as a white solid 
(0.233 g, 0.668 mmol, 43%), mp156 -158°C. 
 
1H-NMR (500MHz, CDCl3): δ 7.49 (d, 2H, J=8.7, H-2’/6’), 7.23 (d, 1H, J=8.0, H-5), 
7.18 (d, 2H, J=8.6, H-3’/5’), 6.97 (s, 1H, H-4), 6.85 (d of d, 1H, J=2.5, 8.1, H-6), 6.84 
(s, 1H, H-8), 6.01 (s, 1H, H-2), 2.32 (s, 3H, CH3), 2.30 (s, 3H, CH3). 13C-NMR 
(75MHz, CDCl3): δ 169.1 (C=O), 168.9 (C=O), 151.9 (C8a’), 151.1 (C7), 150.3 (C4’), 
131.9 (C3), 128.3 (C5), 126.2 (C2’), 125.9 (C1’), 122.4 (C3’), 122.3 (C4), 119.1 (C4a), 
117.0 (C6), 116.0 (CN), 110.5 (C8), 64.3 (C2), 21.1 (CH3). MS (CI+): m/z 323 (-CN, 
100%), 349 (M+, 8%). MS (ES+): m/z 367 (M++H2O, 100%). Microanalysis: Found: 
C=69.20%; H=4.34, 4.35%; N= 3.67%; C20H15NO5 requires: C=68.76%; H=4.33%, 
N=4.01%. 
 
Synthesis of 7-acetxoy-3-p-acetoxyphenyl-2cyano-2H-1-benzopyran (116a) using 
trityl hexafluorophosphate salt 
Freshly distilled anhydrous DCM (50 mL) was 
added to (118a) (0.503 mg, 1.550 mmol), trityl 
hexafluorophosphate (0.879 g, 2.265 mmol) and 
powdered 3Å molecular sieves. The murky 


















(0.480 g, 485 mmol) was then injected into the reaction mixture and left to stir at rt 
overnight. The solution was filtered. The filtrate was then dried and dissolved in DCM 
(4 mL) and applied to a silica column. A gradient column was then run starting with 5% 
hexane in DCM then run using 100% DCM. The product 116a was collected in 80% 
yield as a white solid (0.431 g, 1.235 mmol), mp 156-158°C. 
 
Synthesis of 7-acetxoy-3-p-acetoxyphenyl-2cyano-2H-1-benzopyran (116a) using 
trityl pentachlorostannate 
Freshly distilled anhydrous DCM (50 mL) was added to 118a (0.499 g, 1.5398 mmol), 
trityl pentachlorostannate (1.273 g, 1.834 mmol) and powdered 3Å molecular sieves. 
The murky brown solution was stirred at room temperature for 30 min. Trimethylsilyl 
cyanide (0.550 g, 556 mmol) was then injected into the reaction mixture and left to stir 
at rt overnight. The solution was filtered. The filtrate was then dried and dissolved in 
DCM (4 mL) and applied to a silica column. The column was then run starting with 
100% in DCM, then 5% ethyl acetate in DCM. The product 116a was collected in 76% 
yield as a white solid (0.408 g, 1.170 mmol), mp 164-165ºC.  
 
Synthesis of 7-acetoxy-3-p-acetoxyphenyl-2-(2-thiazoyl)-2H-1-benzopyran (116b) 
Anhydrous DCM (50 mL) was added to 118a 
(0.451 g, 1.390 mmol), trityl hexafluorophosphate 
(0.849 g, 2.188 mmol) and powdered 3Å molecular 
sieves. The murky brown solution was stirred at 
























into the reaction mixture and the mixture left to stir at room temperature for 2h. The 
solution was filtered. The filtrate was then dried (MgSO4) and dissolved in DCM (4 
mL) and applied to a silica column. A gradient column was then run starting with 100% 
DCM increasing polarity by 5% ethyl acetate increments and ending with 10% ethyl 
acetate in DCM. The product 116b was collected in 78% yield as a creamy white solid 
(0.695 g 1.707 mmol), mp 136-138ºC. 
 
1H-NMR (300MHz, CDCl3): δ 7.60 (bd, 1H, J=2.7, H-2”), 7.37 (d, 2H, J=8.7, H-2’/6’), 
7.23 (d, 1H, J=6.3, H-5), 7.08 (d, 1H, J=2.7, H-3”), 6.93 (d, 2H, J=8.4, H-3’/5’), 6.89 
(s, 1H, H-4), 6.57 (d of d, 1H, J=8.4, 2.7, H-6), 6.53 (d, 1H, J=2.4, H-8), 6.44 (bs, 1H, 
H-2), 2.13 (s, 3H, CH3), 2.10 (s, 3H, CH3). 13C-NMR (75MHz, CDCl3): δ 169.5 (C=O), 
169.3 (C=O), 169.3 (C1”), 151.8 (C8a), 151.7 (C7), 150.8 (C4’) 143.3 (C4”), 134.0 
(C3), 131.5 (C1’), 127.9 (C5), 126.9 (C2’), 122.2 (C3’), 121.1 (C3”), 120.9 (C4), 120.2 
(C4a), 115.7 (C6), 110.6 (C8), 74.7 (C2), 21.3 (CH3CO). MS (CI+): m/z 407.8 (M+1, 
100%). HR (CI+) MS: m/z calcd for [M+] C22H17NO5S: 408.0906, found: 408.0887. 
 
Synthesis of 7-acetoxy-3-p-acetoxyphenyl-2-ethynyl-2H-1-benzopyran-2 (116c) 
Anhydrous DCM (50 mL) was added to 118a (0.646 g, 1.995 mmol), trityl 
hexafluorophosphate (1.159 g, 2.987 mmol) and powdered 3Å molecular sieves. The 
brown-yellow solution was stirred at room temperature for 1 h. TMS acetylene (1.4 mL) 
was then injected into the reaction mixture and the mixture left to stir at room 
temperature for 1 h. The solution was filtered. The filtrate was then dried (MgSO4) and 
dissolved in DCM (4 mL) and applied to a silica column. A gradient column was then 
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run starting with 100% DCM increasing polarity by 5% ethyl acetate increments and 
ending with 10% ethyl acetate in DCM. The product 116c was collected in 7% yield as 
a creamy white solid (0.047 g, 0.1397 mmol), mp 179-181 °C decomp., and the dimeric 




1H-NMR (300MHz, CDCl3): δ  7.56 (d, 2H, J=8.7, 
H-2’), 7.19 (d, 1H, J=8.1, H-5), 7.10 (d, 2H, J=8.7, 
H-3’), 6.91 (s, 1H, H-4), 6.80 (d, 1H, J=2.4, H-8), 
6.75 (d of d, 1H, J=8.4, 2.4, H-6), 6.19 (d, 1H, J=7.5, H-2), 3.71 (d, 1H, J=7.8, C≡CH), 
2.30 (s, 3H, COCH3), 2.29 (s, 3H, COCH3).13C-NMR (75MHz, CDCl3): δ 169.8 (C=O), 
169.7 (C=O), 134.2 (C7), 131.0 (C8a), 128.0 (C4’), 127.0 (C3), 127.0 (C1’), 122.2 
(C5), 122.1 (C2’), 120.8 (C4), 119.0 (C3’), 115.6 (C6), 110.8 (C8), 91.7 (C2), 21.4 
(COCH3). MS (CI+): m/z 323 (isoflavylium, M-C≡CH, 100%). Microanalysis: Found: 
C=72.39%; H=4.66%; C20H16O5 requires: C=72.41%; H=4.63%. 
 
(130): 
1H-NMR (300MHz, d6-DMF): δ  7.11 (d, 
2H, J=9.0, H-2’), 7.02 (d, 1H, J=8.4, H-5), 
6.98 (s, 1H, H-4), 6.73 (d of d, 1H, J=2.4, 










































(s, 1H, H-2), 6.51 (d of d, 1H, J=8.4, 2.4, H-6), 1.94 (s, 3H, COCH3), 1.88 (s, 3H, 
COCH3). 13C-NMR (75MHz, d6-DMSO): δ 169.2 (C=O), 169.1 (C=O), 151.8 (C7), 
150.8 (C8a), 150.2 (C4”), 133.0 (C3), 128.4 (C1’), 128.2 (C5), 126.4 (C2’), 122.2 (C4), 
121.5 (C3’), 119.4 (C6), 116.3 (C4a), 110.7 (C8), 92.5 (C≡), 91.7 (C2), 20.4 (COCH3), 
20.3 (COCH3). MS (ES+): m/z 323 (M+1, 100%). Microanalysis: Found: C=69.27%, 
H=4.62%; C41H34O10 requires: C=69.28%, H=4.60%, 
 
Synthesis of the dimeric compound 130  
Anhydrous DCM (50 mL) was added to 118a (0.646 g, 1.995 mmol), trityl 
hexafluorophosphate (1.159 g, 2.987 mmol) and powdered 3Å molecular sieves. The 
brown-yellow solution was stirred at rt overnight. TMS acetylene (1.4 mL) was then 
injected into the reaction mixture and the mixture left to stir at rt for 1 hr. The solution 
was filtered. The filtrate was then dried (MgSO4) and dissolved into DCM (4 mL) and 
applied to a silica column. A gradient column was then run starting with 100% DCM 
increasing polarity by 5% ethyl acetate increments and ending with 10% ethyl acetate in 




Anhydrous DCM (50 mL) was added to 118a 
(0.404 g, 1.246 mmol), trityl hexafluorophosphate 























sieves. The orange-yellow solution was stirred at rt for 30 min. Anhydrous methanol (3 
mL) was then injected into the reaction mixture and the mixture stirred at room 
temperature overnight. The solution was filtered. The filtrate was then dried (MgSO4) 
and dissolved in DCM (4 mL) and applied to a silica column. A gradient column was 
then run starting with 100% DCM increasing polarity by 5% ethyl acetate increments 
and ending with 10% ethyl acetate in DCM. The product 116d was collected in 45% 
yield as a creamy white solid (0. 255 g, 0.5612 mmol), mp 52-54 °C. 
 
1H-NMR (300MHz, CDCl3): δ  7.64 (d, 1H, J=8.7, H-5), 7.52 (d, 1H, J=8.7, H-2’), 7.48 
(d, 1H, J=8.7, H-2’), 7.13 (d, 2H, H=8.7), 6.98 (d of d, 1H, J=8.7, 2.4, H-6), 6.91 (d, 
1H, J=2.8, H-4), 6.67 (d, 0.6H, J=2.1, H-8), 6.66 (d, 0.4H, J=2.1, H-8), 5.44 (d of d, 
0.4H, J=11.0, 2.4, NH), 5.15 (d of d of d, 1H, J=11.1, 6.0, 2.4, H-2), 4.86 (bt, 0.3H, 
J=1.5, NH), 4.76 (bd, 0.3H, J=1.2, NH), 2.59 (d of d, 1H, J=15.0, 10.0, CH2), 2.20 (d, 
1H, J=15.0, CH2), 2.31 (s, 3H, COCH3), 2.23 (s, 3H, COCH3), 2.16 (s 9H,C(CH3)3). 
13C-NMR (75MHz, CDCl3): δ 169.5 (COCH3),155.2 (CONH), 150.1 (C8a), 147.0 (C7), 
143.7 (C4’), 134.7 (C3), 130.7 (C1’), 127.5 (C5), 125.2 (C2’), 122.2 (C2’), 121.9 (C4), 
120.2 (C3’), 116.1 (C6), 114.9 (C4a), 109.5 (C8), 75.5 (C(CH3)), 72.4 (C2), 43.1 (CH2), 
30.7 (C(CH3)3), 21.3 (COCH3). MS (ES+): m/z 453.2 (M+, 33.3%), 396.2 (M-C(CH3)3, 
9.2%), 379.2 (M-O-C(CH3)3, 25.3%), 338 (M+1-2xboc, 100%), 323.0 (Isoflavylium, 




Attempted synthesis of 7-acetoxy-3-p-acetoxyphenyl-2-tert-butyloxycarbonyl(N-
benzyl)aminomethyl-2H-1-benzopyran (116e) 
Freshly distilled anhydrous DCM (50 mL) was added to 118a (0.524 g, 1.617 mmol), 
trityl hexafluorophosphate (0.799 g, 2.059 mmol) and powdered 3Å molecular sieves. 
The reaction mixture was stirred at room temperature for 30 min. tert-butyl N-benzyl-N-
(trimethylsilyl)methylcarbamate (122b) (0.750 g, 2.557 mmol) was then injected into 
the flask and the mixture left to stir at rt for 3 hours. The solution was filtered. The 
filtrate was then dried (MgSO4) and dissolved in DCM (4 mL) and applied to a silica 
column. A gradient column was then run starting with 5% hexane in DCM as the mobile 
phase, then 100% DCM. No product was isolated, with material remaining on the base 
line. 
 
Synthesis 7-acetoxy-3-p-acetoxyphenyl-2-allyl-2H-2-allyl-1-benzopyran (116f)  
Freshly distilled anhydrous DCM (50 mL) was 
added to 118a (0.492 g, 1.517 mmol) and trityl 
hexafluorophosphate (0.865 g, 2.228 mmol). The 
murky brown solution was stirred at room 
temperature for 25 min. Allyl tributyltin (1.053 g, 
3.180 mmol) was then injected into the flask and the mixture left to stir at rt overnight. 
The solution was filtered. The filtrate was then dried (MgSO4) and dissolved in DCM (4 
mL) and applied to a silica column. A gradient column was then run starting with 5% 
hexane in DCM as the mobile phase, then 100% DCM. The product 116f was collected 


























1H-NMR (300MHz, CDCl3): δ  7.45 (d, 2H, J=9.0, H-2’), 7.11 (d, 2H, J=8.7, H-3’), 
7.06 (d, 1H, J=8.0, H-5), 6.71 (s, 1H, H-4), 6.67 (d, 1H, J=2.4, H-8), 6.64 (d of d, 1H, 
J=2.4,1.5, H-6), 5.94-5.80 (m, 1H, H-2”), 5.34 (d of d, 1H, J=3.0, 12.0, H-2), 5.07 (d, 
1H, J=0.9, H-3”b), 5.04 (d, 1H, J=12.0, H-3”a), 2.62-2.51 (m, 1H, H-1”), 2.31 (s, 3H, 
CH3CO), 2.27 (s, 4H, CH3CO, H-1”). 13C-NMR (75MHz, CDCl3): δ 169.5 (C=O), 
169.3(C=O), 152.4 (C8a), 151.5 (C7), 150.5 (C4’), 134.7 (C1’), 134.4 (2”), 133.8 (C5), 
127.4 (2’), 126.6 (C3), 122.2 (C3’), 120.8 (C4), 119.5 (4a), 118.1 (6), 114.8 (C3”), 
110.4 (C8), 75.6 (C2), 38.0 (C1”), 21.5 (CH3CO). MS (CI+): m/z 365.0 (M+1, 34%), 
323 (M+-allyl, 100%). HR (CI+) MS: m/z calcd for [MH+] C22H20NO5: 365.1384, 
found: 365.1380.  
 
Synthesis of 7-acetoxy-3-p-acetoxyphenyl-2-methoxy-2H-1-benzopyran (116g) 
Anhydrous DCM (50 mL) was added to 118a 
(0.376 mg, 1.159 mmol), trityl hexafluorophosphate 
(0.956 g, 2.4647 mmol) and powdered 3Å 
molecular sieves. The brown-yellow solution was stirred at room temperature for 30 
min. Anhydrous methanol (3 mL) was then injected into the reaction mixture and the 
mixture stirred at rt overnight. The solution was filtered. The filtrate was then dried 
(MgSO4) and dissolved into DCM (4 mL) and applied to a silica column. A gradient 
column was then run starting with 100% DCM increasing polarity by 5% ethyl acetate 
increments and ending with 10% ethyl acetate in DCM. The product 116g was collected 





















1H-NMR (300MHz, CDCl3): δ 7.53 (d, 2H, J=9.0, H-2’), 7.24 (d, 1H, J=8.4, H-5), 7.13 
(d, 2H, J=8.4, H-3’), 6.98 (s, 1H, H-4), 6.85 (d, 1H, J=2.1, H-8), 6.77 (d of d, 1H, 
J=8.4, 2.1, H-6), 5.85 (s, 1H, H-2), 3.58 (s, 3H, OCH3), 2.32 (s, 3H, CH3CO), 2.30 (s, 
3H, CH3CO). 13C-NMR (75MHz, CDCl3): δ 169.5 (C=O), 169.3(C=O), 151.6 (C7), 
150.7 (C8a), 150.4 (C4’), 133.7 (Ca), 128.3 (Ca), 128.1(C5), 127.0 (C2’), 122.1(C3’), 
121.6 (C4), 119.6 (C4a), 115.6 (C6), 110.5 (C8), 98.3 (C2), 55.5 (OCH3), 21.3 
(CH3CO).  
Ca: C3 or C1’ 
MS (CI+): m/z 323 (100%, M-OCH3). Microanalysis: Found: C=67.82%; H=5.13, 
4.35%; C20H18O6 requires: C=67.79%; H=5.12 %. 
 
Synthesis of 7-acetoxy-3-p-acetoxyphenyl-2-ethoxy-2H-1-benzopyran (116h) 
Anhydrous DCM (50 mL) was added to 118a 
(0.502 g, 1.549 mmol), trityl hexafluorophosphate 
(0.872 g, 2.247 mmol) and powdered 3Å molecular 
sieves. The murky brown solution was stirred at rt for 30 min. Anhydrous ethanol (3 
mL) was then injected into the reaction mixture and left to stir at rt overnight. The 
solution was filtered. The filtrate was then dried (MgSO4) and dissolved into DCM (4 
mL) and applied to a silica column. A gradient column was then run starting with 100% 
DCM increasing polarity by 5% ethyl acetate increments and ending with 10% ethyl 
acetate in DCM. The product 116h was obtained in 63% yield as a creamy white solid 




















1H-NMR (300MHz, CDCl3): δ 7.53 (d, 2H, J=9.0, H-2’), 7.23 (d, 1H, J=8.4, H-5), 7.12 
(d, 2H, J=8.4, H-3’), 6.98 (s, 1H, H-4), 6.82 (d, 1H, J=2.1, H-8), 6.76 (d of d, 1H, 
J=8.4, 2.1, H-6), 5.95 (s, 1H, H-2), 4.00 (m, 1H, OCH2CH3), 3.78 (m, 1H, OCH2CH3) 
2.32 (s, 3H, CH3CO), 2.30 (s, 3H, CH3CO), 1.25 (t, 3H, J=7.2, CH2CH3). 13C-NMR 
(75MHz, CDCl3): δ 169.5 (C=O), 169.3 (C=O), 151.4 (C7), 151.1 (C8a), 150.6 (C4’), 
134.6 (Ca), 129.7 (Ca), 128.0 (C5), 126.9 (C2’), 122.1 (C3’), 121.5 (C4), 119.6 (C4a), 
115.4 (C6), 110.4 (C8), 97.2 (C2), 64.1 (CH2CH3), 21.5 (CH3CO), 15.7 (CH3CH2).  
Ca: C3 or C1’ 
MS (CI+): m/z 323 (isoflavylium, 100%). Microanalysis: Found: C=68.49%; 
H=5.53%; C21H20O6 requires: C=68.40%; H=5.48 %. 
 
Synthesis of 7-acetoxy-3-p-acetoxyphenyl-2-(3-bromopropoxy)-2H-1-benzopyran 
synthesis (116i) 
Freshly distilled anhydrous DCM (50 mL) was 
added to 118a (0.434 g, 1.338 mmol), trityl 
hexaflurorphosphate (0.9910 g, 2.570 mmol) and 
powdered 3Å molecular sieves under argon. The 
murky brown solution was stirred at room temperature for 1 h. 3-Bromopropanol (1.2 
mL) was then injected into the reaction mixture and the mixture stirred for 1.5 h. The 
solution was filtered. The filtrate was then concentrated by evaporation under reduced 





















DCM. The product 116i was collected in 66% yield as a white solid (0.407 g, 0.8831 
mmol), mp 123-125 °C. 
 
1H-NMR (300MHz, CDCl3): δ 7.54 (d, 2H, J=8.7, H-2’), 7.23 (d, 1H, J=8.4, H-5), 7.14 
(d, 2H, J=8.7, H-3’), 7.00 (s, 1H, H-4), 6.85 (d, 1H, J=2.4, H-8), 6.78 (d of d, 1H, 
J=2.1, 8.1, H-6), 5.97 (s, 1H, H-2), 4.11 (m, 1H, OCH2), 3.88 (m, 1H, OCH2), 3.41 (m, 
2H, BrCH2), 2.31 (s, 3H, CH3CO), 2.30 (s, 3H, CH3CO), 2.11 (m, 2H, 
OCH2CH2CH2Br). 13C-NMR (75MHz, CDCl3): δ 169.6 (C=O), 169.4 (C=O), 151.5 
(C7), 151.0 (C8a), 150.7 (C4’), 134.3 (Ca), 129.5 (Ca), 128.1 (C5), 126.8 (C2’), 122.2 
(C3’), 121.4 (C4), 119.5 (C4a), 115.6 (C6), 110.4 (C8), 97.6 (C2), 65.6 (OCH2), 32.7 
(OCH2CH2), 30.8 (CH2Br), 21.4 (COCH3), 21.4 (COCH3). 
 Ca: C3 or C1’ 
MS (CI+): m/z 463/461 (M+1, 13/17%), 462/460 (M+, 14/13%), 418/420 (M+1-COCH3, 
4/4%), 323 (M-OCH2CH2CH2Br, 100%), 281 (M-OCH2CH2CH2Br-COCH3, 75%), 239 
(M-OCH2CH2CH2Br-2xCOCH3, 38%). HR (CI+) MS: m/z calcd for [MH+] 
C22H21BrO6: 461.0594, found: 461.0590. 
 
Attempted Synthesis of 7-actetoxy-3-p-acetoxyphenyl-2-(5-triazoyl)-2H-1-
benzopyran (132) 
The isoflavene 116c (0.024 g, 0.0688 mmol) was stirred with CuSO4.5H2O (0.003 g, 
0.00120 mmol), sodium ascorbate (0.008 g, 0.0404 mmol) and TMS azide (0.154 g, 
1.337 mmol) in a 1:1 mixture of ethanol and water (2mL) for 48 hours. Water was 
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added and the precipitate collected, 1H-NMR analysis only showed the starting 
isoflavene 116c. 
 
Attempted synthesis of aminomethyl 7-hydroxy-3-p-hydroxyphenyl-2H-1-
benzopyran  (70)  
The diacetoxy protected nitrile compound 116a (0.100 g, 0.2871 mmol) in anhydrous 
THF (0.9 mL) was added dropwise to a suspension of LiAlH4 (0.026 g, 0.6772 mmol) at 
0ºC. Upon the nitrile addition gelatinisation of the mixture began and thus an additional 
amount of anhydrous THF (1 mL) was added. This stopped the gelatinisation process 
and dissolved the gel that had already formed. The resulting suspension was stirred at 
0ºC for 10 min, then at rt for 2.75 h. Water (25mL) was added to the reaction mixture 
and the mixture filtered. The filtrate was evaporated to dryness. Attempts to purify the 
product 70 were unsuccessful, as recrystallisation proved difficult and product absorbed 
strongly to the base line on PLC (silica gel). Attempts to extract further product from 
the aluminium hydroxide precipitate with DCM, ether and ethyl acetate were 
unsuccessful. 
 
Attempted deprotection of 7-acetoxy-3-p-acetoxyphenyl-2cyano-2H-1-benzopyran 
(115a) 
Compound 116a (0.300 g, 0.8602 mmol) in a 5M imidazole in methanol solution 
(10ml) was heated at reflux for 1.5 h. The solution was then cooled to rt and the 
methanol was evaporated off under reduced pressure. Water (25 ml) was added, 
resulting in a milky precipitate. This suspension was stored in the refrigerator for 13 h, 
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resulting in a more coarse precipitate. The off white precipitate was collected by suction 
filtration. 1H-NMR analysis of this product revealed it only containing aromatic 
hydrogens, and no characteristic signal between 6.0-6.2ppm (for H2). 
 
Synthesis of 2-cyano-7-hydroxy-3-p-hydroxyphenyl-2H-1-benzopyran (115a) 
The nitrile 116a (0.0845 g, 0.243 mmol) was stirred at 
room temperature in THF (3mL) and 50% methanol/water 
1M NaOH (9mL) for 4 h. The solution was then 
neutralized with 5M HCl and extracted with DCM (2x50mL). The DCM extract was the 
concentrated, and then applied to a silica plug (short column). 15% Diethyl ether in 
DCM was passed through the plug to give the product 115a as a red glass (0.061 g, 
0.233mmol) in 96% yield. 
 
1H-NMR (300MHz, d6-acetone): δ 8.79 (bs, H, OH), 7.52 (d, 2H, J=8.7, H-2’), 7.19 (d, 
1H, J=8.1, H-5), 7.09 (s, 1H, H-4), 6.93 (d, 2H, J=8.7, H-3’), 6.59 (d of d, 1H, J=8.4, 
2.4, H-6), 6.55 (d, of d,  J=2.1, 0.3, H-8), 6.46 (s, 1H, H-2). 13C-NMR (75MHz, d6-
acetone): δ 160.0 (C8a), 158.1 (C7), 156.6 (C4), 142.8 (C3), 139.7 (C1’), 128.9 (C2’), 
125.8 (C5), 115.4 (C3’), 113.4 (C4), 110.3 (CN), 105.0 (C6), 103.5 (C4a), 102.8 (C8), 
61.2 (C2). MS (CI+): m/z 266 (M+1, 3%), 239 (isoflavylium, 100%). Microanalysis: 





















Synthesis of 2-allyl-7-hydroxy-3-p-hydroxyphenyl-2H-1-benzopyran (115f) 
Compound 116f (0.095 g, 2.61 mmol) was stirred at 
room temperature in a 1M NaOH, 50% methanol/50% 
water solution (12 mL) for 7h. The solution was 
neutralised with 5M HCl and extracted with DCM (2x50mL). The DCM extract was 
concentrated, then applied to a silica plug. 15% Diethyl ether in DCM was passed 
through the plug to give the product 115f as a red glass (0.071 g, 0.253 mmol) in 97% 
yield. 
  
1H-NMR (300MHz, d6-acetone): δ 8.33 (s, 1H, OH), 8.27 (s, 1H, OH), 7.41 (d, 2H, 
J=8.7, H-2’), 6.98 (d, 1H, J=7.8, H-5), 6.87 (d, 2H, J=8.7, H-3’), 6.75 (s, 1H, H-4), 6.42 
(d of d, 1H, J=8.1, 2.4, H-6), 6.35 (d, 1H, J=2.4, H-8), 5.94 (m, 1H, H-2”), 5.35 (d of d, 
1H, J=9.3, 3.3, H-2), 5.04 (d of d, 1H, J=6.0, 1.2, H-3”), 5.0 (d, 1H, J=1.2, H-3”), 2.52 
(m, 1H, H-1”), 2.25 (m, 1H, H-1”). 13C-NMR (75MHz, d3-acetone): δ 158.6 (C7), 
157.3 (C4’), 152.8 (C8a), 134.8 (C3), 132.0 (C2”), 128.7 (C1’), 127.6 (C5), 126.5 
(C2’), 117.2 (C4), 116.8 (C3”), 115.8 (C3’), 108.7 (C6), 107.6 (C4a) 103.7 (C8), 76.0 
(C2), 37.9 (C1”). MS (CI+): m/z 281.1 (M+1, 22%), 239.3 (M+1-allyl, 100%). HR 






















Synthesis of 2-ethoxy-7-hydroxy-3-p-hydroxyphenyl-2H-1-benzopyran (115h) 
The 2-ethoxy compound 116h (0.011 g, 0.03013 mmol) 
was stirred at rt in a 0.1M NaOH, 50% methanol/50% 
water solution (0.6 mL) and THF (4.5 mL) for 2h. The 
solution was neutralised with 5M HCl and extracted with DCM (2 x 25mL). The DCM 
layers were then combined, dried with MgSO4 and concentrated, then applied to a silica 
plug. 15% Diethyl ether in DCM was passed through the plug to give the product 115h 
as a red glass (0.005 g, 0.016 mmol) in 53% yield. 
 
1H-NMR (300MHz, d4-methanol): δ 7.08 (d, 2H, J=8.4, H-2’), 7.00 (d, 1H, J=7.8, H-
5), 6.81 (s, 1H, H-4), 6.48 (d, 2H, J=8.4, H-3’), 6.44 (d of d, 1H, J=7.8, 2.4, H-6), 6.35 
(d, 1H, J=2.1, H-8), 6.13 (s, 1H, H-2), 4.80 (m, 1H, OCH2CH3), 3.63 (m, 1H, 
OCH2CH3). 13C-NMR (75MHz, d4-methanol): δ 158.7 (C8a), 156.9 (C7), 150.9 (C4’), 
127.7 (C*), 126.8 (C*), 126.6 (C2’), 126.3 (C5), 119.5 (C4), 115.3 (C4a), 115.3 (C3’), 
109.7 (C6), 103.6 (C8), 92.0 (C2), 67.8 (CH2CH3), 20.5 (CH3CH2).  
Ca: C3 or C1’ 
MS (CI+): m/z 239.3 (isoflavylium, 100%). Microanalysis: Found: C=71.78%; H=4.21, 























Synthesis of 2-(3-bromopropoxy)-7-hydroxy-3-p-hydroxyphenyl-2H-1-benzopyran 
(115i) 
The diacetoxy 2-bromopropoxy compound 116i (0.106 g, 
0.231 mmol) was stirred at room temperature in a 0.1M 
NaOH, 50% methanol/50% water solution (1 mL) and 
THF (9 mL) for 20h. An additional portion of aqueous 5M NaOH was added (0.2mL) 
The solution was neutralised with 5M HClaq and extracted with DCM (2x50mL). The 
DCM layers were then combined, dried with MgSO4 and concentrated, then the residue 
applied to a silica plug. 15% Diethyl ether in DCM was passed through the plug to give 
the product 115i as a red glass (0. 057 g, 0.1507 mmol) in 65% yield. 
 
1H-NMR (300MHz, d6-acetonitrile): δ 7.53 (d, 2H, J=8.7, H-2’), 7.23 (d, 1H, J=9.0, H-
5), 7.08 (s, 1H, H-4), 6.96 (d, 2H, J=8.7, H-3’), 6.62 (m, 2H, H6, H-8), 6.11 (s, 1H, H-
2), 4.16 (d of t, 1H, J=10.2, 5, OCH2), 3.96 (d of d of d, 1H, J=12.3, 6.9, 5.7, OCH2), 
3.52 (t, 2H, J=6.6, OCH2CH2CH2Br), 2.18 (t of d, 2H, J=6.5, 4.8, OCH2CH2CH2Br). 
13C-NMR (75MHz, d6-acetonitrile): δ 158.4 (C8a), 157.2 (C7), 151.7 (C4’), 129.0 (C3), 
128.4 (C1’), 127.9 (C5), 127.1 (C2’), 119.5 (C4), 116.0 (C3’), 115.3 (C4a), 109.8 (C6), 
103.8 (C8), 97.8 (C2), 65.7 (OCH2), 33.1 (CH2CH2Br), 31.2 (CH2Br). (CI+) MS: m/z 
379.3/377.1 (M+1, 9/10%), 239 (M-O(CH2)3Br, 100%). HR (CI+) MS: m/z calcd for 




















8.2.3 Chemistry Experimental Relating to Chapter 4 
 
Deprotection of 7-acetoxy-3-p-acetoxyphenyl-2,3-dihydrobenzopyran-4-one (134a) 
The acetate protected ketone 127a (0.910 g, 2.668 mmol) was 
heated at reflux in a 5M solution of imidazole in methanol (10 
mL) for 4 h. The solution was concentrated by evaporation 
under reduced pressure and was poured into water (50mL). The 
resulting precipitate was then filtered. The residue was collected by suction filtration 
and dried under reduced atmosphere providing the desired free phenolic product 30 in a 
93% yield (0.635 g, 2.481 mmol) mp over 270ºC, as a pale pink powder. 
 
1H-NMR (300MHz, d6-acetone): δ 7.74 (d, 1H, J=8.7, H-5), 7.07 (d, 2H, J=8.4, H-2’), 
6.74 (d, 2H, J=8.4, H-3’), 6.50 (d of d, 1H, J=8.7, 2.1, H-6), 6.33 (d, 1H, J=2.7, H-8), 
4.55 (d, 1H, J=2.4, H-2), 4.53 (d, 1H, J=2.7, H-2), 3.83 (d of d, 1H, J=6.2, 1.2, H-3).  
13C-NMR (75MHz, d6-acetone): δ 190.4 (CO), 164.4 (C7), 163.8 (C8a), 156.9 (C4’), 
129.9 (C2’), 129.5 (C5), 127.3 (C1’), 115.5 (C3’), 114.6 (C4a), 110.7 (C6), 102.7 (C8), 
72.0 (C2), 51.1 (C3). MS (CI+): m/z 341 (M+1 100%). 
 
Attempted synthesis of 7-cyclohexyloxy-3-p-cyclohexyloxyphenyl-2,3-dihydro-4H-
1-benzopyran-4-one (134b) 
A solution of 1M BF3-etherate (0.1 mL) was added to a stirred solution of 30 (0.495 g, 
1.457 mmol) in cyclohexene (3 mL). The reaction mixture was stirred at rt for 48 h. 

















reflux overnight. TLC analysis again showed only starting material present. The 
reaction mixture was evaporated to dryness under reduced pressure. 1H-NMR and MS 




A mixture of 30 (1.978 g, 7.750 mmol), 
imidazole (5.429 g, 79.74 mmol),                             
t-butyldimethylsilyl chloride (5.875 g, 
mmol) and powdered 3Å molecular sieves in DMF (45 mL) was stirred at rt for 30 h. 
The reaction mixture was then filtered. Ice-water (50 mL) was added to the filtrate 
resulting in precipitate formation. The product was extracted with DCM (2 x 50mL), 
washed with water (50 mL), brine (50 mL) and dried over MgSO4. The solution was 
then filtered. The filtrate was evaporated under reduced pressure. The resulting solid 
(2.820 g, 5.829 mmol, 75% yield) was recrystallised from ethanol to afford 127b as a 
white powder, mp103-104ºC. 
 
1H-NMR (500MHz, CDCl3): δ 7.88 (d, 1H, J=9.0, H-5), 7.12 (d, 2H, J=8.0, H-2’), 8.50 
(d, 2H, J=8.5, H-3’), 6.52 (d, 1H, J=8.5, H-6), 6.41 (s, 1H, H-8), 4.60 (m, 2H, H-2), 
3.86 (d of d, 1H, J=8.0, 5.0, H-3), 0.97 (s, 18H, SiC(CH3)3), 0.18 (s, 6H, SiCH3), 0.00 
(s, 6H, SiCH3). 13C-NMR (75MHz, CDCl3): δ 191.4 (CO), 163.2 (C*), 162.8 (C*), 



















(C6), 107.6 (C8), 72.0 (C2), 51.3 (C3), 25.6 (SiC(CH3)3), 25.5 (SiC(CH3)3), 18.2 
(SiC(CH3)3), 18.2 (SiC(CH3)3), -4.4 (SiCH3), -4.3 (SiCH3).  
C*: C7 or C8a 
MS (CI+): m/z 485 (M+1, 100%), 371 (M+1- t-BDMS, 9%), 257 (M+2- 2x t-BDMS, 
9%). 
 
Attempted reaction of 134a with trimethylsilylcyanide 
 A mixture of 134a (0.552 g, 1.624 mmol), trimethylsilyl cyanide (0.383 g, 3.870 mmol) 
and p-toluenesulfonic acid (ca. 2 mg) was heated at reflux in acetonitrile (50 mL) for 27 
h. The solution was then evaporated to dryness. The resulting solid showed only the 






The ketone 134a (0.317 g, 0.9323 mmol) and 
trimethylsilyl cyanide (0.38mL) in dry toluene 
(3mL) was heated at reflux for 3.5 h. The reaction 
mixture was then poured into ice water (15mL) and 
extracted with ether (2x50mL). The ether extracts were combined, the solvent 




















DCM as the mobile phase. This produced the TMS ether nitrile 154 in 5% yield (0.0205 
g, 0.0466 mmol), mp 161-162ºC.  
 
1H-NMR (300MHz, CDCl3): δ 7.60 (d, 1H, J=8.7, H-5), 7.71 (d, 2H, J=9.0, H-2’), 7.13 
(d, 2H, J=9.0, H-3’), 6.77 (d of d, 1H, J=8.7, 2.7, H-6), 6.69 (d, 1H, J=2.1, H-8), 4.62 (d 
of d, 1H, J=11.0, 12.6, H-2), 4.32 (d of d, 1H, J=10.8, 3.6, H-2), 3.46 (d of d, 1H, 
J=12.6, 3.9), 2.33 (s, 3H, CH3), 2.31 (s, 3H, CH3), 0.07 (s, 9H, Si(CH3)3). 13C-NMR: δ 
169.1 (C=O), 168.9 (C=O), 159.7 (C8a), 153. 3 (C7), 150.0 (C4’), 149.4 (C4a), 147.3 
(C1’) 130.2 (C5), 130.8 (C2’), 121.9 (C3’), 114.3 (C6), 103.8 (C8), 71.3 (C4), 69.0 
(C2), 29.5 (C3), 22.3 (CH3), 0.02 (Si(CH3)3). CI-MS: m/z 440 (M+1, 100%), 367 
(M+1-TMS, 26%). HR (CI+) MS: m/z calcd for [MH+] C23H25NO6Si: 440.1524, found: 
440.1529. 
 
Synthesis of 7-acetoxy-3-p-acetoxyphenyl-2cyano-2H-1-benzopyran (133) 
The ketone 134a (0.317 g, 0.9324 mmol), 
BF3.etherate (3 drops) and trimethylsilyl cyanide 
(0.38mL) in dry toluene (3mL) was heated at reflux 
for 3.5 h. Pyridine (1.7mL) and freshly distilled POCl3 (0.35mL) was added and the 
reaction mixture was heated at reflux for a further 2hr. The reaction mixture was then 
poured into ice water (15mL) and extracted with diethyl ether (2 x 50mL). The diethyl 
ether was evaporated in vacuo and the crude product was then purified through silica gel 
chromatography using DCM as the eluant. This gave the product 133 in 12% (0.039 g, 




















1H-NMR (500MHz, CDCl3): δ 7.56 (d, 2H, J=8.5, H2’), 7.42 (d, 1H, J=8.5, H-5), 7.18 
(d, 2H, J=8.5, H-3’), 6.74 (d of d, 1H, J=8.5, 2.5, H-6), 6.65 (d, 1H, J=2.5, H-8), 4.05 
(s, 2H, H-2), 2.28 (s, 3H, CH3), 2.25 (s, 3H, CH3). 13C-NMR: 169.9 (C=O), 169.5 
(C=O), 152.3 (C8a), 147.7 (C7), 144.6 (C4’), 131.9 (C3), 128.9 (C2’), 126.6 (C5), 
126.4 (CN), 122.6 (C3’), 117.0 (C4a), 116.0 (C6), 110.4 (C8), 68.6 (C2), 21.4 (CH3), 
21.3 (CH3). CI+-MS: m/z 350 (M+1, 100%), 334 (-16). HR (CI+) MS: m/z calcd for 
[MH+] C20H15NO5: 350.1023, found: 350.1019. 
 
7-hydroxy-3-p-hydroxyphenyl-2,3-dihydro-4-oxime -4H-1-benzopyran (142) 
A mixture of the ketone 134a (0.347 g, 1.021 mmol), 
hydroxylamine hydrochloride (0.203 g, 2.920 mmol) and 
sodium acetate (0.180 g, 2.188 mmol) in absolute ethanol 
(4 mL) was heated at reflux for 4 h. Mass spectral analysis revealed the acetate groups 
had been removed with no oxime addition. An additional quantity of hydroxylamine 
hydrochloride (0.304 g, 4.372mmol) was added. The mixture was heated at reflux for an 
additional 4h. The resulting suspension was cooled to rt and filtered. The filtrate was 
evaporated under reduced pressure at 50°C. The residue was dissolved in DCM and 
ethyl acetate, then loaded onto a silica column. A column was run using 15% ethyl 
acetate in DCM as the eluting solvent to give the product 142 as a glass (0.177 g, 0.6539 



















1H-NMR (300MHz, CD3OD): δ  7.72 (d, 1H, J=8.7, H-5), 7.07 (d, 2H, J=8.4, H-2’), 
6.65 (d, 2H, J=8.4, H-3’), 6.43 (d of d, 1H, J=8.7, 2.1, H-6), 6.26 (d, 1H, J=2.7, H-8), 
4.51 (bd, 1H, J=1.6, H-3), 4.39 (d of d, 1H, J=9.0, 1.6, H-2), 4.21 (d of d, 1H, J=2.7, 
9.0, H-2). 13C-NMR (75MHz, CD3OD): δ 159.8 (C4), 158.8 (C7), 157.4 (C8a), 150.9 
(C4’), 130.0 (C1’), 128.5 (C5), 125.4 (C2’), 114.9 (C3’), 110.8 (C4a), 110.1 (C6), 103.0 
(C8), 70.9 (C2), 60.8 (C3). MS (CI+): m/z 272 (M+1, 100%), 257 (30, 47%). HRMS 




A mixture of the ketone 134a (1.992 g, 5.858 mmol), 
phenylhydrazine hydrochloride (3.021 g, 20.891 mmol) and 
sodium acetate (3.330 g, 40.60 mol) in absolute ethanol (27 
mL) was heated at reflux for 7 h. The resulting suspension 
was cooled to room temperature and filtered. The filtrate was 
evaporated under reduced pressure at 50°C. The residue was 
dissolved in DCM and diethyl ether, then loaded onto a silica column. A gradient 
column was run, starting with 100% DCM, then increasing polarity by 5% diethyl ether 
increments and ending with 15% diethyl ether in DCM. This gave the phenyl hydrazone 
76 as a yellow-brown glass (1.660 g, 4.80 mmol) in 82% yield and the ketone 























1H-NMR (300MHz, d6-acetone): δ 8.03 (d, 1H, J=8.4, H5), 7.79 (bs, 1H, NH), 7.19 (m, 
5H, H-2’, H3”, H4”), 6.78 (d, 2H, J=8.9, H-3’), 6.75 (t, 2H, J=7.2, H-2”), 6.54 (d of d, 
1H, J=8.4, 2.1, H-6), 6.29 (d, 1H, J=2.4, H-8), 4.36 (d of q, 2H, J=11.4, 2.1, H-2), 4.20 
(bs, 1H, H-3). 13C-NMR (75MHz, d6-acetone): δ 159.0 (C7), 157.4 (C8a), 156.9 (C4’), 
146.2 (C4), 138.0 (C1”), 129.4 (C1’), 129.1 (C5), 128.5 (C3”), 125.7 (C2’), 119.3 
(C4”), 115.6 (C2”), 114.6 (C3’), 112.9 (C4a), 110.4 (C6), 103.2 (C8), 71.5 (C2), 38.7 
(C3). MS (CI+): m/z 347 (M+1, 22%), 330 (M-OH, 18%), 257 (30, 100%). HR (CI+) 
MS: m/z calcd for [MH+] C21H18N2O3: 347.1390, found: 347.1393. 
 
Synthesis of 7-hydroxy-3-p-hydroxyphenyl-2,3-dihydro-4H-1-benzopyran-4-p-
chlorophenyl hydrazone (159a) 
A mixture of the ketone 134a (0.331 g, 0.974 mmol), p-
chlorophenylhydrazine hydrochloride (0.6078 g, mmol) 
and sodium acetate (0.508 g, mmol) in absolute ethanol (4 
mL) was heated at reflux for 7 h. The resulting suspension 
was cooled to rt and filtered. The filtrate was evaporated 
under reduced pressure at 50°C. The residue was dissolved 
in DCM and diethyl ether, then loaded onto a silica column. A gradient column was run, 
starting with 100% DCM, then increasing polarity by 5% diethyl ether increments and 
ending with 15% diethyl ether in DCM. This gave the phenyl hydrazone product 159a 
(0.239 g, 0.6271 mmol) as an orange glass in 64 %yield and the ketone intermediate 30 
























1H-NMR (300MHz, d6-acetone): δ 8.37 (s, 1H, NH), 8.06 (d, 1H, J=8.7, H-5), 7.13 (m, 
6H, H-2’, H-2”, H-3”), 6.77 (d, 2H, J=12.3, H-3’), 6.59 (d of d, 1H, J=9.0, 2.7, H-6), 
6.33 (d, 1H, J=2.4, H-8), 4.42 (d of d, 1H, J=11.1, 2.1, H-2), 4.33 (d of d, 1H, J=10.8, 
3.0, H-2), 4.29 (bd, 1H, J=2.1, H-3). 13C-NMR (75MHz, d6-acetone): δ 159.2 (C7), 
157.5 (C8a), 156.9 (C4’), 145.1 (C4), 139.0 (C1”), 129.9 (C1’), 129.4 (C2’), 128.9 
(C3’), 125.8 (C5), 123.2 (C4”), 115.8 (C2”), 115.6 (C4a), 114.3 (C3’), 110.5 (C6), 
103.2 (C8), 71.4 (C2), 38.7 (C3). MS (EI+): m/z 382/381/380 (M+1, 36/27/100%). HR 
(EI+) MS: m/z calcd for [MH+] C21H17ClN2O3: 380.0929, found: 380.0928. 
 
Synthesis of 7-hydroxy-3-p-hydroxyphenyl-2,3-dihydro-4H-1-benzopyran-4-m-
chlorophenyl hydrazone (159b) 
A mixture of the ketone 134a (0.333 g, 0.9791 mmol), m-
chlorophenylhydrazine hydrochloride (0.621 g, 3.468 
mmol) and sodium acetate (0.461 g, 5.624 mmol) 
absolute ethanol (4 mL) was heated at reflux for 7 h. The 
resulting suspension was cooled to rt and filtered. The 
filtrate was evaporated under reduced pressure at 50°C. The residue was dissolved in 
DCM and ether, then loaded onto a silica column. A gradient column was run, starting 
with 100% DCM, then increasing polarity by 5% diethyl ether increments and ending 
with 15% ether in DCM. This gave the phenyl hydrazone product 159b (0.209 g, 0.5487 
mmol) as a yellowy orange glass in 56% yield and the ketone intermediate 30 as a 


























1H-NMR (300MHz, d6-acetone): δ 8.69 (bs, 1H, OH), 8.57 (s, 1H, NH), 8.36 (bs, 1H, 
OH), 8.00 (d, 1H, J=9.0, H-5), 7.21 (t, 1H, J=2.1, H2”), 7.17-7.14 (m, 1H, H-5”), 7.13 
(d, 2H, J=8.7, H-2’), 7.00 (d of d of d, 1H, J=8.1, 2.1, 0.9, H-4”), 6.77 (d, 2H, J= 9.0, 
H-3’), 6.73 (d of d of d, 1H, J=7.8, 2.1, 0.6, H-6”), 6.60 (d of d, 1H, J=8.7, 2.4, H-6), 
6.32 (d, 1H, J=2.4, H-8), 4.46 (d of d, 1H, J=12.3, 3.3, H-2), 4.37 (d, 1H, J=2.7, H-2), 
4.34 (bs,1H, H-3). 13C-NMR (75MHz, d6-acetone): δ 159.4 (C7), 157.6 (C8a), 156.9 
(C4’), 147.6 (C4), 139.5 (C1”), 134.6 (C1’), 130.5 (C5), 129.3 (C2’), 128.2 (C3”), 
125.8 (C2”), 118.7 (C5”), 115.8 (C3’), 114.1 (C4a), 112.5 (C4”), 111.4 (C6”), 110.5 
(C6), 103.2 (C8), 71.4 (C2), 38.7 (C3). MS (EI+): m/z 382/381/380 (M+1, 36/27/100%). 
HR (EI+) MS: m/z calcd for [MH+] C21H17ClN2O3: 380.0929, found: 380.0928. 
 
Synthesis of 7-hydroxy-3-p-hydroxyphenyl-2,3-dihydro-4H-1-benzopyran-4-o-
chlorophenyl hydrazone (159c) 
A mixture of the ketone 134a (0.325 g, 0.9568 mmol), o-
chlorophenylhydrazine hydrochloride (0.554 g, 3.0947 
mmol) and sodium acetate (0.259 g, 3.154 mmol) in 
absolute ethanol (4 mL) was heated at reflux for 7 h. The 
resulting suspension was cooled to rt and filtered. The 
filtrate was evaporated under reduced pressure at 50°C. The residue was dissolved in 
DCM and diethyl ether, then loaded onto a silica column. A gradient column was run, 
starting with 100% DCM, then increasing polarity by 5% diethyl ether increments and 


























glass (0.226 g, 0.5932 mmol) in 62% yield the ketone intermediate 30 as a cream 
coloured powder (0.074 g, 0.2870 mmol) in 30% yield. 
 
1H-NMR (300MHz, d6-acetone): δ 8.11 (d, 1H, J=8.7, H-5), 7.82 (s, 1H, NH), 7.74 (d 
of d, 1H, J=8.4, 1.2, H-3”), 7.21 (d of d, 2H, J=8.7, 2.1, H-2’), 7.21 (m, 2H, H-4”, H-
5”), 6.85 (d, 2H, J=8.4, H-3’), 6.75 (d of t, 1H, J=8.1, 1.5, H-6”), 6.65 (d of d, 1H, 
J=9.0, 2.7, H-6), 6.44 (d, 1H, J=2.7, H-8), 4.39 (d of d, 1H, J=11.0, 3.6, H-2), 4.35 (d of 
d, 1H, J= 11.1, 2.7, H-2), 4.23 (t, 1H, J=3.0, H-3). 13C-NMR (75MHz, d6-acetone): δ 
159.7 (C7), 158.1 (C8a), 157.3 (C4’), 142.1 (C4), 141.5 (C1”), 129.6 (C2’), 129.0 (C*), 
128.2 (C*), 128.1 (C1’), 125.9 (C5), 120.0 (C6”), 117.3 (C2”), 116.2 (C3’), 114.2 
(C4a), 114.1 (C3”), 110.8 (C6), 103.4 (C8), 71.9 (C2), 40.5 (C3).  
C*: C4” or C5” 
MS (EI+): m/z 382/381/380 (M+1, 36/27/100%). HR (EI+) MS: m/z calcd for [MH+] 
C21H17ClN2O3: 380.0929, found: 380.0928. 
 
Synthesis of 7-hydroxy-3-p-hydroxyphenyl-2,3-dihydrobenzopyran-4-p-
nitrophenyl hydrazone (159d) 
A mixture of the ketone 143a (0.338 g, 0.9926 mmol), p-
nitrophenylhydrazine (0.488 g, 2.576 mmol) in absolute 
ethanol (4 mL) was heated at reflux for 4 h. The resulting 
suspension was cooled to rt and filtered. The filtrate was 
evaporated under reduced pressure at 50°C. The residue 























column was run, starting with 100% DCM, then increasing polarity by 5% diethyl ether 
increments and ending with 15% ether in DCM. This gave the free phenolic product 
159d (0.2681 g, 0.6849 mmol, 69%) as a red glass and the diacetate hydrazone 160 as a 
red glass (0.071 g, 0.1489 mmol, 15%). 
 
159d: 
1H-NMR (300MHz, d4-methanol): δ 8.58 ( s, 2H, OH), 8.07 (d, 2H, J=8.1, H-3”), 
8.04 (d, 1H, J=7.5, H-5), 7.17 (d, 2H, J=9.0, H-2”), 7.07 (d, 2H, J=8.4, H-2’), 6.70 (d, 
2H, J=8.4, H-3’), 6.53 (d of d, 1H, J=9.0, 2.1, H-6), 6.26 (d, 1H, J=2.1, H-8), 4.48 (d of 
d, 1H, J=11.4, 2.1, H-2), 4.35 (d of d, 1H, J=11.4, 2.7, H-2), 4.25 (bs, 1H, H-3). 13C-
NMR (75MHz, d4-methanol): δ 160.0 (C7), 158.1 (C8a), 156.6 (C4’), 151.3 (C4), 142.8 
(C1”), 139.3 (C4”), 128.9 (C2’), 127.8 (C5), 125.9 (C1’), 125.6 (C3”), 115.4 (C2”), 
113.4 (C4a), 111.5 (C3’), 110.3 (C6), 102.8 (C8), 71.3 (C2), 39.0 (C3). 
MS (EI+): m/z 392 (M+1, 25%), 391 (M+, 100%). HR (EI+) MS: m/z calcd for [MH+] 
C21H17N3O5: 391.1168, found: 391.1169. 
 
160: 
1H-NMR (300MHz, d4-methanol): Z isomer δ 8.18 
(d, 1H, J=9.0, H-5), 8.05 (d, 2H, J=9.0, H-3”), 7.26 
(d, 2H, J=8.7, H-2’), 7.16 (d, 2H, J=9.3, H-2”), 7.01 
(d, 2H, J=8.7, H-3’), 6.77 (d of d, 1H, J=8.7, 2.4, H-
6), 6.14 (d, 1H, J=2.4, H-8), 4.46 (d, 1H, J=9.0, H-

























13C-NMR (75MHz, d6-acetone): δ 170.2 (C=O), 169.8 (C=O), 157.1 (C8a), 152.4 (C7), 
150.9 (C4), 150.2 (C4’), 141.1 (C1”), 139.8 (C4”), 139.4 (C1’), 135.0 (C5), 128.9 
(C2’), 125.7 (C3”), 121.9 (C3’), 115.4 (C4a), 111.9 (C2”), 110.5 (C6), 102.8 (C8), 71.0 
(C2), 38.8 (C3), 19.8 (CH3), 19.7 (CH3). 
MS (EI+): m/z 476 (M+1, 9%), 475 (M+, 23%), 433 (M+-OAc, 100%), 391 (M+-2xAc, 
28%). HR (EI+) MS: m/z calcd for [MH+] C25H21N3O7: 475.1374, found: 475.1370. 
 
Synthesis of 7-hydroxy-3-p-hydroxyphenyl-2,3-dihydro-4H-1-benzopyran-4-p-
methylphenyl hydrazone (159e) 
A mixture of the ketone 134a (0.359 g, 1.057 mmol), p-
tolylhydrazine hydrochloride (0.580 g, 3.671 mmol) and 
sodium acetate (0.312 g, 3.800 mmol) in absolute ethanol (4 
mL) was heated at reflux for 4 h. The resulting suspension 
was cooled to rt and filtered. The filtrate was evaporated 
under reduced pressure at 50°C. The residue was dissolved in DCM and diethyl ether, 
then loaded onto a silica column. A gradient column was run, starting with 100% DCM, 
then increasing polarity by 5% diethyl ether increments and ending with 15% diethyl 
ether in DCM. This gave the product 159e as an orange brown glass (0.255 g, 0.7064 
mmol) in 67 % yield. 
 
1H-NMR (300MHz, d3-acetonitrile): δ 8.28 (bs, 2H, OH), 8.01 (d, 1H, J=8.7, H-5), 7.70 
(bs, 1H, NH), 7.08 (d, 2H, J=8.4, H-2’), 7.00 (d, 1H, J=9.0, 3.3 H-3”), 6.97 (d, 1H, 






















J=2.4, H-8), 4.37 (d of q, 2H, J=10.8, 2.1, 2.7, H-2), 4.18 (bs 1H, H-3), 2.22 (s, 3H, 
CH3). 13C-NMR (75MHz, d3-acetonitrile): δ 159.7 (C7), 158.3 (C8a), 157.6 (C4’), 
146.3 (C4), 138.9 (C1”), 131.8 (C1’), 131.2 (C*), 130.6 (C*), 129.5 (C4”), 126.8 (C5), 
116.7 (C4a), 116.3 (C3’), 114.1 (C3”), 111.8 (C6), 103.8 (C8), 73.1 (C2), 39.8 (C3), 
20.9 (CH3).  
C*: C2’ or C2” 
MS(CI+): m/z 361 (M+1, 100%), 344 (M+1-OH, 30%), 256 (ketone, 43%). HR (CI+) 
MS: m/z calcd for [MH+] C22H20N2O3: 361.1551, found: 361.1548. 
 
Synthesis of 7-hydroxy-3-p-hydroxyphenyl-2,3-dihydro-4H-1-benzopyran-4-p-
cyanophenyl hydrazone (159f) 
A mixture of 134a (0.326 g, 0.9574 mmol), p-
cyanophenylhydrazine hydrochloride (0.524 g, 3.187 
mmol) and sodium acetate (0.564 g, 6.876 mmol) in 4.5 
mls absolute ethanol was heated at reflux for 7 hours. The 
resulting suspension was cooled to rt and filtered. The 
filtrate was evaporated under reduced pressure at 50°C. The residue was dissolved in 
DCM and ether, then loaded onto a silica column. A gradient column was run, starting 
with 100% DCM, and ending with 35% ether in DCM. This gave the product 159f 
(0.209 g, 0.5625mmol) in 59% yield, mp 224-225 °C decomp. 
 
1H-NMR (300MHz, d6-acetone): δ 9.06 (s, 1H, NH), 8.10 (d, 1H, J=8.7, H-5), 7.52 (d, 























J=8.7, H-3’), 6.60 (d of d, 1H, J=9.0, 2.7, H-6), 6.32 (d, 1H, J=2.4, H-8), 4.49 (d of d, 
1H, J=3.0, 12.0, H-2), 4.37 (m, 2H, H-2, H-3). 13C-NMR (75MHz, d6-acetone): δ 165.0 
(C7), 163.1(C8a), 162.1(C4’), 154.5 (C4), 146.6(C1”), 138.7 (C3”), 134.5 (C2’), 133.1 
(C5), 131.3(C1’), 125.1(CN), 121.0 (C3’), 119.0(C4a), 118.2 (C2”), 118.2 (C4”), 115.8 
(C6), 108.4 (C8), 106.0, 76.5 (C2), 43.9 (C3). MS (CI+): m/z 369 (M-2, 7%), 257 





A mixture of the ketone 134a (0.323 mg, 0.9494 mmol), 2-
hydrazinopyridine (0.475 g, 4.352 mmol) in absolute 
ethanol (4mL) was heated at reflux for 4 h. The resulting 
suspension was cooled to rt. The filtrate was evaporated 
under reduced pressure at 50°C. The residue was dissolved 
in DCM and diethyl ether, then loaded onto a silica column. A gradient column was run, 
starting with 100% DCM, then increasing polarity by 5% diethyl ether increments and 
ending with 35% ether in DCM. This gave the product 159g as a pale pink powder 
(0.106 g, 0.321 mmol), mp 145-146°C in 34% yield. 
 
1H-NMR (300MHz, d6-acetone): δ 8.72 (bs, 1H, OH), 8.30 (bs, 1H, OH), 8.07 (d, 1H, 
J=8.7, H-5), 7.99 (d of q, 1H, J=5.1, 0.9, H-3”), 7.61 (d of d of d, 1H, J=9.0, 7.2, 2.1, H-

























3’), 6.72 (d of d of d, 1H, J=6.7, 4.8, 0.9, H-4”), 6.59 (d of d, J=9.0, 2.7, H-6), 6.36 (d, 
J=2.1, H-8), 4.41 (bs, 1H, H-3), 4.39 (bs, 2H, H-2). 13C-NMR (75MHz, d6-acetone): δ 
159.6 (C7), 158.0 (C8a), 157.6 (C4’), 157.1 (C1”), 147.9(C3”), 140.3 (C4), 137.9 
(C5”), 129.4 (C2’), 128.5 (C1’), 125.8 (C5), 116.0 (C3’), 115.5 (C4”), 114.1 (C4a), 
110.6 (C6), 107.0 (C2”), 103.3 (C8), 71.8 (C2), 39.3 (C3). MS (CI+): m/z 348 (M+1, 
7%), 257 (ketone+1, 100%). MS (ES+): m/z 348 (M+1, 100%). HR (ES+) MS: m/z 
calcd for [MH+] C20H17N3O3: 348.1348, found: 348.1348. 
 
Attempted synthesis of 7-hydroxy-3-p-hydroxyphenyl-2,3-dihydro-4H-1-
benzopyran-4-diphenyl hydrazone (161) 
A mixture of the ketone 134a (0.239 g, 0.7032 mmol), diphenylhydrazine hydrochloride 
(0.803 g, 3.638 mmol) and sodium acetate (0.290 g, 3.540 mmol) in absolute ethanol (4 
mL) was heated at reflux for 5 h. TLC analysis showed only the formation of the 
diphenolic ketone product 30. The reaction mixture was heated at reflux for an 
additional 12 h. The resulting suspension was cooled to room temperature and filtered. 
The filtrate was evaporated under reduced pressure at 50°C. The residue was dissolved 
in DCM and diethyl ether, then loaded onto a silica column. A gradient column was run, 
starting with 100% DCM, then increasing polarity by 5% diethyl ether increments and 
ending with 15% diethyl ether in DCM. This gave the deprotected ketone product 30 




Attempted synthesis of 7-hydroxy-3-p-hydroxyphenyl-2,3-dihydrobenzopyran-4-
(2-imidazoyl) hydrazone (162) 
A mixture of the ketone 134a (0.409 g, 1.1200 mmol), 2-imidazoylhydrazine 
hydrobromide (0.571 g, 3.187 mmol) and sodium acetate (0.522 g, 6.361 mmol) in 
absolute ethanol (4mL) was heated at reflux for 7 h. The solution was cooled to rt and 
filtered. The filtrate was dried under reduced pressure and applied to a silica column. A 
gradient column was then run in 15% ether in DCM, then increasing polarity by 5% 
diethyl ether increments and ending with 35% ether in DCM. This gave the 
benzofuranone 162 as a cream powder (0.119 g, 0.4928 mmol, mp >280°C) in 44 
%yield. 
 
1H-NMR (300MHz, CD3OH): δ 8.13 (s, 1H, OH), 
8.05 (d, 1H, J=8.7, H-4), 7.36 (d, 2H, J=8.7, H-2’), 
6.93 (d of d, 1H, J=9.0, 2.4, H-5), 6.84 (d, 2H, 
J=8.4, H-3’), 6.84 (d, 1H, J=2.4, H-7), 5.15 (s, 1H, H-2). 13C-NMR (75MHz, CD3OH): 
δ 164.5 (C3), 163.8 (C7a), 159.7 (C6), 156.9 (C4’), 129.9 (C2’), 129.5 (C4), 127.3 
(C1’), 115.5 (C3’), 110.7 (C5), 110.0 (C3a), 102.7 (C7), 51.1 (C2). MS (CI+): m/z 243 





















Attempted Synthesis of 7-hydroxy-3-p-hydroxyphenyl-2,3-dihydrobenzopyran-4-
(p-trifluoro)pyrimidine hydrazone (164) 
A mixture of the ketone 134a (0.326 g, 0.9588 mmol), 2-hydrazino-2-imidazole 
hydrobromide (0.544 g, 3.040 mmol) and sodium acetate (0.521 g, 5.264 mmol) in 
absolute ethanol (4mL) was heated at reflux for 7 h. The reaction mixture was then 
filtered and the filtrate evaporated to dryness. The crude material was subjected to silica 





The ketone 134c (0.334 g, 0.6880 mmol) in THF (1 mL) was added dropwise to a 
stirred a 0.5 M solution of 5-methylthien-2-ylzinc bromide 177 in THF (3 mL) and the 
mixture was then stirred at rt overnight. The reaction mixture was added to ice-water 
(50 mL) and DCM (2x50 mL) was added. The DCM fractions were combined and 
washed with water (50 mL), saline (50 mL) and then dried over MgSO4. The DCM was 
then evaporated under reduced pressure. The crude material was then redissolved in 
DCM and applied to a silica column. A gradient column was then run over 25 min 
initially using 50% Pet. Spirit (40-60) 50% DCM as the eluting solvent, then increasing 
polarity by 10% DCM increments and ending with 100% DCM. This gave the desired 
product 145 in 8% yield (0.027 g, 0.0550 mmol, ) 62-63°C mp as pale yellow crystals 






1H-NMR (300MHz, CDCl3): δ 12.69 (s, 1H, OH), 7.60 
(d, 1H, J=8.7, H-5), 7.09 (d, 2H, J=8.7, H-2’), 6.98 (d, 
1H, J=5.1, H-4”), 6.74 (d, 2H, J=8.7, H-3’), 6.68 (d, 
1H, J=4.8, H-3”), 6.33 (d, 1H, J=2.4, H-8), 6.25 (d of d, 
1H, J=9.3,2.7, H-6), 4.65 (t, 1H, J=6.9, H-3), 4.44 (d of d, 1H, J=6.9, 14.7, H-2), 3.18 
(d of d, 1H, J=7.5, 15.0, H-2), 1.96 (s, 3H, C4”CH3), 0.96 (s, 9H, SiC(CH3)3), 0.95 (s, 
9H, SiC(CH3)3), 0.21 (s, 6H, SiCH3), 0.16 (s, 6H, SiCH3). 13C-NMR (75MHz, CDCl3) 
δ: 203.6 (C4), 165.8 (C8a), 163.0 (C7), 155.2 (C4’), 135.3 (C1”), 134.4 (C1”), 132.3 
(C5), 131.9 (C4”), 129.9 (C3”), 129.2 (C2’), 122.1 (C4”), 120.7 (C3’), 114.0 (C4a), 
112.4 (C6), 108.3 (C8), 54.3 (C3), 32.1 (C2), 25.9 (SiC(CH3)3), 25.7 (SiC(CH3)3), 22.8 
(ArCCH3), -4.2 (SiCH3), -4.2 (SiCH3). MS (ES-): m/z 581 (M-1, 5%), 492.5 (-tBu-H2O, 
16%), 313 (, 100%). MS (ES+): m/z 583 (M+1, 18%), 485 (M-thienyl, double bond 
compound, 100%). HR (ES+) MS: m/z calcd for [MH+] C32H46O4SSi2: 583.2734, found: 




1H-NMR (300MHz, CDCl3): δ 12.30 (s, 1H, OH), 7.24  (d, 
1H, J=9.0, H-4), 7.10 (d, 2H, J=8.7, H-2’), 6.61 (d, 2H, 







































J=9.0, 2.1, H-5), 5.66 (s, 1H, CH2), 5.16 (s, 1H, CH2), 0.78 (s, 18H, CCH3), 0.05 (s, 6H, 
SiCH3), 0.00 (s, 6H, SiCH3). 13C-NMR (75MHz, CDCl3) δ: 206.4 (C3), 170.3 (C2), 
168.0 (C7a), 160.6 (C6), 150.9 (C4’), 139.6 (C4), 134.1 (C1’), 132.1 (C2’), 124.7 (C3’), 
120.1 (C=CH2), 118.5 (C3a), 116.6 (C5), 112.4 (C7), 30.1 (SiC(CH3)3), 29.9 
(SiC(CH3)3), 22.6 (SiC(CH3)3), 0.1 (SiCH3). MS (ES+): m/z 485 (M+1, 100%). HR 




Attempted synthesis of 144 
The ketone 143c (0.325 g, 0.9559 mmol) in THF and a 0.5 M solution of 5-methyl 
thienlylzinc bromide in THF (2.5 mL) was added and stirred at room temperature 
overnight. The reaction mixture was added to ice-water (50 mL) and DCM was added. 
The DCM was collected and an addition DCM (3x50 mL) extraction was performed. 
The DCM fractions were combined and washed with water (2x100mL), saline (100mL) 
and dried over MgSO4. The DCM was then evaporated under reduced pressure. The 
crude material was then redissolved in DCM and applied to a silica column. A gradient 
column was then run in 2 hr initially using 50% Pet. Spirit (40-60) 50% DCM as the 
eluting solvent, increasing polarity by 10% DCM increments and ending with 100% 





Attempted dehydration of 144 using copper sulfate 
A mixture of the thienyl alcohol 144 (0.269 g, 0.4625 mmol) and benzofuran 178 (0.336 
g, 0.6938 mmol) was heated at reflux in a suspension of ground anhydrous CuSO4 
(0.410 g, 2.567 mmol) in dry toluene (2.5 mL) for 2 h. TLC analysis and ES-MS 
showed no reaction had occurred. The reaction mixture was then heated at reflux 
overnight. The reaction mixture was filtered and the solvent removed under reduced 
pressure. TLC and 1H-NMR analysis showed only the presence of the starting material 
alcohol 144 and the benzofuran 178. 
 
Attempted dehydration of 144 using P2O5  
A crude mixture of the thienyl alcohol 144 (0.108 g, 0.1852 mmol) and 178 (0.135 g, 
0.2778 mmol) was stirred with P2O5 (1.274 g, 13.851 mmol) at rt in DCM (10 mL) for 3 
h. The reaction mixture was then poured into water and extracted with DCM (3x 50 
mL). The DCM extracts were then combined, washed with water (50mL) and brine (50 
mL) and dried with MgSO4. Evaporation of the solvent gave an off white powder which 
was found to be the starting ketone 134c (0.075 g, 0.2214 mmol) by ES-MS, TLC 
analysis and 1H-NMR spectroscopy.  
 
Attempted dehydration of 144 using the Burgess reagent  
A solution of the crude thienyl alcohol 144 (0.079 g, 0.1364 mmol), crude benzofuran 
178 (0.099 g, 0.2044 mmol) and the Burgess reagent (CH3OCON-SO2N+(CH2CH3)3) 
(0.039 g, 0.1632 mmol) in toluene (1.5 mL) was heated at reflux for 1 h. The solution 
was poured into water and filtered through celite. The filtrate was extracted with DCM 
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(2 x 50 mL), washed with brine and then dried over MgSO4. Evaporation of the solvent 
gave a residue which did not contain any of the dehydrated product 143 on the basis of 
1H-NMR and ES-MS spectroscopic analysis. 
 
Enolate Anion Stability Experiment 
A solution of 134c (0.506 g, 1.0335mmol) in DMF (1 mL) was added dropwise to 60% 
sodium hydride (0.085 g, mmol) in mineral oil in DMF (4 mL) at 0°C which produced 
bubbling. The solution turned yellow and was stirred for 1 h. The solution was then 
added to ice-water (100 mL) and extracted with DCM. There was a precipitate in the 
water layer which was not DCM soluble, this precipitate was collected. The DCM layer 
was evaporated to dryness. This gave a mixture of the rearranged product 178 and 
ketone 134c in a 15% ratio of rearranged product to the starting ketone by NMR 
analysis. 
 
Attempted Synthesis of 7-tert-butyldimethylsilyloxy-3-p-tert-
butyldimethylsilyloxyphenyl-4-(5-methylthien-2-yl)-3,4-dihydro-2H-1-benzopyrene 
(176) 
A solution of 134c (0.602 g, 1.034 mmol) in DMF (2 mL) was added dropwise to 60% 
sodium hydride (0.147 g, 1.608 mmol) in mineral oil in DMF (8 mL) at -48°C which 
produced bubbling. The solution turned yellow and was stirred for 1 h. N-phenyl 
bis(trifluoromethane) sulfonimide (1.213 g, 3.4081 mmol) was added at -48°C for 2 h, 
then allowed to cool to rt at which the reaction mixture was stirred overnight. Thienyl 
ZnBr 171 in THF (0.5 M, 7 mL, mmol), then Pd(PPh)4 (0.006 g, mmol) was added to 
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the reaction mixture. The reaction mixture was poured into water and extracted with 
DCM. The DCM was washed with water and brine. The DCM layer was then dried over 
MgSO4. The 1H-NMR spectrum of the crude material obtained after evaporation of the 
DCM did not reveal the presence of the desired thienyl product 143 as it did not contain 
the diagnostic C2 signals expected between 5.0 ppm and 6.5 ppm. 
 
Attempted synthesis of 145a 
A solution of 134c (0.602 g, 1.034 mmol) in DMF (2 mL) was added dropwise to 
sodium hydride (0.147 g, 1.608 mmol, 60% in mineral oil) in DMF (8 mL) at -48°C. 
The solution turned yellow and was stirred for 1 h. N-phenyl bis(trifluoromethane) 
sulfonimide (1.213 g, 3.4081 mmol) was added at -48°C and the mixture stirred at this 
temperature for 2 h. The mixture was then allowed to warm to rt and then stirred 
overnight. The reaction mixture was poured into water and extracted with DCM. The 
DCM was washed with water and brine. The DCM layer was then dried over MgSO4. 
The DCM was removed by evaporation in vacuo and the residue subjected to column 
chromatography on alumina (eluting with 60% pet spirit in DCM and ending with 20% 
pet. spirit in DCM, increasing polarity by 10% increments). However no characterisable 







methoxy-2H-1-benzopyran 145b in DMF 
A solution of 134c (0.298 g, 1.034 mmol) in DMF (1 
mL) was added dropwise to 60% sodium hydride 
(0.0643 g, 1.608 mmol) in mineral oil in DMF (4 mL) 
at -48°C which produced bubbling. The solution turned yellow and was stirred for 1.25 
h. methyl iodide (0.3125 g, 2.202 mmol) was added and the reaction mixture stirred at -
48°C for 4 h. The reaction mixture was allowed to warm to rt and stirred overnight. The 
reaction mixture was poured into water and extracted with DCM (2x100 mL). The 
DCM was washed with water and brine. The DCM layer was then dried over MgSO4. 
After filtration, the DCM layer was evaporated under reduced pressure to dryness. The 
crude material was then redissolved in DCM (2 mL) and applied to an alumina column. 
Gradient chromatography was performed, starting with 5% DCM in pet. spirit, and 
increasing in polarity by increments of 10% DCM, to 60% DCM in pet. spirit. This 
gave the product 145b as a colourless glass (0.325 g, 0.6511 mmol), mp 67-68ºC in 
63% yield.  
 
1H-NMR (500MHz, CDCl3): δ 7.89 (d, 1H, J=9.0, H-5), 7.13 (d, 2H, J=9.0, H-2’), 
6.80 (d, 2H, J=8.5, H-3’), 6.61 (d of d, 1H, J=8.5, 2.0, H-6), 6.44 (d, 1H, J=2.0, H-8), 
4.65-4.57 (m, 2H, H-2), 3.85 (s, 3H, OCH3) 0.97 (s, 18H, SiC(CH3)3), 0.18 (s, 6H, 
SiCH3), 0.00 (s, 6H, SiCH3). 13C-NMR (75MHz, CDCl3) δ: 169.3 (Cq), 169.0 (Cq), 
151.4 (C8a), 150.5 (C7), 150.1 (C4’), 133.4 (C4), 128.9 (C5), 128.1 (C1’), 126.8 (C2’), 




















21.2 (SiC(CH3)3),  21.1 (SiC(CH3)3), 0.00 (SiCH3). MS (ES+): m/z 498 (M+, 12%), 441 
(M-C(CH3)3, 100%), 385 (M-2(C(CH3)3), 42%). HR (ES+) MS: m/z calcd for [M+] 
C28H42O4Si2: 498.2626, found: 498.2623. 
 
Synthesis of 7-tert-butyldimethylsilyloxy-3-p-tert-butyldimethylsilyloxyphenyl-4-
methoxy-2H-1-benzopyran 145b in THF 
The ketone 134c (0.5816 g, 1.1200 mmol) was reacted with 60% sodium hydride (0.132 
g, 1.608 mmol), then iodomethane (0.266 g, 1.8746 mmol) in a similar method to that 
described above, however using THF(2 mL, 8 mL) as the solvent. This produced the 
product 145b in 75% yield (0.426 g, 0.8496 mmol). 
 
 
Attempted synthesis of 143 from 145b  
The thienylzinc bromide 177 in THF (0.5M, 2 mL, 1.0 mmol) was added to 145b (0.375 
g, 0.7534 mmol) at -98 °C and the mixture stirred at -98 °C for 4 h. The reaction 
mixture was then allowed to warm to rt and stirred at rt for 7 days. The reaction mixture 
was then poured into water (50 mL) and extracted with DCM (2 x 50 mL). Evaporation 
of the DCM solvent afforded a crude product which was subjected to a silica gradient 
column was then run starting with 40% DCM in pet spirit, and the DCM was then 
increased by 10% increments until 60% DCM in pet spirit was reached. This gave an 





1H-NMR (300MHz, CDCl3): δ 7.70 (d, 1H, J=9.0), 7.17 (d, 2H, J=9.0), 7.10 (s, 1H), 
6.67 (d, 2H, J=9.0), 6.39 (d of d, 1H, J=8.7, 2.7), 6.18 (d, 1H, J=2.4), 4.65 (d, 1H, 
J=12.0), 4.17 (d, 1H, J=12.0) , 3.63 (s, 2H), 3.59 (s, 3H). 13C-NMR (75MHz, 
CDCl3): δ 163.1, 159.0, 129.8, 127.8, 127.8, 120.2, 114.3, 110.3, 100.6, 75.4, 55.8, 
55.4, 48.6, 25.8, 21.6. MS (EI+): m/z 568 (7%), 432 (39%), 376 (100%), 332 (57%). 
 
Attempted synthesis of 143 from 145b using NiCl2 as a catalyst 
The thienylzinc bromide 177 in THF (0.5M, 2 mL, 1.0 mmol), was added to the 4-
methoxy compound 145b (0.3752 g, 0.7534 mmol) and NiCl2 (0.003g, 0.02 mmol) at -
98ºC and stirred at -98ºC for 4h, the reaction mixture was then allowed to warm to rt 
and stirred at rt for 7 days. The reaction mixture was poured into water (50 mL) and 
extracted with DCM (2 x 50 mL). Evaporation of the DCM in vacuo afforded a crude 
solid, which was subjected to a silica gradient column, which was then run starting with 
40% DCM in pet spirit, DCM was increased by 10% increments until 60% DCM in pet 








8.3 Biological Experimental Section 
Cellular Preparation 
Testosterone treated and untreated LNCaP cells were cultured. 
 
Protein Extraction 
LNCaP cells were transferred from a T-75 culture flask into a 50 ml centrifuge 
tube with its medium.  The T-75 culture flask was washed with 3 mls of ice cold 
phosphate buffer solution (PBS) to collect any residual cells. The cells were centrifuged 
at 1000 rpm for 7 mins at 4°C. The supernatant was discarded and 1 ml of ice cold PBS 
was added to the pellet in the 50 ml centrifuge tube. This was gently pipetted up and 
down to create a suspension of the cells. This suspension was transferred to a 1.5 ml 
eppendorph tube, which was then centrifuged on a microcentrifuge for 3 min. The 
supernatant was then discarded and 1 ml of ice cold PBS was added to the pellet, then 
gently pipetted up and down to create a suspension. This was then centrifuged in a 
microcentrifuge for 3 min. The eppendorph tube was then placed on ice. 150 µL of 
solubilization buffer was added to the pellet and gently pipetted up and down to create a 
suspension. The tube was then placed into liquid nitrogen for 20 seconds and allowed to 
thaw out at room temperature. This freeze thaw process was repeated 5 times. However, 
the last thaw was done while the tube was on ice. After it has fully thawed, centrifuge 
the tube at 11000 rpm at 4°C for 10 min. A cloudy supernatant was then collected. The 
protein concentration was then determined according to the pierce instructions.212 




 The concentration of protein in the assay was 2 µg/ml, the concentration of 
NADPH in the assay was 150 µΜ. The concentration of 3H testosterone and finasteride 
were varied over a range from 10 nM to 500 nM and 0.5 µΜ to 2 µΜ respectively. Each 
sample was made up with 50 mM tris-citrate buffer at ph6 to reach a final volume of 
100 µL. Negative controls were carried out and the assay was carried out in duplicate. 
The ingredients of the assay were added and mixed together, with the exclusion 
of the testosterone. The inhibitors were allowed an incubation time of 30 min while 
cooled on ice. The testosterone was then added, and the sample incubated for 1.5 h. The 
assay was stopped by the addition of ethyl acetate (1 ml), and then the sample was 
shaken. The sample was then stored in the freezer (-4ºC) overnight. The ethyl acetate 
was then decanted from the ice and evaporated by passing nitrogen over the sample. 
Then 20 µL of ethanol was added to the glass tube. The ethanol was then spotted onto a 
silica TLC plate. The plate was developed with 15% diethylether in dichloromethane. 
The spots corresponding to androstenedione, testosterone and dihydrotestosterone were 
cut out and placed in a poly Q scintillation vial. 5ml of Scintillation fluid (5mL) was 
added and the sample counted, on a Wallac 1409, 1480 Wizard™ 3” Gamma Counter 
for 5 min each. 
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Appendix 1 Training Set Compounds 
 
Three training sets containing inhibitors for human 5-α-reductase I and II, and rat 
5-α-reductase type II are shown in this appendix. 
The references for each molecule are included. 
The naming of the compounds comprise of the reference number and the 
compound number within the reference; protonation of any nitrogens are also 
indicated in the naming system. 
The initial number of the compound name is the reference number. 
The following 3 or 4 o’s are included as spacers. 
The following number/letter is the number of the compound within the reference. 
If the name of the compound has an ending of ‘ooop’ the compound has been 
protonated in the training set. If the name the compound does not have an 
ending of ‘ooop’ the compound has not been protonated. 
5α-Reductase inhibition activities are given as IC50’s (nM). 
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Appendix 2 Processes log for the 5AR type II Pharmacophore Generation 
 
Human 5AR type II Hypotheses Generation 
 
Summary of parameters: 
  HyposReported    10                               
  Spacing   300                               
  MinPoints     4                               
  MinSubsetPoints     4                               
  SuperpositionError     1                               
  Misses     1                               
  FeatureMisses     1                               
  CompleteMisses   0.0e+00                           
  ToleranceFactor     1                               
  CheckSuperposition     1                               
  WeightVariation     0.3                             
  MappingCoeff   0.0e+00                           
  Mem    60                               
  IdealHBondGeomOnly   0.0e+00                           
  VariableWeight   0.0e+00                           
  VariableTolerance   0.0e+00                           
 
Constraints on numbers of features: 
Name:       HBA         HYDROPHOBIC   HYDROPHOB aromaticNegIonizable   RING 
AROMATIC  Total 
Min:         0               0               0               0               0          3 
Max:         5               5               5               5               5          10 
 
 
Best records in pass 6. 
 
dumping score for the 1st hypothesis  
 
Definition:          HBA       NegIonizable   RING AROMATIC  RING AROMATIC 
Weights:          2.52172        2.52172        2.52172        2.52172 
Tolerances:    1.60    2.20       1.60       1.60    1.60   1.60    1.60 
Coords: X      -6.04   -7.48      2.00       0.30    -0.45  2.75    4.03 
      : Y      1.25    2.75       -3.17      1.25    -1.21  -2.07   -4.40 
      : Z      -0.14   -2.33      -4.82      1.24    -0.30  -1.64   -0.25 
                 o--------->         o         o--------->    o---------> 
HBA          o 
         --->  3.0 
NegIonizable o 10.3    11.4 
RING AROMATIC o6.5     8.7        7.7 
         --->  6.1     8.3        5.5        3.0 
RING AROMATIC o9.5     11.3       3.4        5.0     3.6 
         --->  11.5    13.7       5.1        6.9     5.5    3.0 
 
Name           Fit  Cnf/Enan      Mapping        Est        Act      Error     Unc 
11ooo2o        8.61 19    + [1   31  23  10  ]      0.16       0.29  -   1.8     3 
12oooo2s       7.26 12    - [*   13  18  1   ]      3.6        0.56  +   6.3     3 
11ooo2r        7.31 3     - [*   1   23  10  ]      3.2        0.57  +   5.7     3 
11oooo2g       7.23 9     + [*   22  14  1   ]      3.9        1.1   +   3.5     3 
12oooo2g       7.28 2     + [*   13  17  27  ]      3.4        1.5   +   2.3     3 
12oooo2j       7.04 3     - [*   13  18  1   ]      5.9        2.5   +   2.4     3 
12oooo2l       7.30 15    + [*   13  18  1   ]      3.2        2.7   +   1.2     3 
11oooo2b       7.25 16    + [*   38  14  1   ]      3.7        3.4   +   1.1     3 
12oooo2f       7.25 10    + [*   13  20  15  ]      3.7        4.1   -   1.1     3 
12oooo2h       7.11 7     + [*   13  17  1   ]      5.1        6.4   -   1.3     3 
12oooo2r       7.22 10    + [*   13  18  1   ]      4          7.3   -   1.8     3 
11ooo2k        7.20 19    - [*   22  14  1   ]      4.1        9.3   -   2.3     3 
17oooo40       5.02 18    + [53  6   *   *   ]    620          9.8   +  63       3 
12oooo2k       6.70 13    + [*   13  18  1   ]     13         10     +   1.3     3 
11ooo2q        7.16 11    - [*   1   23  10  ]      4.5       11     -   2.4     3 
11oooo2c       7.23 31    - [*   22  14  1   ]      3.9       12     -   3.1     3 
13ooo22        6.01 17    + [24  *   1   12  ]     63         38     +   1.7     3 
6oooo6         4.90 3     + [12  *   19  *   ]    820         52     +  16       3 
13oooo12       6.08 149   + [50  *   19  33  ]     55         56     -   1       3 
12oooo2b       6.03 46    + [*   37  2   25  ]     61         59     +   1       3 
3oooo7         5.00 28    + [*   17  *   1   ]    650         60     +  11       3 
17oooo39       5.03 11    + [*   6   *   1   ]    610         71     +   8.5     3 
18oooo10       4.97 2     + [*   23  *   1   ]    710        220     +   3.2     3 
13oooo13       5.86 146   - [50  *   33  19  ]     90        230     -   2.6     3 
13ooo21        5.79 167   + [*   24  17  12  ]    110        300     -   2.8     3 
6oooo10        4.92 8     + [12  *   19  *   ]    790        320     +   2.5     3 
13ooo18        5.43 164   + [39  64  15  *   ]    240        330     -   1.4     3 
18oooo8        5.00 4     + [*   23  *   1   ]    650        330     +   2       3 
1oooo11        5.01 3     + [*   18  *   1   ]    630        340     +   1.9     3 
3oooo6         5.04 4     + [15  17  *   *   ]    600        530     +   1.1     3 
11ooooONO3805  5.03 92    + [62  2   *   *   ]    610        540     +   1.1     3 
3oooo11        4.95 9     + [12  *   19  *   ]    730        550     +   1.3     3 
18oooo9        5.00 5     + [*   23  *   1   ]    650        640     +   1       3 
3oooo12        5.00 28    + [*   17  *   1   ]    650        750     -   1.2     3 
13oooo11       5.20 87    - [50  *   19  33  ]    410        810     -   2       3 
3oooo9         5.03 4     + [*   17  46  *   ]    610        830     -   1.4     3 
17oooo19       5.03 2     + [*   6   *   1   ]    610        830     -   1.4     3 
6oooo3         5.01 13    + [12  40  *   *   ]    630        870     -   1.4     3 
13oooo2        5.16 119   - [65  *   7   19  ]    450       1200     -   2.7     3 
6oooo9         4.94 10    + [12  *   19  *   ]    740       1300     -   1.8     3 
18oooo13       5.03 2     + [*   23  *   1   ]    610       2300     -   3.8     3 
18oooo12       4.97 5     + [*   23  *   1   ]    700       4000     -   5.7     3 
18oooo14       4.99 3     + [*   23  *   1   ]    670       4700     -   7       3 
6oooo5a        4.88 6     + [12  *   19  *   ]    860      10000     -  12       3 
18oooo7        5.03 4     + [27  23  *   *   ]    610      10000     -  16       3 
18oooo6        4.98 2     + [*   23  *   1   ]    690      10000     -  14       3 
************************************************************* 
Mirror image used.  To turn this option off, put  
catHypo.forceAbsoluteStereochemistry=1 in the .Catalyst file. 
************************************************************* 
 totalcost=209.123 RMS=1.23867 correl=0.878901 




 totalcost=172.342 RMS=0 correl=0 
 Cost components: Error=154.726 Weight=1.12491 Config=16.4912 Tolerance=0 
 
 
dumping score for the 2nd hypothesis  
 
Definition:          HBA       NegIonizable   RING AROMATIC  RING AROMATIC 
Weights:          2.51074        2.51074        2.51074        2.51074 
Tolerances:    1.60    2.20       1.60       1.60    1.60   1.60    1.60 
Coords: X      -5.51   -6.42      3.60       3.00    2.78   0.51    1.86 
      : Y      2.02    3.57       -3.57      -2.07   0.36   1.16    3.09 
      : Z      -0.02   -2.45      -3.22      0.38    -1.36  1.21    3.06 
                 o--------->         o         o--------->    o---------> 
HBA          o 
         --->  3.0 
NegIonizable o 11.2    12.3 
RING AROMATIC o9.5     11.3       3.9 
         --->  8.6     9.8        4.4        3.0 
RING AROMATIC o6.2     8.2        7.2        4.2     3.5 
         --->  8.1     10.0       9.3        5.9     5.3    3.0 
 
Name           Fit  Cnf/Enan      Mapping        Est        Act      Error     Unc 
11ooo2o        8.37 19    + [1   31  10  23  ]      0.19       0.29  -   1.5     3 
12oooo2s       7.16 9     - [*   13  1   18  ]      3.1        0.56  +   5.5     3 
11ooo2r        7.13 24    + [*   1   10  23  ]      3.3        0.57  +   5.8     3 
11oooo2g       7.14 7     + [*   22  1   14  ]      3.2        1.1   +   2.9     3 
12oooo2g       7.12 7     - [*   13  27  17  ]      3.4        1.5   +   2.3     3 
12oooo2j       6.89 2     + [*   13  1   18  ]      5.8        2.5   +   2.3     3 
12oooo2l       7.12 12    - [*   13  1   18  ]      3.4        2.7   +   1.2     3 
11oooo2b       7.09 13    - [*   38  1   14  ]      3.6        3.4   +   1.1     3 
12oooo2f       7.05 11    - [*   13  15  20  ]      4          4.1   -   1       3 
12oooo2h       6.87 7     + [*   13  1   17  ]      5.9        6.4   -   1.1     3 
12oooo2r       7.14 4     - [*   13  1   18  ]      3.2        7.3   -   2.3     3 
11ooo2k        7.14 35    + [*   22  1   14  ]      3.3        9.3   -   2.9     3 
17oooo40       5.01 12    + [31  6   *   *   ]    430          9.8   +  44       3 
12oooo2k       6.39 2     + [*   13  1   18  ]     18         10     +   1.8     3 
11ooo2q        6.99 11    - [*   1   10  23  ]      4.6       11     -   2.4     3 
11oooo2c       7.20 7     - [*   22  1   14  ]      2.8       12     -   4.3     3 
13ooo22        5.84 17    + [24  *   12  1   ]     64         38     +   1.7     3 
6oooo6         4.75 3     + [12  *   *   19  ]    800         52     +  15       3 
13oooo12       5.30 126   - [48  *   19  7   ]    220         56     +   4       3 
12oooo2b       4.94 12    + [*   37  25  *   ]    510         59     +   8.6     3 
3oooo7         4.99 29    + [15  17  1   *   ]    450         60     +   7.5     3 
17oooo39       4.93 3     + [*   6   1   *   ]    520         71     +   7.3     3 
18oooo10       4.92 2     + [*   23  1   *   ]    530        220     +   2.4     3 
13oooo13       5.06 145   + [*   48  7   19  ]    390        230     +   1.7     3 
13ooo21        5.43 176   - [27  *   12  1   ]    160        300     -   1.8     3 
6oooo10        4.62 2     + [12  *   *   19  ]   1100        320     +   3.3     3 
13ooo18        5.41 164   + [39  64  *   15  ]    170        330     -   1.9     3 
18oooo8        4.98 6     + [27  23  *   *   ]    470        330     +   1.4     3 
1oooo11        4.94 4     + [*   18  1   *   ]    510        340     +   1.5     3 
3oooo6         5.00 14    + [*   17  *   37  ]    450        530     -   1.2     3 
11ooooONO3805  5.33 175   - [62  2   14  *   ]    210        540     -   2.6     3 
3oooo11        4.67 6     + [12  *   *   19  ]    950        550     +   1.7     3 
18oooo9        4.92 4     + [*   23  1   *   ]    530        640     -   1.2     3 
3oooo12        4.99 29    + [15  17  1   *   ]    450        750     -   1.7     3 
13oooo11       5.02 161   + [*   48  *   33  ]    430        810     -   1.9     3 
3oooo9         4.99 40    + [*   17  *   46  ]    450        830     -   1.8     3 
17oooo19       4.93 16    + [*   6   1   *   ]    520        830     -   1.6     3 
6oooo3         4.93 20    + [12  40  *   *   ]    520        870     -   1.7     3 
13oooo2        5.25 145   - [65  *   33  19  ]    250       1200     -   4.8     3 
6oooo9         4.62 4     + [12  *   *   19  ]   1100       1300     -   1.3     3 
18oooo13       4.92 8     + [*   23  1   *   ]    530       2300     -   4.4     3 
18oooo12       4.92 5     + [*   23  1   *   ]    530       4000     -   7.5     3 
18oooo14       4.96 2     + [27  23  *   *   ]    490       4700     -   9.5     3 
6oooo5a        4.49 6     + [12  *   *   19  ]   1400      10000     -   6.9     3 
18oooo7        4.92 5     + [*   23  1   *   ]    530      10000     -  19       3 
18oooo6        4.99 7     + [27  23  *   *   ]    450      10000     -  22       3 
************************************************************* 
Mirror image used.  To turn this option off, put  
catHypo.forceAbsoluteStereochemistry=1 in the .Catalyst file. 
************************************************************* 
 totalcost=212.105 RMS=1.29099 correl=0.867615 




 totalcost=172.342 RMS=0 correl=0 
 Cost components: Error=154.726 Weight=1.12491 Config=16.4912 Tolerance=0 
 
 
dumping score for the 3rd hypothesis  
 
Definition:          HBA       NegIonizable   RING AROMATIC  RING AROMATIC 
Weights:          2.37169        2.37169        2.37169        2.37169 
Tolerances:    1.60    2.20       1.60       1.60    1.60   1.60    1.60 
Coords: X      -5.42   -5.73      4.50       0.19    0.10   3.41    3.13 
      : Y      1.49    4.44       -1.87      -0.34   -1.05  -2.16   0.83 
      : Z      -1.13   -1.53      -4.31      1.57    -1.34  -0.81   -0.69 
                 o--------->         o         o--------->    o---------> 
HBA          o 
         --->  3.0 
NegIonizable o 10.9    12.3 
RING AROMATIC o6.5     8.2        7.4 
         --->  6.1     8.0        5.4        3.0 
RING AROMATIC o9.6     11.3       3.7        4.4     3.5 
         --->  8.6     9.6        4.7        3.9     3.6    3.0 
 
Name           Fit  Cnf/Enan      Mapping        Est        Act      Error     Unc 
11ooo2o        7.94 19    + [1   31  23  10  ]      0.32       0.29  +   1.1     3 
12oooo2s       6.96 11    + [*   13  18  1   ]      3          0.56  +   5.4     3 
11ooo2r        6.95 3     - [*   1   23  10  ]      3.2        0.57  +   5.6     3 
11oooo2g       7.00 19    - [*   22  14  1   ]      2.8        1.1   +   2.5     3 
12oooo2g       6.99 2     + [*   13  17  27  ]      2.8        1.5   +   1.9     3 
12oooo2j       6.53 3     - [*   13  18  1   ]      8.2        2.5   +   3.3     3 
12oooo2l       7.01 15    + [*   13  18  1   ]      2.7        2.7   +   1       3 
11oooo2b       7.02 16    + [*   38  14  1   ]      2.7        3.4   -   1.3     3 
12oooo2f       6.86 10    + [*   13  20  15  ]      3.9        4.1   -   1.1     3 
12oooo2h       6.75 7     + [*   13  17  1   ]      5          6.4   -   1.3     3 
12oooo2r       6.84 10    + [*   13  18  1   ]      4          7.3   -   1.8     3 
11ooo2k        7.00 19    - [*   22  14  1   ]      2.8        9.3   -   3.4     3 
17oooo40       4.74 10    + [*   6   *   1   ]    510          9.8   +  52       3 
12oooo2k       6.31 13    + [*   13  18  1   ]     14         10     +   1.4     3 
11ooo2q        6.73 11    - [*   1   23  10  ]      5.2       11     -   2.1     3 
11oooo2c       6.98 24    - [*   22  14  1   ]      2.9       12     -   4.1     3 
13ooo22        6.07 17    + [24  *   1   12  ]     24         38     -   1.6     3 
6oooo6         4.53 3     + [12  *   19  *   ]    820         52     +  16       3 
13oooo12       4.74 158   + [30  48  *   *   ]    510         56     +   9.1     3 
12oooo2b       4.74 3     + [*   37  *   25  ]    500         59     +   8.5     3 
3oooo7         4.74 7     + [*   17  *   1   ]    500         60     +   8.4     3 
17oooo39       4.74 9     + [*   6   *   1   ]    500         71     +   7.1     3 
18oooo10       4.74 7     + [*   23  *   1   ]    510        220     +   2.3     3 
13oooo13       4.81 47    + [*   48  19  33  ]    430        230     +   1.9     3 
13ooo21        5.29 86    + [8   24  17  *   ]    140        300     -   2.1     3 
6oooo10        4.53 2     + [12  *   19  *   ]    820        320     +   2.6     3 
13ooo18        5.27 139   - [39  64  15  *   ]    150        330     -   2.2     3 
18oooo8        4.74 6     + [27  23  *   *   ]    510        330     +   1.5     3 
1oooo11        4.74 2     + [*   18  *   1   ]    510        340     +   1.5     3 
3oooo6         4.74 43    + [*   17  *   1   ]    500        530     -   1.1     3 
11ooooONO3805  4.81 175   - [62  2   *   14  ]    430        540     -   1.2     3 
3oooo11        4.59 9     + [12  *   19  *   ]    720        550     +   1.3     3 
18oooo9        4.74 3     + [*   23  *   1   ]    500        640     -   1.3     3 
3oooo12        4.74 7     + [*   17  *   1   ]    500        750     -   1.5     3 
13oooo11       4.74 81    + [*   48  33  *   ]    500        810     -   1.6     3 
3oooo9         4.74 12    + [*   17  *   1   ]    500        830     -   1.6     3 
17oooo19       4.74 6     + [*   6   *   1   ]    510        830     -   1.6     3 
6oooo3         4.70 24    + [12  40  *   *   ]    550        870     -   1.6     3 
13oooo2        4.95 103   + [65  *   7   19  ]    320       1200     -   3.8     3 
6oooo9         4.52 10    + [12  *   19  *   ]    840       1300     -   1.6     3 
18oooo13       4.74 4     + [*   23  *   1   ]    510       2300     -   4.6     3 
18oooo12       4.74 4     + [*   23  *   1   ]    500       4000     -   7.9     3 
18oooo14       4.74 6     + [*   23  *   1   ]    510       4700     -   9.3     3 
6oooo5a        4.47 6     + [12  *   19  *   ]    950      10000     -  11       3 
18oooo7        4.74 3     + [*   23  *   1   ]    510      10000     -  20       3 
18oooo6        4.74 3     + [*   23  *   1   ]    500      10000     -  20       3 
************************************************************* 
Mirror image used.  To turn this option off, put  
catHypo.forceAbsoluteStereochemistry=1 in the .Catalyst file. 
************************************************************* 
 totalcost=212.843 RMS=1.31453 correl=0.862115 




 totalcost=172.342 RMS=0 correl=0 
 Cost components: Error=154.726 Weight=1.12491 Config=16.4912 Tolerance=0 
 
 
dumping score for the 4th hypothesis  
 
Definition:          HBA        HYDROPHOBIC   RING AROMATIC  RING AROMATIC 
Weights:          2.30926        2.30926        2.30926        2.30926 
Tolerances:    1.60    2.20       1.60       1.60    1.60   1.60    1.60 
Coords: X      6.07    7.28       5.16       2.66    3.81   -1.24   -2.61 
      : Y      -1.83   0.45       2.54       -0.68   -1.74  0.73    3.35 
      : Z      -0.86   0.67       1.10       0.76    3.31   1.22    1.73 
                 o--------->         o         o--------->    o---------> 
HBA          o 
         --->  3.0 
HYDROPHOBIC  o 4.9     3.0 
RING AROMATIC o3.9     4.8        4.1 
         --->  4.7     4.9        5.0        3.0 
RING AROMATIC o8.0     8.5        6.7        4.2     6.0 
         --->  10.4    10.4       7.8        6.7     8.3    3.0 
 
Name           Fit  Cnf/Enan      Mapping        Est        Act      Error     Unc 
11ooo2o        7.59 21    - [31  13  10  23  ]      0.99       0.29  +   3.4     3 
12oooo2s       8.43 8     + [15  38  1   18  ]      0.14       0.56  -   3.9     3 
11ooo2r        7.35 27    - [31  17  10  23  ]      1.7        0.57  +   3       3 
11oooo2g       7.28 19    - [22  8   1   14  ]      2          1.1   +   1.8     3 
12oooo2g       6.61 5     - [25  *   27  17  ]      9.4        1.5   +   6.3     3 
12oooo2j       6.45 3     - [15  *   1   18  ]     14          2.5   +   5.4     3 
12oooo2l       6.54 15    + [15  *   1   18  ]     11          2.7   +   4.1     3 
11oooo2b       6.81 16    + [39  8   1   14  ]      6          3.4   +   1.8     3 
12oooo2f       6.68 8     + [27  *   15  20  ]      8          4.1   +   2       3 
12oooo2h       6.46 7     + [14  *   1   17  ]     13          6.4   +   2.1     3 
12oooo2r       6.45 9     - [15  *   1   18  ]     14          7.3   +   1.9     3 
11ooo2k        7.29 2     + [22  8   1   14  ]      1.9        9.3   -   4.8     3 
17oooo40       5.82 3     + [20  7   16  *   ]     58          9.8   +   5.9     3 
12oooo2k       6.08 13    + [15  *   1   18  ]     32         10     +   3.2     3 
11ooo2q        6.69 8     + [5   *   10  23  ]      7.9       11     -   1.4     3 
11oooo2c       6.92 24    - [30  8   1   14  ]      4.6       12     -   2.6     3 
13ooo22        5.96 42    - [*   58  12  1   ]     42         38     +   1.1     3 
6oooo6         4.51 3     + [*   26  *   39  ]   1200         52     +  23       3 
13oooo12       5.95 126   - [30  *   19  7   ]     43         56     -   1.3     3 
12oooo2b       4.90 21    + [39  27  *   2   ]    490         59     +   8.2     3 
3oooo7         4.59 7     + [32  *   1   *   ]    990         60     +  16       3 
17oooo39       5.68 16    + [26  55  16  *   ]     80         71     +   1.1     3 
18oooo10       4.62 10    + [*   14  1   *   ]    930        220     +   4.2     3 
13oooo13       5.76 94    - [30  57  33  *   ]     67        230     -   3.4     3 
13ooo21        5.74 223   - [*   4   1   12  ]     69        300     -   4.3     3 
6oooo10        4.61 5     + [*   48  *   19  ]    940        320     +   2.9     3 
13ooo18        5.62 131   - [*   23  15  52  ]     92        330     -   3.6     3 
18oooo8        4.62 10    + [*   13  1   *   ]    920        330     +   2.8     3 
1oooo11        4.62 6     + [*   7   4   *   ]    930        340     +   2.7     3 
3oooo6         4.62 7     + [*   18  *   37  ]    920        530     +   1.7     3 
11ooooONO3805  5.69 81    - [*   69  51  28  ]     78        540     -   6.9     3 
3oooo11        4.60 9     + [*   48  *   19  ]    970        550     +   1.8     3 
18oooo9        4.62 3     + [*   13  1   *   ]    920        640     +   1.4     3 
3oooo12        4.59 7     + [32  *   1   *   ]    990        750     +   1.3     3 
13oooo11       5.63 25    + [15  *   19  33  ]     89        810     -   9.1     3 
3oooo9         5.38 19    + [*   5   46  26  ]    160        830     -   5.2     3 
17oooo19       4.62 19    + [*   5   16  *   ]    920        830     +   1.1     3 
6oooo3         4.56 12    + [*   32  *   19  ]   1000        870     +   1.2     3 
13oooo2        5.60 67    - [*   10  7   19  ]     95       1200     -  13       3 
6oooo9         4.61 5     + [*   26  *   42  ]    930       1300     -   1.4     3 
18oooo13       4.62 9     + [*   5   13  *   ]    930       2300     -   2.5     3 
18oooo12       4.62 11    + [*   13  1   *   ]    920       4000     -   4.3     3 
18oooo14       4.62 11    + [*   5   13  *   ]    920       4700     -   5.1     3 
6oooo5a        4.61 2     + [*   8   *   37  ]    950      10000     -  11       3 
18oooo7        4.62 6     + [*   5   13  *   ]    930      10000     -  11       3 
18oooo6        4.62 8     + [*   5   13  *   ]    920      10000     -  11       3 
************************************************************* 
Mirror image used.  To turn this option off, put  
catHypo.forceAbsoluteStereochemistry=1 in the .Catalyst file. 
************************************************************* 
 totalcost=213.029 RMS=1.32144 correl=0.860472 




 totalcost=172.342 RMS=0 correl=0 
 Cost components: Error=154.726 Weight=1.12491 Config=16.4912 Tolerance=0 
 
 
dumping score for the 5th hypothesis  
 
Definition:          HBA       NegIonizable   RING AROMATIC  RING AROMATIC 
Weights:          2.35120        2.35120        2.35120        2.35120 
Tolerances:    1.60    2.20       1.60       1.60    1.60   1.60    1.60 
Coords: X      -4.47   -4.15      3.20       -0.15   1.06   2.14    2.06 
      : Y      3.46    6.01       -3.17      -0.39   0.26   -3.55   -6.53 
      : Z      -0.33   -1.86      -4.02      1.82    4.49   -0.49   -0.82 
                 o--------->         o         o--------->    o---------> 
HBA          o 
         --->  3.0 
NegIonizable o 10.8    12.0 
RING AROMATIC o6.2     8.4        7.3 
         --->  8.0     10.0       9.4        3.0 
RING AROMATIC o9.6     11.5       3.7        4.5     6.4 
         --->  11.9    14.0       4.8        7.0     8.7    3.0 
 
Name           Fit  Cnf/Enan      Mapping        Est        Act      Error     Unc 
11ooo2o        8.34 19    + [1   31  23  10  ]      0.12       0.29  -   2.4     3 
12oooo2s       6.91 9     - [*   13  18  1   ]      3.2        0.56  +   5.7     3 
11ooo2r        6.90 24    + [*   1   23  10  ]      3.3        0.57  +   5.7     3 
11oooo2g       6.92 7     + [*   22  14  1   ]      3.1        1.1   +   2.8     3 
12oooo2g       6.77 7     - [*   13  17  27  ]      4.4        1.5   +   3       3 
12oooo2j       6.60 2     + [*   13  18  1   ]      6.5        2.5   +   2.6     3 
12oooo2l       6.79 12    - [*   13  18  1   ]      4.2        2.7   +   1.6     3 
11oooo2b       6.77 13    - [*   38  14  1   ]      4.5        3.4   +   1.3     3 
12oooo2f       6.70 10    + [*   13  20  15  ]      5.1        4.1   +   1.3     3 
12oooo2h       6.59 7     + [*   13  17  1   ]      6.6        6.4   +   1       3 
12oooo2r       6.84 4     - [*   13  18  1   ]      3.8        7.3   -   1.9     3 
11ooo2k        6.92 35    + [*   22  14  1   ]      3.1        9.3   -   3       3 
17oooo40       4.70 24    + [26  6   *   *   ]    520          9.8   +  53       3 
12oooo2k       6.21 2     + [*   13  18  1   ]     16         10     +   1.6     3 
11ooo2q        6.82 4     - [*   1   23  10  ]      4         11     -   2.8     3 
11oooo2c       6.90 34    - [*   22  14  1   ]      3.3       12     -   3.7     3 
13ooo22        5.98 17    + [24  *   1   12  ]     28         38     -   1.4     3 
6oooo6         4.45 3     + [12  *   19  *   ]    930         52     +  18       3 
13oooo12       5.04 23    - [48  *   7   19  ]    240         56     +   4.2     3 
12oooo2b       5.06 46    + [*   37  2   25  ]    220         59     +   3.8     3 
3oooo7         4.70 7     + [*   17  *   1   ]    520         60     +   8.6     3 
17oooo39       4.70 9     + [*   6   *   1   ]    520         71     +   7.3     3 
18oooo10       4.69 7     + [*   23  *   1   ]    530        220     +   2.4     3 
13oooo13       4.94 51    - [48  *   7   19  ]    300        230     +   1.3     3 
13ooo21        4.96 85    - [24  *   17  12  ]    280        300     -   1.1     3 
6oooo10        4.40 2     + [12  *   19  *   ]   1000        320     +   3.3     3 
13ooo18        5.21 164   + [39  64  15  *   ]    160        330     -   2.1     3 
18oooo8        4.70 2     + [*   23  *   1   ]    520        330     +   1.6     3 
1oooo11        4.70 2     + [*   18  *   1   ]    520        340     +   1.5     3 
3oooo6         4.70 13    + [*   17  *   1   ]    520        530     -   1       3 
11ooooONO3805  4.70 171   + [*   2   51  *   ]    520        540     -   1       3 
3oooo11        4.43 9     + [12  *   19  *   ]    960        550     +   1.7     3 
18oooo9        4.70 3     + [*   23  *   1   ]    520        640     -   1.2     3 
3oooo12        4.70 7     + [*   17  *   1   ]    520        750     -   1.5     3 
13oooo11       4.84 87    - [50  *   19  33  ]    380        810     -   2.1     3 
3oooo9         4.70 12    + [*   17  *   1   ]    520        830     -   1.6     3 
17oooo19       4.70 6     + [*   6   *   1   ]    520        830     -   1.6     3 
6oooo3         4.64 6     + [12  40  *   *   ]    600        870     -   1.5     3 
13oooo2        5.50 41    + [65  *   7   19  ]     82       1200     -  15       3 
6oooo9         4.42 4     + [12  *   19  *   ]    990       1300     -   1.4     3 
18oooo13       4.70 4     + [*   23  *   1   ]    520       2300     -   4.5     3 
18oooo12       4.70 4     + [*   23  *   1   ]    520       4000     -   7.8     3 
18oooo14       4.70 6     + [*   23  *   1   ]    520       4700     -   9.1     3 
6oooo5a        4.31 6     + [12  *   19  *   ]   1300      10000     -   7.9     3 
18oooo7        4.70 3     + [*   23  *   1   ]    520      10000     -  19       3 
18oooo6        4.70 3     + [*   23  *   1   ]    520      10000     -  19       3 
************************************************************* 
Mirror image used.  To turn this option off, put  
catHypo.forceAbsoluteStereochemistry=1 in the .Catalyst file. 
************************************************************* 
 totalcost=213.09 RMS=1.31994 correl=0.860858 




 totalcost=172.342 RMS=0 correl=0 
 Cost components: Error=154.726 Weight=1.12491 Config=16.4912 Tolerance=0 
 
 
dumping score for the 6th hypothesis  
 
Definition:          HBA       NegIonizable   RING AROMATIC  RING AROMATIC 
Weights:          2.30525        2.30525        2.30525        2.30525 
Tolerances:    1.60    2.20       1.60       1.60    1.60   1.60    1.60 
Coords: X      -5.69   -8.11      4.01       0.19    0.65   3.37    5.70 
      : Y      2.59    1.33       -3.83      0.17    0.13   -1.11   0.55 
      : Z      0.30    1.54       -3.38      1.53    4.50   -1.25   -2.17 
                 o--------->         o         o--------->    o---------> 
HBA          o 
         --->  3.0 
NegIonizable o 12.2    14.1 
RING AROMATIC o6.5     8.4        7.4 
         --->  8.0     9.3        9.4        3.0 
RING AROMATIC o9.9     12.1       3.5        4.4     6.5 
         --->  11.8    14.3       4.8        6.6     8.4    3.0 
 
Name           Fit  Cnf/Enan      Mapping        Est        Act      Error     Unc 
11ooo2o        8.67 44    + [1   31  23  10  ]      0.053      0.29  -   5.5     3 
12oooo2s       6.70 4     - [*   13  18  1   ]      4.9        0.56  +   8.8     3 
11ooo2r        6.79 24    - [*   1   23  10  ]      4          0.57  +   7.1     3 
11oooo2g       6.74 53    + [*   22  14  1   ]      4.5        1.1   +   4.1     3 
12oooo2g       6.80 7     + [*   13  17  27  ]      4          1.5   +   2.7     3 
12oooo2j       6.54 2     - [*   13  18  1   ]      7.3        2.5   +   2.9     3 
12oooo2l       6.62 12    + [*   13  18  1   ]      6          2.7   +   2.2     3 
11oooo2b       6.68 13    + [*   38  14  1   ]      5.2        3.4   +   1.5     3 
12oooo2f       6.69 11    + [*   13  20  15  ]      5.1        4.1   +   1.2     3 
12oooo2h       6.51 7     - [*   13  17  1   ]      7.7        6.4   +   1.2     3 
12oooo2r       6.65 4     + [*   13  18  1   ]      5.6        7.3   -   1.3     3 
11ooo2k        6.78 4     - [*   22  14  1   ]      4.1        9.3   -   2.2     3 
17oooo40       4.98 29    - [31  6   *   1   ]    260          9.8   +  27       3 
12oooo2k       5.84 11    + [*   13  18  1   ]     36         10     +   3.6     3 
11ooo2q        6.63 4     + [*   1   23  10  ]      5.8       11     -   1.9     3 
11oooo2c       6.82 34    + [*   22  14  1   ]      3.8       12     -   3.2     3 
13ooo22        5.40 200   - [24  *   1   12  ]     99         38     +   2.6     3 
6oooo6         4.31 2     + [12  *   19  *   ]   1200         52     +  23       3 
13oooo12       4.95 23    + [48  *   7   19  ]    280         56     +   5       3 
12oooo2b       4.91 12    - [*   37  2   25  ]    310         59     +   5.2     3 
3oooo7         4.61 11    + [*   17  *   1   ]    610         60     +  10       3 
17oooo39       5.14 11    + [31  6   *   1   ]    180         71     +   2.5     3 
18oooo10       4.61 2     + [*   23  *   1   ]    610        220     +   2.8     3 
13oooo13       5.44 102   - [48  *   7   19  ]     90        230     -   2.6     3 
13ooo21        5.27 162   + [24  *   1   12  ]    130        300     -   2.2     3 
6oooo10        4.42 6     + [12  *   19  *   ]    960        320     +   3       3 
13ooo18        5.89 146   + [67  *   15  52  ]     32        330     -  10       3 
18oooo8        4.61 6     + [*   23  *   1   ]    610        330     +   1.9     3 
1oooo11        4.61 5     + [*   18  *   1   ]    610        340     +   1.8     3 
3oooo6         4.61 19    + [*   17  *   1   ]    610        530     +   1.2     3 
11ooooONO3805  4.75 97    - [3   *   51  28  ]    440        540     -   1.2     3 
3oooo11        4.39 5     + [12  *   19  *   ]   1000        550     +   1.8     3 
18oooo9        4.61 4     + [*   23  *   1   ]    610        640     -   1       3 
3oooo12        4.61 11    + [*   17  *   1   ]    610        750     -   1.2     3 
13oooo11       4.88 20    + [50  *   7   19  ]    330        810     -   2.5     3 
3oooo9         4.61 29    + [*   17  *   1   ]    610        830     -   1.4     3 
17oooo19       5.32 5     + [31  6   16  *   ]    120        830     -   6.9     3 
6oooo3         4.45 7     + [12  40  *   *   ]    880        870     +   1       3 
13oooo2        5.53 41    - [65  *   7   19  ]     73       1200     -  16       3 
6oooo9         4.37 8     + [12  *   19  *   ]   1100       1300     -   1.3     3 
18oooo13       4.61 8     + [*   23  *   1   ]    610       2300     -   3.8     3 
18oooo12       4.61 5     + [*   23  *   1   ]    610       4000     -   6.5     3 
18oooo14       4.61 7     + [*   23  *   1   ]    610       4700     -   7.7     3 
6oooo5a        4.42 4     + [12  *   19  *   ]    950      10000     -  11       3 
18oooo7        4.61 5     + [*   23  *   1   ]    610      10000     -  16       3 
18oooo6        4.61 2     + [*   23  *   1   ]    610      10000     -  16       3 
************************************************************* 
Mirror image used.  To turn this option off, put  
catHypo.forceAbsoluteStereochemistry=1 in the .Catalyst file. 
************************************************************* 
 totalcost=217.268 RMS=1.38964 correl=0.844335 




 totalcost=172.342 RMS=0 correl=0 
 Cost components: Error=154.726 Weight=1.12491 Config=16.4912 Tolerance=0 
 
 
dumping score for the 7th hypothesis  
 
Definition:          HBA        HYDROPHOBIC   RING AROMATIC  RING AROMATIC 
Weights:          2.02431        2.02431        2.02431        2.02431 
Tolerances:    1.60    2.20       1.60       1.60    1.60   1.60    1.60 
Coords: X      5.40    6.72       5.16       2.68    3.80   -1.39   -2.45 
      : Y      -1.99   -3.80      2.54       -0.56   -1.85  1.07    3.81 
      : Z      -1.40   -3.39      1.10       0.80    3.27   0.78    1.37 
                 o--------->         o         o--------->    o---------> 
HBA          o 
         --->  3.0 
HYDROPHOBIC  o 5.2     7.9 
RING AROMATIC o3.8     6.7        4.0 
         --->  4.9     7.5        5.1        3.0 
RING AROMATIC o7.8     10.3       6.7        4.4     6.5 
         --->  10.1    12.8       7.7        6.8     8.6    3.0 
 
Name           Fit  Cnf/Enan      Mapping        Est        Act      Error     Unc 
11ooo2o        6.79 14    - [31  13  10  23  ]      2.6        0.29  +   9       3 
12oooo2s       7.95 8     + [15  38  1   18  ]      0.18       0.56  -   3.1     3 
11ooo2r        6.83 3     - [5   17  10  23  ]      2.3        0.57  +   4.1     3 
11oooo2g       6.89 19    - [22  8   1   14  ]      2          1.1   +   1.9     3 
12oooo2g       6.02 2     + [25  *   27  17  ]     15          1.5   +  10       3 
12oooo2j       5.88 3     - [15  *   1   18  ]     21          2.5   +   8.4     3 
12oooo2l       6.01 15    + [15  *   1   18  ]     15          2.7   +   5.7     3 
11oooo2b       6.69 16    + [39  8   1   14  ]      3.3        3.4   -   1       3 
12oooo2f       5.96 10    + [27  *   15  20  ]     17          4.1   +   4.3     3 
12oooo2h       5.85 7     + [14  *   1   17  ]     23          6.4   +   3.5     3 
12oooo2r       5.93 10    + [14  *   1   18  ]     19          7.3   +   2.6     3 
11ooo2k        6.86 19    - [22  8   1   14  ]      2.2        9.3   -   4.2     3 
17oooo40       5.80 3     - [20  7   16  *   ]     25          9.8   +   2.6     3 
12oooo2k       5.47 16    - [15  *   1   18  ]     54         10     +   5.4     3 
11ooo2q        6.44 11    - [5   13  10  23  ]      5.8       11     -   1.9     3 
11oooo2c       6.85 24    - [30  8   1   14  ]      2.3       12     -   5.3     3 
13ooo22        5.53 130   + [8   *   12  17  ]     47         38     +   1.2     3 
6oooo6         4.04 2     + [12  8   *   *   ]   1400         52     +  28       3 
13oooo12       5.56 82    + [15  *   19  33  ]     44         56     -   1.3     3 
12oooo2b       4.99 46    + [38  31  *   2   ]    160         59     +   2.8     3 
3oooo7         4.88 20    - [17  48  1   *   ]    210         60     +   3.5     3 
17oooo39       4.47 14    + [31  61  *   1   ]    540         71     +   7.7     3 
18oooo10       4.05 8     + [*   13  1   *   ]   1400        220     +   6.5     3 
13oooo13       5.60 101   + [15  *   19  33  ]     40        230     -   5.8     3 
13ooo21        5.66 235   - [8   20  *   49  ]     35        300     -   8.6     3 
6oooo10        4.05 7     + [*   49  *   19  ]   1400        320     +   4.5     3 
13ooo18        5.52 82    - [17  *   52  40  ]     48        330     -   6.8     3 
18oooo8        4.10 7     - [27  31  13  *   ]   1300        330     +   3.9     3 
1oooo11        4.88 2     - [27  22  1   *   ]    210        340     -   1.6     3 
3oooo6         5.02 35    + [32  52  1   *   ]    150        530     -   3.5     3 
11ooooONO3805  5.09 25    + [6   66  51  *   ]    130        540     -   4.1     3 
3oooo11        4.05 3     + [*   48  *   19  ]   1400        550     +   2.6     3 
18oooo9        4.57 7     + [27  36  13  *   ]    430        640     -   1.5     3 
3oooo12        4.88 20    - [17  48  1   *   ]    210        750     -   3.6     3 
13oooo11       5.58 148   + [15  *   19  33  ]     42        810     -  19       3 
3oooo9         4.94 19    + [*   5   46  26  ]    180        830     -   4.5     3 
17oooo19       4.05 17    + [*   5   16  *   ]   1400        830     +   1.7     3 
6oooo3         4.04 2     + [12  34  *   *   ]   1500        870     +   1.7     3 
13oooo2        5.27 114   - [15  *   19  33  ]     87       1200     -  14       3 
6oooo9         4.05 11    + [*   26  *   42  ]   1400       1300     +   1.1     3 
18oooo13       4.05 9     + [*   5   13  *   ]   1400       2300     -   1.6     3 
18oooo12       4.04 11    + [*   13  1   *   ]   1400       4000     -   2.8     3 
18oooo14       4.05 11    + [*   22  1   *   ]   1400       4700     -   3.3     3 
6oooo5a        4.04 2     + [*   26  37  *   ]   1500      10000     -   6.8     3 
18oooo7        4.05 6     + [*   13  1   *   ]   1400      10000     -   7       3 
18oooo6        4.04 8     + [*   13  1   *   ]   1400      10000     -   6.9     3 
************************************************************* 
Mirror image used.  To turn this option off, put  
catHypo.forceAbsoluteStereochemistry=1 in the .Catalyst file. 
************************************************************* 
 totalcost=218.29 RMS=1.41336 correl=0.838323 




 totalcost=172.342 RMS=0 correl=0 
 Cost components: Error=154.726 Weight=1.12491 Config=16.4912 Tolerance=0 
 
 
dumping score for the 8th hypothesis  
 
Definition:          HBA       NegIonizable   RING AROMATIC  RING AROMATIC 
Weights:          2.16352        2.16352        2.16352        2.16352 
Tolerances:    1.60    2.20       1.60       1.60    1.60   1.60    1.60 
Coords: X      -5.70   -8.10      4.01       3.58    1.58   0.30    0.54 
      : Y      1.81    0.50       -3.83      -1.26   -3.00  0.43    -0.13 
      : Z      0.30    1.54       -3.38      -1.17   0.23   1.54    4.48 
                 o--------->         o         o--------->    o---------> 
HBA          o 
         --->  3.0 
NegIonizable o 11.8    13.8 
RING AROMATIC o9.9     12.1       3.4 
         --->  8.7     10.4       4.4        3.0 
RING AROMATIC o6.3     8.4        7.5        4.6     3.9 
         --->  7.8     9.1        9.4        6.5     5.2    3.0 
 
Name           Fit  Cnf/Enan      Mapping        Est        Act      Error     Unc 
11ooo2o        8.58 44    + [1   31  10  23  ]      0.03       0.29  -   9.7     3 
12oooo2s       6.29 2     + [*   13  1   18  ]      5.8        0.56  +  10       3 
11ooo2r        6.36 9     + [*   1   10  23  ]      5          0.57  +   8.7     3 
11oooo2g       6.34 22    - [*   22  1   14  ]      5.1        1.1   +   4.7     3 
12oooo2g       6.34 7     + [*   13  27  17  ]      5.1        1.5   +   3.4     3 
12oooo2j       6.36 2     - [*   13  1   18  ]      4.9        2.5   +   2       3 
12oooo2l       6.34 12    + [*   13  1   18  ]      5.1        2.7   +   1.9     3 
11oooo2b       6.38 13    + [*   38  1   14  ]      4.7        3.4   +   1.4     3 
12oooo2f       6.33 11    + [*   13  15  20  ]      5.3        4.1   +   1.3     3 
12oooo2h       5.99 2     - [*   13  1   17  ]     11          6.4   +   1.8     3 
12oooo2r       6.32 4     + [*   13  1   18  ]      5.4        7.3   -   1.3     3 
11ooo2k        6.34 20    + [*   22  1   14  ]      5.1        9.3   -   1.8     3 
17oooo40       4.78 37    + [31  6   *   16  ]    190          9.8   +  19       3 
12oooo2k       4.93 2     - [*   13  1   18  ]    130         10     +  13       3 
11ooo2q        6.44 9     + [*   1   10  23  ]      4.1       11     -   2.7     3 
11oooo2c       6.26 4     - [*   22  1   14  ]      6.2       12     -   1.9     3 
13ooo22        5.34 35    - [24  *   12  1   ]     52         38     +   1.4     3 
6oooo6         3.89 2     + [12  *   *   19  ]   1400         52     +  28       3 
13oooo12       4.83 173   + [48  *   19  7   ]    170         56     +   3       3 
12oooo2b       4.32 31    + [*   37  25  *   ]    530         59     +   9.1     3 
3oooo7         4.44 19    - [15  17  1   *   ]    410         60     +   6.8     3 
17oooo39       4.79 14    + [31  6   *   16  ]    180         71     +   2.6     3 
18oooo10       4.32 4     + [*   23  1   *   ]    540        220     +   2.4     3 
13oooo13       4.68 122   - [48  *   19  7   ]    230        230     +   1       3 
13ooo21        5.03 176   + [27  *   12  1   ]    100        300     -   2.9     3 
6oooo10        3.90 6     + [12  *   *   19  ]   1400        320     +   4.4     3 
13ooo18        5.09 146   + [67  *   52  15  ]     92        330     -   3.6     3 
18oooo8        4.32 6     + [*   23  1   *   ]    540        330     +   1.6     3 
1oooo11        4.32 5     + [*   18  1   *   ]    540        340     +   1.6     3 
3oooo6         4.97 16    + [15  17  1   *   ]    120        530     -   4.4     3 
11ooooONO3805  4.49 97    - [3   *   28  51  ]    370        540     -   1.5     3 
3oooo11        3.87 5     + [12  *   *   19  ]   1500        550     +   2.8     3 
18oooo9        4.32 4     + [*   23  1   *   ]    540        640     -   1.2     3 
3oooo12        4.44 19    - [15  17  1   *   ]    410        750     -   1.8     3 
13oooo11       4.76 78    - [48  *   19  7   ]    190        810     -   4.2     3 
3oooo9         4.35 40    + [15  17  *   46  ]    510        830     -   1.6     3 
17oooo19       5.24 5     + [31  6   *   16  ]     65        830     -  13       3 
6oooo3         4.31 7     + [12  40  *   *   ]    560        870     -   1.6     3 
13oooo2        4.58 41    - [65  *   19  7   ]    300       1200     -   4       3 
6oooo9         3.83 8     + [12  *   *   19  ]   1700       1300     +   1.3     3 
18oooo13       4.32 7     + [*   23  1   *   ]    540       2300     -   4.3     3 
18oooo12       4.32 3     + [*   23  1   *   ]    540       4000     -   7.5     3 
18oooo14       4.32 8     + [*   23  1   *   ]    540       4700     -   8.8     3 
6oooo5a        3.92 5     + [12  *   *   19  ]   1400      10000     -   7.3     3 
18oooo7        4.32 2     + [*   23  1   *   ]    540      10000     -  19       3 
18oooo6        4.32 5     + [*   23  1   *   ]    530      10000     -  19       3 
************************************************************* 
Mirror image used.  To turn this option off, put  
catHypo.forceAbsoluteStereochemistry=1 in the .Catalyst file. 
************************************************************* 
 totalcost=219.077 RMS=1.42322 correl=0.83587 




 totalcost=172.342 RMS=0 correl=0 
 Cost components: Error=154.726 Weight=1.12491 Config=16.4912 Tolerance=0 
 
 
dumping score for the 9th hypothesis  
 
Definition:          HBA       NegIonizable   RING AROMATIC  RING AROMATIC 
Weights:          2.10881        2.10881        2.10881        2.10881 
Tolerances:    1.60    2.20       1.60       1.60    1.60   1.60    1.60 
Coords: X      -6.23   -5.89      6.43       -0.02   1.01   4.15    6.15 
      : Y      3.70    6.66       -3.86      0.70    2.37   -2.12   0.10 
      : Z      1.62    1.14       -2.98      0.50    -1.77  -0.57   -0.84 
                 o--------->         o         o--------->    o---------> 
HBA          o 
         --->  3.0 
NegIonizable o 15.4    16.7 
RING AROMATIC o7.0     8.4        8.6 
         --->  8.1     8.6        8.3        3.0 
RING AROMATIC o12.1    13.4       3.7        5.1     5.6 
         --->  13.1    13.8       4.5        6.3     5.7    3.0 
 
Name           Fit  Cnf/Enan      Mapping        Est        Act      Error     Unc 
11ooo2o        7.92 40    + [1   31  23  10  ]      0.084      0.29  -   3.5     3 
12oooo2s       6.07 18    + [*   13  18  1   ]      5.9        0.56  +  11       3 
11ooo2r        6.17 22    - [*   1   23  10  ]      4.6        0.57  +   8.1     3 
11oooo2g       6.19 48    + [*   22  14  1   ]      4.5        1.1   +   4.1     3 
12oooo2g       6.11 9     - [*   13  17  27  ]      5.3        1.5   +   3.5     3 
12oooo2j       6.19 6     - [*   13  18  1   ]      4.4        2.5   +   1.8     3 
12oooo2l       6.16 3     + [*   13  18  1   ]      4.7        2.7   +   1.8     3 
11oooo2b       6.19 18    - [*   38  14  1   ]      4.4        3.4   +   1.3     3 
12oooo2f       6.14 15    - [*   13  20  15  ]      5          4.1   +   1.2     3 
12oooo2h       6.13 12    + [*   13  17  1   ]      5.1        6.4   -   1.3     3 
12oooo2r       6.07 12    + [*   13  18  1   ]      5.8        7.3   -   1.3     3 
11ooo2k        6.21 55    - [*   22  14  1   ]      4.3        9.3   -   2.2     3 
17oooo40       4.58 20    + [*   6   16  1   ]    180          9.8   +  19       3 
12oooo2k       4.74 15    - [*   13  18  1   ]    130         10     +  13       3 
11ooo2q        6.12 16    - [*   1   23  10  ]      5.2       11     -   2.1     3 
11oooo2c       6.17 37    - [*   22  14  1   ]      4.7       12     -   2.6     3 
13ooo22        5.02 153   + [27  *   1   12  ]     66         38     +   1.7     3 
6oooo6         3.64 2     + [12  *   19  *   ]   1600         52     +  31       3 
13oooo12       4.21 124   + [*   48  33  *   ]    420         56     +   7.5     3 
12oooo2b       4.20 11    + [*   37  *   25  ]    430         59     +   7.3     3 
3oooo7         4.20 2     + [*   17  *   1   ]    430         60     +   7.2     3 
17oooo39       4.66 3     - [*   6   16  1   ]    150         71     +   2.1     3 
18oooo10       4.20 4     + [*   23  *   1   ]    440        220     +   2       3 
13oooo13       4.29 147   + [48  *   19  33  ]    350        230     +   1.5     3 
13ooo21        5.29 99    + [*   24  12  1   ]     35        300     -   8.6     3 
6oooo10        3.67 6     + [12  *   19  *   ]   1500        320     +   4.6     3 
13ooo18        4.63 163   + [67  *   15  52  ]    160        330     -   2       3 
18oooo8        4.19 6     + [*   23  *   1   ]    440        330     +   1.3     3 
1oooo11        4.19 4     + [*   18  *   1   ]    440        340     +   1.3     3 
3oooo6         4.39 29    - [*   17  37  47  ]    280        530     -   1.9     3 
11ooooONO3805  4.20 33    + [62  2   *   *   ]    430        540     -   1.2     3 
3oooo11        3.84 9     + [12  *   *   41  ]    990        550     +   1.8     3 
18oooo9        4.20 4     + [*   23  *   1   ]    440        640     -   1.5     3 
3oooo12        4.20 2     + [*   17  *   1   ]    430        750     -   1.7     3 
13oooo11       5.48 96    - [50  *   7   19  ]     23        810     -  35       3 
3oooo9         4.21 22    + [*   17  *   1   ]    420        830     -   2       3 
17oooo19       4.20 7     + [*   6   *   1   ]    430        830     -   1.9     3 
6oooo3         3.95 20    + [*   40  *   19  ]    770        870     -   1.1     3 
13oooo2        4.19 202   + [*   64  19  *   ]    450       1200     -   2.7     3 
6oooo9         3.63 5     + [12  *   19  *   ]   1600       1300     +   1.2     3 
18oooo13       4.20 7     + [*   23  *   1   ]    440       2300     -   5.3     3 
18oooo12       4.19 3     + [*   23  *   1   ]    440       4000     -   9.1     3 
18oooo14       4.20 8     + [*   23  *   1   ]    440       4700     -  11       3 
6oooo5a        3.49 4     + [12  *   19  *   ]   2200      10000     -   4.5     3 
18oooo7        4.20 3     + [*   23  *   1   ]    440      10000     -  23       3 
18oooo6        4.19 5     + [*   23  *   1   ]    440      10000     -  23       3 
************************************************************* 
Mirror image used.  To turn this option off, put  
catHypo.forceAbsoluteStereochemistry=1 in the .Catalyst file. 
************************************************************* 
 totalcost=220.681 RMS=1.44875 correl=0.8293 




 totalcost=172.342 RMS=0 correl=0 
 Cost components: Error=154.726 Weight=1.12491 Config=16.4912 Tolerance=0 
 
 
dumping score for the 10th hypothesis  
 
Definition:          HBA       NegIonizable   RING AROMATIC  RING AROMATIC 
Weights:          2.01746        2.01746        2.01746        2.01746 
Tolerances:    1.60    2.20       1.60       1.60    1.60   1.60    1.60 
Coords: X      -5.60   -8.00      5.08       3.64    6.10   -0.14   0.18 
      : Y      2.37    3.12       -2.95      -1.68   -0.06  -0.08   2.19 
      : Z      0.79    2.46       -4.14      -1.16   -0.63  1.56    -0.38 
                 o--------->         o         o--------->    o---------> 
HBA          o 
         --->  3.0 
NegIonizable o 12.9    15.9 
RING AROMATIC o10.3    13.1       3.6 
         --->  12.0    14.8       4.7        3.0 
RING AROMATIC o6.0     8.5        8.2        4.9     6.6 
         --->  5.9     8.7        8.0        5.2     6.3    3.0 
 
Name           Fit  Cnf/Enan      Mapping        Est        Act      Error     Unc 
11ooo2o        7.96 72    + [1   31  10  23  ]      0.056      0.29  -   5.2     3 
12oooo2s       5.97 19    - [*   13  1   18  ]      5.6        0.56  +  10       3 
11ooo2r        6.03 32    + [*   1   10  23  ]      4.8        0.57  +   8.4     3 
11oooo2g       5.96 65    + [*   22  1   14  ]      5.6        1.1   +   5.1     3 
12oooo2g       5.77 9     - [*   13  27  17  ]      8.7        1.5   +   5.8     3 
12oooo2j       5.66 6     - [*   13  1   18  ]     11          2.5   +   4.6     3 
12oooo2l       5.82 20    + [*   13  1   18  ]      7.9        2.7   +   2.9     3 
11oooo2b       6.05 22    + [*   38  1   14  ]      4.6        3.4   +   1.4     3 
12oooo2f       5.78 16    + [*   13  15  20  ]      8.6        4.1   +   2.1     3 
12oooo2h       5.82 13    + [*   13  1   17  ]      7.8        6.4   +   1.2     3 
12oooo2r       5.97 8     - [*   13  1   18  ]      5.5        7.3   -   1.3     3 
11ooo2k        6.02 67    + [*   22  1   14  ]      4.9        9.3   -   1.9     3 
17oooo40       5.03 13    - [31  6   *   16  ]     48          9.8   +   4.9     3 
12oooo2k       5.08 15    + [*   13  1   18  ]     43         10     +   4.3     3 
11ooo2q        6.02 14    - [*   1   10  23  ]      4.9       11     -   2.2     3 
11oooo2c       6.02 39    + [*   22  1   14  ]      5         12     -   2.4     3 
13ooo22        4.82 152   + [27  *   12  1   ]     78         38     +   2.1     3 
6oooo6         3.12 3     + [12  *   *   19  ]   3900         52     +  75       3 
13oooo12       5.34 117   + [50  *   19  7   ]     23         56     -   2.4     3 
12oooo2b       4.03 49    + [*   37  25  *   ]    480         59     +   8.1     3 
3oooo7         4.03 39    + [*   17  1   *   ]    480         60     +   7.9     3 
17oooo39       4.33 16    + [31  6   1   *   ]    240         71     +   3.4     3 
18oooo10       4.03 9     + [*   23  1   *   ]    480        220     +   2.2     3 
13oooo13       4.95 5     - [48  *   19  7   ]     58        230     -   4       3 
13ooo21        5.03 9     - [27  *   12  1   ]     48        300     -   6.2     3 
6oooo10        3.42 8     + [12  *   *   19  ]   2000        320     +   6.1     3 
13ooo18        4.68 31    - [67  *   52  15  ]    110        330     -   3.1     3 
18oooo8        4.03 10    + [*   23  1   *   ]    480        330     +   1.4     3 
1oooo11        4.03 6     + [*   18  1   *   ]    480        340     +   1.4     3 
3oooo6         4.03 15    + [*   17  1   *   ]    480        530     -   1.1     3 
11ooooONO3805  4.03 128   + [*   2   *   51  ]    480        540     -   1.1     3 
3oooo11        3.55 3     + [12  *   *   19  ]   1500        550     +   2.7     3 
18oooo9        4.03 8     + [*   23  1   *   ]    480        640     -   1.3     3 
3oooo12        4.03 39    + [*   17  1   *   ]    480        750     -   1.6     3 
13oooo11       4.98 20    + [30  48  *   8   ]     54        810     -  15       3 
3oooo9         4.03 51    + [*   17  1   *   ]    480        830     -   1.7     3 
17oooo19       4.03 21    + [*   6   1   *   ]    480        830     -   1.7     3 
6oooo3         3.55 20    + [*   40  19  *   ]   1400        870     +   1.7     3 
13oooo2        4.62 24    + [65  *   19  7   ]    120       1200     -   9.7     3 
6oooo9         3.42 10    + [12  *   *   19  ]   2000       1300     +   1.5     3 
18oooo13       4.03 10    + [*   23  1   *   ]    480       2300     -   4.9     3 
18oooo12       4.03 11    + [*   23  1   *   ]    480       4000     -   8.4     3 
18oooo14       4.03 11    + [*   23  1   *   ]    480       4700     -   9.9     3 
6oooo5a        3.43 6     + [12  *   *   19  ]   1900      10000     -   5.2     3 
18oooo7        4.03 7     + [*   23  1   *   ]    480      10000     -  21       3 
18oooo6        4.03 8     + [*   23  1   *   ]    480      10000     -  21       3 
************************************************************* 
Mirror image used.  To turn this option off, put  
catHypo.forceAbsoluteStereochemistry=1 in the .Catalyst file. 
************************************************************* 
 totalcost=221.249 RMS=1.45819 correl=0.826819 




 totalcost=172.342 RMS=0 correl=0 
 Cost components: Error=154.726 Weight=1.12491 Config=16.4912 Tolerance=0 
 
 
dumping score for the null hypothesis:  
 totalcost=309.309 RMS=2.59249 correl=5.67491e-05 
 Cost components: Error=309.309 Weight=0 Config=0 Mapping=0 Tolerance=0 
 
Version:      catHypo  4.5 (272)  Wednesday, July 28, 1999 at 04:56 AM  
Confs (cpd):  /birchfiles/jane/riihuman10-294Dir/ 
Spreadsheet:  /birchfiles/jane/riihuman10-294Dir/riihuman10minus2.spst  
Dictionary:   /birchfiles/jane/riihuman10-294Dir/dict.chm  
Host:         birch 
Outname:      riihuman10 
Logname:      riihuman10-294.log 
CPU time = 74298 s  System time = 408 s  
Complexity 208.701  
Concluded pass 6. 
Finished generating a hypothesis. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
